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SUMMARY 
Fragile X syndrome (FXS) is the leading cause of inherited intellectual disability (ID) and 
autism. This neurodevelopmental disorder is caused by silencing of the FMR1 gene and 
lack of its product, Fragile X Mental Retardation Protein (FMRP). FMRP, an RNA-binding 
protein, is highly expressed in the brain and plays an important role in the transport and 
translation of many different mRNA targets. Lack of FMRP causes disruption in synapse 
morphology and function, as well as disruption in synaptic plasticity. These molecular 
and synaptic abnormalities cause FXS symptoms like ID, autism, hyperactivity, epilepsy 
and anxiety. Therefore, understanding of the molecular pathogenesis of FXS is also 
important for other neurodevelopmental and psychiatric disorders. In last two decades, 
extensive research in basic neurobiology and pathophysiology led to significant advances 
in FXS field.  However, although caused by only one gene, the molecular mechanisms of 
FXS are not yet well understood. Since FMRP is characterized as a translational regulator 
with multiple mRNA targets, it is crucial to understand the changes of the proteome in 
the absence of FMRP. As multiple FMRP-regulated proteins are involved in conserved 
neuronal signal transduction pathways, it is also necessary to study FMRP-dependent 
changes in the phosphoproteome dynamics. In my thesis I applied mass spectrometry-
based proteomics to address several aspects of the disorder in different FXS models, such 
as Fmr1-KO cell lines and mice.   
To analyze the influence of FMRP on major signal transduction networks, I first 
performed a global analysis of the proteome and phosphoproteome of  Fmr1- and Fmr1+ 
mouse embryonic fibroblast (MEF) cell lines using stable isotope labeling by amino acids 
in cell culture (SILAC) and high resolution mass spectrometry. In this study I detected 
6,703 proteins and 9,181 phosphorylation events, and mapped 266 significantly 
changing proteins and 142 phosphorylation sites onto major signal transduction 
pathways. My results confirmed a downregulation of the MEK/ERK pathway in absence 
of FMRP, with decreased phosphorylation on ERK1/2. Several proteins involved in mTOR, 
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Wnt, p53 and MAPK signaling cascades were also significantly regulated; they were 
previously shown to be associated with autism, but not with FXS. Additionally, I detected 
a significant increase of p53 and proteins linked to p53 signaling, as well as a decreased 
level of the major prion protein (Prp) in Fmr1- cells. Decreased p53 signaling is the likely 
cause for previously observed dysregulation of cell cycle control in FXS, whereas reduced 
levels of Prp could contribute to the cognitive deficits observed in the FXS patients. These 
proteins and signal transduction pathways may represent novel targets for treatment of 
FXS symptoms. 
In the second part of the thesis, I used the same MEF cell line in order to analyze potential 
substrates of glycogen synthase kinase 3β (GSK-3β), an emerging therapeutic target for 
treatment of FXS. I used two inhibitors of GSK3-β kinase, lithium and TDZD-8, to identify 
potential substrates of the kinase in Fmr1- and Fmr1+ cells. Lithium treatment was poorly 
reproducible on the proteome and phosphoproteome level, reflecting its reported low 
specificity for GSK3- β, whereas TDZD-8 treatment showed good reproducibility between 
biological replicates. Of a total of 7,285 detected phosphorylation events, 91 were 
significantly decreased upon TDZD-8 treatment in Fmr1+ and 146 in Fmr1- MEF cells – 
these phosphorylation events were likely targets of GSK-3β. Overlap of these potential 
substrates was poor in Fmr1+ and Fmr1- cells, pointing to different substrates of the GSK-
3β kinase in Fmr1+ and Fmr1- MEF cells. Importantly, downregulation of multiple 
phosphorylation events on MAP1B, a well characterized GSK-3β substrate whose mRNA 
is a known FMRP target, was observed only in Fmr1+ MEF cell line. In healthy neurons, 
MAP1B is coordinating microtubule dynamics. Since abnormal axon branching is one of 
the leading symptoms of FXS, I postulate that the lack of regulation of MAP1B by GSK-3β 
is the likely cause for aberrant morphology of neurons in FXS. Functional enrichment 
analysis revealed an implication of the potential GSK-3β substrates in different processes 
in MEF cell lines. For example, in Fmr1- MEFs potential substrates seem to be more 
involved in cell cycle, DNA replication and RNA processing. Since downregulation of DNA 
damage/repair pathway in FXS patients was recently reported, this data will shed new 
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light on differential activity of GSK-3β in Fmr1+ and Fmr1- MEF cells and deepen our 
understanding of molecular mechanisms regulated by this kinase. 
In the third part of my thesis, I postulated that increased protein synthesis in FXS is 
accompanied by increased protein degradation in order to maintain cellular 
homeostasis.  Since increased protein synthesis and degradation lead to increased 
protein turnover, I used stable isotope labeling (“dynamic SILAC” approach) to measure 
protein turnover rate in mouse primary cortical neurons derived from the WT and Fmr1-
KO model. Analysis showed that most of the proteins have a similar half-life in WT and 
Fmr1-KO, although calculated median protein half-life was higher in Fmr1-KO neurons 
than in WT. Functional enrichment analysis showed that proteins with the lowest 
turnover rates are involved in oxidative phosphorylation, Alzheimer’s, Parkinson’s and 
Huntington’s diseases, whereas proteins with the highest turnover rates are involved in 
phagosome, Wnt signaling pathway and gap junction, for both, WT and Fmr1-KO 
neurons. The experimental design employed did not allow for detection of low SILAC 
incorporation rates and proteins with very short half-lifes and further optimization of 
experimental conditions is needed to fully address differences in protein turnover 
between Fmr1-KO and WT cells.  
In the fourth and final part of the thesis, I investigated molecular mechanisms of the 
genetic “rescue” of the FXS, recently reported to occur in Fmr1-KO mice after reduction 
of activity of the mGluR5 receptor. To that end, I performed a proteome-wide 
quantitative comparison of protein levels in the hippocampi between WT, Fmr1-KO mice 
and Fmr1-KO/mGluR5-het cross mice (the “rescued” FXS model), obtained from the 
laboratory of Mark Bear (MIT). Pearson correlation of protein intensities showed good 
technical reproducibility between biological replicates and also showed that different 
genotypes are very similar to each other – of 5,238 detected proteins, only about 198 
were significantly changing between genotypes. Yet, pairwise comparison of Fmr1-KO 
and WT revealed proteins that are known to be involved in memory, learning and long 
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term potentiation. Moreover, the data suggests disturbed mitochondrial transcription 
regulation in FXS model. One of the significantly changing proteins, the major prion 
protein, had a lower expression level in Fmr1-KO in comparison with WT. Since I detected 
the same expression pattern in MEF cell lines, I postulate that Prp plays a significant role 
in FXS pathogenesis. In the FXS rescue model, most of the significantly changing proteins 
are involved in metabolic processes, with the exception of Citron Rho-interacting kinase 
which is functionally linked to Fmr1 gene and it is interacting with mGluR5 receptor, and 
therefore may be involved in the rescue mechanism. I also addressed absolute protein 
levels in analyzed mouse models. This approach showed no difference in the total 
proteome abundance between the three genotypes; however, it did show that proteins 
with higher upregulation levels in Fmr1-KO are more abundant that those that were 
found to be downregulated. This imbalance may be the cause of the overall increased 
protein levels previously detected in brains of FXS mice. However, a portion of changing 
proteins is rather small and therefore not significant and further experiments need to be 
performed to address this.  
Overall, this thesis presents an extensive proteomics analysis of the different cellular and 
animal models of FXS. Combined, these approaches compile a substantial source of 
information for the FXS research community. In addition, this data is contributing to the 
better understanding of FXS pathophysiology and development of a potential new 
treatments.   
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ZUSAMMENFASSUNG 
Das Fragile X Syndrom (FXS) ist die Hauptursache bei erblich bedingter geistiger 
Behinderung (ID) sowie bei Autismus. Diese Entwicklungsstörung des Nervensystems 
wird durch Ausschalten des FMR1 Gens und das Fehlen seines Produkts, des Fragile X 
Mental Retardation Proteins (FMRP), ausgelöst. FMRP, ein RNA-bindendes Protein, liegt 
im Gehirn hoch exprimiert vor und spielt beim Transport und bei der Translation vieler 
verschiedener Ziel-mRNAs eine bedeutende Rolle. Das Fehlen von FMRP führt zur 
Zerstörung der Morphologie und Funktion der Synapsen, wie auch zur Zerstörung der 
synaptischen Plastizität. Diese molekularen und synaptischen Anomalien führen zu FXS 
Symptomen wie ID, Autismus, Hyperaktivität, Epilepsie und Angstzuständen. Das 
Verständnis der molekularen Pathogenese des Fragile X Syndroms ist deshalb nicht nur 
relevant für die FXS Patienten, sondern auch für andere Entwicklungsstörungen des 
Nervensystems und psychiatrische Erkrankungen. In den letzten zwei Jahrzehnten 
führten umfassende Grundlagenforschungen in der Neuro- und Pathophysiologie zu 
signifikanten Fortschritten im FXS-Bereich.  Obwohl die Ursache nur an einem einzelnen 
Gen liegt, ist der molekulare Mechanismus von FXS noch wenig erforscht. Seitdem FMRP 
als Translationsregulator zahlreicher Ziel-mRNAs beschrieben ist, ist es unumgänglich ein 
Verständnis über die Änderungen im Proteom bei Abwesenheit von FMRP zu erlangen. 
Da viele FMRP-Zielmoleküle in konservierten neuronalen Signaltransduktionswegen 
eingebunden sind, ist es auch wichtig, FMRP-abhängige Veränderungen in der Dynamik 
des Phosphoproteoms zu studieren. In meiner Dissertationsarbeit führte ich 
Massenspektrometrie-basierende Proteomanalysen durch, um verschiedene Aspekte 
einer Störung in verschiedenen FXS-Modellen, wie Fmr1-KO Zelllinien und Mäuse, zu 
untersuchen. 
Um den Einfluss von FMRP auf die wesentlichen Signalübertragungsnetzwerke zu 
analysieren, führte ich zuerst, unter Verwendung von SILAC (Stable Isotope Labeling by 
Amino Acids in Cell Culture) und hochauflösender Massenspektrometrie, eine 
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umfassende Analyse des Proteoms und des Phosphoproteoms von Fmr1-- und Fmr1+- 
embryonalen Maus-Fibroblastenzelllinien (MEF) durch. Bei dieser Studie detektierte ich 
6 703 Proteine und 9 181 Phosphorylierungsstellen, darunter 266 Proteine und 142 
Phosphorylierungsstellen, die   signifikant reguliert waren und in wichtigen 
Signaltransduktionswegen vorkommen. Meine Ergebnisse bestätigten eine 
Herunterregulierung des MEK/ERK-Signalweges mit verminderter Phosphorylierung von 
ERK1/2 bei Abwesenheit von FMRP.  
Auch viele in mTOR-, Wnt-, p53- und MAPK-Signalkaskaden involvierte Proteine waren 
signifikant reguliert; sie waren zuvor mit Autismus, aber nicht mit FXS in Zusammenhang 
gebracht worden. Außerdem detektierte ich sowohl einen signifikanten Anstieg von p53 
und von Proteinen, die mit dem p53-Signalweg in Verbindung stehen, als auch einen 
verminderten Expression von wichtigen Prionproteinen (Prp). Der abgeschwächte p53-
Signalweg ist vermutlich der Grund für die zuvor beobachtete Fehlregulation der 
Zellzykluskontrolle in FXS, dahingegen könnte ein verminderter Prp-Anteil zu den in FXS-
Patienten beobachteten kognitiven Mängeln beitragen. Diese Proteine und 
Signaltransduktionswege können neue Zielstrukturen für die Behandlung von FXS-
Symptomen sein. 
Im zweiten Teil meiner Dissertationsarbeit verwendete ich dieselbe MEF-Zelllinie, um 
potentielle Substrate der Glykogen-Synthase-Kinase 3β (GSK-3β), ein neu 
aufkommendes therapeutisches Zielmolekül zur Behandlung von FXS, zu untersuchen. 
Ich verwendete zwei Inhibitoren der GSK3-β-Kinase, Lithium und TDZD-8, um mögliche 
Substrate der Kinase in Fmr1-- und Fmr1+-Zellen zu identifizieren. Die Behandlung mit 
Lithium war sowohl auf Proteom-, als auch auf Phosphoproteomebene schlecht 
reproduzierbar, was seine bereits bekannte geringe Spezifität gegenüber GSK3- β 
widerspiegelt, während die Behandlung mit TDZD-8 eine gute Reproduzierbarkeit 
zwischen biologischen Replikaten zeigte. Unter insgesamt 7 285 detektierten 
Phosphorylierungsstellen waren nach TDZD-8-Behandlung 91 in Fmr1+- und 146 in Fmr1-
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-MEF-Zellen signifikant zurückgegangen – diese Phosphorylierungsstellen waren 
wahrscheinlich GSK-3β-Targets. Die geringe Überlappung dieser potentiellen Substrate 
in Fmr1-- und Fmr1+-Zellen deutet auf verschiedene Substrate der GSK3- β-Kinase in 
Fmr1+- und Fmr1--MEF-Zellen hin. Nennenswert ist, dass die Herunterregulierung 
mehrerer Phosphorylierungsstellen auf   MAP1B, einem gut beschriebenen Substrat der 
GSK3β, dessen mRNA als ein Zielmolekül von  FMRP bekannt ist, nur in der  Fmr1+ -MEF-
Zelllinie gesehen wurde. In gesunden Neuronen koordiniert MAP1B die Mikrotubuli-
Dynamik. Da die abweichende Verzweigung der Axone eines der führenden FXS-
Symptome ist, postuliere ich, dass die fehlende Regulation von MAP1B durch GSK-3β der 
mögliche Grund für die abweichende Morphologie der Neuronen in FXS ist. Eine 
Anreicherungsanalyse auf funktionaler Ebene zeigte die Auswirkung potentieller GSK-3β-
Substrate in verschiedenen MEF-Zelllinien. Zum Beispiel scheinen in Fmr1- -MEFs die 
potentiellen GSK-3β-Substrate mehr im Zellzyklus, in der DNA-Replikation und in der 
RNA-Prozessierung involviert zu sein. Da kürzlich von einer Herunterregulation des DNA-
Schädigung/-Reparatur-Systems in FXS-Patienten berichtet wurde, werden diese Daten 
Aufschluss über verschiedene Aktivitäten der GSK-3β in Fmr1+- und Fmr1--MEF-Zellen 
liefern und unser Verständnis für den, durch diese Kinase regulierten, molekularen 
Mechanismus vertiefen. 
Im dritten Teil meiner Dissertationsarbeit postuliere ich, dass die gesteigerte 
Proteinsynthese in FXS durch eine erhöhte Proteindegradierung begleitet wird, um die 
zelluläre Homöostase zu erhalten. Da eine erhöhte Proteinsynthese und –degradation zu 
einem erhöhten Proteinumsatz führt, verwendete ich die stabile Isotopenmarkierung 
(dynamischer SILAC-Versuch), um die Proteinumsatzrate in primären kortikalen 
Neuronen von WT-und Fmr1-KO-Mausmodellen zu messen. Die Analyse zeigte, dass die 
Mehrzahl der Proteine ähnliche Halbwertszeiten im WT und im Fmr1-KO haben, obwohl 
die berechnete mediane Proteinhalbwertszeit in Fmr1-KO-Neuronen  höher war als im 
WT. Eine Anreicherungsanalyse auf funktionaler Ebene zeigte, dass die Proteine mit den 
niedrigsten Umsatzraten in oxidativen Phosphorylierungsprozessen, Alzheimer-, 
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Parkinson- und Huntington-Erkrankungen beteiligt sind, während die Proteine mit den 
höchsten Umsatzraten im Phagosom, Wnt-Signalweg und Gap Junction involviert sind. 
Diese Ergebnisse waren konsistent in WT und Kmr1-KO Neuronen. Das angewendete 
Versuchskonzept gestattete nicht die Detektion geringer SILAC-Inkorporationsraten und 
Proteine mit sehr kurzen Halbwertszeiten, d.h. es ist eine weitere Optimierung der 
experimentellen Konditionen nötig, um Unterschiede in der Proteinumsatzrate zwischen 
Fmr1-KO- und WT-Zellen vollständig zu erfassen. 
Im vierten  und letzten Teil meiner Dissertation untersuchte ich den molekularen 
Mechanismus des genetischen “Rescues” von FXS, von dem kürzlich berichtet wurde, 
dass er in Fmr1-KO-Mäusen nach Reduktion der Aktivität des mGluR5-Rezeptors  
aufgetreten sei. Zu diesem Zweck führte ich eine proteomweite, quantitative 
Vergleichsstudie der Proteingehalte zwischen den Hippocampi von WT- und Fmr1-KO-
Mäusen und Fmr1-KO/mGluR5-het gekreuzten Mäusen (FXS-“Rescue”-Model) durch. 
Die Mäuse kamen  aus dem Labor von Mark Bear (MIT).  Die Pearson-Korrelation 
demonstrierte eine gute Reproduzierbarkeit zwischen den biologischen Replikaten und 
zeigte außerdem, dass verschiedene Genotypen zueinander sehr ähnlich sind – von 5 238 
detektierten Proteinen zeigten nur 198 signifikante Unterschiede zwischen Genotypen. 
Dennoch legten paarweise Vergleiche von Fmr1-KO und WT Proteine offen, von denen 
bekannt ist, dass sie eine Funktion im Gedächtnis, beim Lernen und bei der 
Langzeitpotenzierung haben. Darüber hinaus deuten die Daten auf eine gestörte 
mitochondriale Transkriptionsregulation im FXS-Model hin. Eines der signifikant 
regulierten Proteine, das maßgebliche Prionprotein, zeigte im Vergleich zum WT ein 
niedrigeres Expressionslevel in Fmr1-KO. Da ich das gleiche Expressionsmuster in MEF-
Zelllinien detektierte, postuliere ich, dass Prp eine signifikante Rolle in der  FXS-
Pathogenese spielt. Im FXS-“Rescue”-Model sind die meisten signifikant regulierten 
Proteine in metabolische Prozesse involviert. Ausnahme ist die Citron-Rho-
interagierende Kinase, die funktional mit dem Fmr1-Gen verbunden ist und mit dem 
mGluR5-Rezeptor interagiert und damit in den “Rescue”-Mechanismus involviert sein 
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kann. Ich habe auch den absoluten Proteingehalt in den analysierten Mausmodellen 
bestimmt. Dieser Versuch zeigte keinen Unterschied in den gesamten Proteinmenge 
aller drei Genotypen, aber er zeigte, dass Proteine mit höherer Expressionsrate in Fmr1-
KO mehr vertreten sind, als jene mit niedrigerer Expressionsrate. Dieses Missverhältnis 
kann die Ursache für den allgemeinen Anstieg des, zuvor in Gehirnen von FXS-Mäusen 
detektierten, Proteingehalts sein. Jedoch ist der Anteil regulierter Proteine ziemlich 
gering und daher nicht signifikant. Um weiter Erkenntnisse zu erlangen, müssen weitere 
Experimente durchgeführt werden  
In ihrer Gesamtheit demonstriert diese Dissertationsarbeit eine umfangreiche 
proteomische Analyse verschiedener zellulärer und tierischer FXS-Modelle. 
Zusammenfassend lässt sich sagen, dass diese Experimente zur Erstellung einer 
umfangreichen Informationsquelle für die FXS-Forschungsgemeinschaft beigetragen 
haben. Außerdem leisten diese Daten einen Beitrag zum besseren Verständnis der 
Pathologie bei FXS und zur Entwicklung potentiell neuer Behandlungsstrategien.   
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I INTRODUCTION 
In an era where medical science has succeeded in curing patients from a variety of 
diseases through breakthroughs in understanding of the fundamental mechanisms of 
biological systems, it is fascinating to reflect on how much information is still relatively 
unknown within certain biological disciplines. One of areas that reflect this notion is in 
the field of neuroscience: in this broad and complex discipline, the amount of 
information is exponentially growing and to follow up on all of these different avenues 
makes for a very daunting task. One broad area of neuroscience are neurodevelopmental 
disorders (NDDs), which are not only medically relevant but also present a platform to 
understand basic principles of neuronal development and biology. Here I focus on Fragile 
X syndrome, a rare NDD linked to a severe dysregulation of protein synthesis in neurons, 
whose connection to other neurodevelopmental disorders, especially autism, makes it a 
relevant and interesting disorder to study the molecular pathogenesis mechanisms 
relying on protein homeostasis in the brain.  
 
I.1. Fragile X Syndrome 
Fragile X syndrome (FXS), also known as Martin Bell or Escalante’s syndrome, was first 
described in 1943, when Martin and Bell described a family in which, as they believed, 
intellectual disability was transmitted in an X-linked manner [1]. FXS affects 
approximately 1:5000 males and 1:10,000 females worldwide [2]. Although it is classified 
as a rare disorder, it is the most common form of hereditary intellectual disability [2] and 
has been connected to a plethora of other neurodevelopmental disorders [3-6], 
including autism [6]. Its X-linked recessive inherited form of intellectual disability was 
first identified in 1969 when Lubs observed constriction in the end of the long arm of the 
X chromosome in four members of the same family (Figure I.1) [7].  Approximately 15 
years later, observed constriction of the fragile site was localized to the chromosome 
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band Xq27.3 [8]. In 1991, the corresponding gene was identified and named the Fragile 
X mental retardation 1 (Fmr1) [9].  
 
 
Figure I.1 | Normal and Fragile X chromosome. Fragile X chromosome has a fragile site in the end of the 
long chromosome arm (Xq27.3) that appears to have a constriction upon microscopic observation. (Source: 
www.geneticsperiod4.wikispaces.com/Fragile-X%20Syndrome). 
 
Expansion of the Fmr1 gene is the main cause of the disorder. In the 5’ untranslated 
region of the gene, normal individuals have approximately 5-50 CGG trinucleotide 
repeats. Individuals with ~ 50-200 CGGs repeats are classified as premutation carriers 
[10], with increased Fmr1 transcripts, but decreased levels of Fragile X mental 
retardation protein (FMRP) [11, 12]. If the number of the CGG repeats exceeds 200, the 
gene becomes hypermethylated, resulting in transcriptional silencing and lack of FMRP 
[9, 13]. This condition is defined as a full mutation [10] (Table I.1). Around 15 % of male 
patients have incomplete or partial methylation which normally leads to reduced 
production of FMRP and a milder degree of the symptoms [14, 15]. In very rare cases, 
apart from the CGG repeat expansion, FXS can be initiated through deletions [16-19] and 
point mutations [20] that lead to the production of the nonfunctional protein.  
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Table I.1 | Number of CGG repeats from normal individual to the FXS patient. 
 
 
Number of CGG trinucleotide 
repeats 
Normal 5-50 
Premutation 50-200 
Full mutation >200 
 
Individuals affected by FXS show different symptoms that are typically patient-specific. 
The most prominent symptom is mild to severe intellectual disability (ID) [21-23]. Other 
developmental symptoms include memory and learning difficulties [24], decreased 
motor function, and speech impairment [13, 25, 26]. Some individuals show behavioral 
and emotional features such as attention deficit and hyperactivity [27], anxiety [28] and 
autistic behavior (in ca. 30% of cases) [29]. Furthermore, in ca. 20% of cases this disorder 
is characterized by seizures [30, 31] and sensory integration problems (Figure I.2). The 
most prominent physical symptom of FXS is macroorchidism [32]. Others may include 
long narrow face with prominent jaw and ears [33, 34], hypotonia, increased joint laxity 
and high palate [13, 25, 26], but  the physical phenotype is not necessary present. 
Although FXS affects both genders, females tend to have milder symptoms than males. 
This comes from the fact that females have another X chromosome with normal Fmr1 
gene that can produce some FMRP. For example, around one third of females with a full 
mutation do not show any sign of cognitive impairment, while others have mild  to severe 
cognitive, behavioral or social difficulties [35].  
 
I.1.1. FMRP and its function 
Fmr1 gene encodes for FMRP, a highly conserved RNA-binding protein. In various tissues, 
as a result of alternative splicing, Fmr1 can produce 12 protein isoforms with molecular 
weight between 67-80 kDa [36]. 
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Figure I.2 | Percentage of children with FXS and co-occurring conditions. (Source: 
http://www.cdc.gov/ncbddd/fxs/data.html and [37]). 
 
Expression of the different FMRP isoforms is not tissue-specific [36], although FMRP is 
highly abundant in the brain and testis [38]. In the brain, it is primarily expressed in 
neurons and it is predominantly located in the cytoplasm [38]. FMRP has several 
functional domains that are capable to bind mRNA. The central region of the protein 
contains two K Homology domains (KH1 and KH2) and the C–terminal end has arginine-
glycine-glycine (RGG) box [39]. FMRP contains a nuclear localization signal (NLS) and 
although it is mainly localized in cytoplasm, some isoforms can shuttle between the 
nucleus and cytoplasm [40]. Through its domains, FMRP binds approximately 4% of 
mRNA in a mammalian brain [41] and has been associated with actively translating 
polyribosomes [42, 43]. It is believed that FMRP is suppressing translation by stalling 
ribosomal translocation on their respective mRNA targets (Figure I.3) [44]. 
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Therefore, FMRP has an important role towards the regulation of protein synthesis and 
neuronal development [45].  
 
 
Figure I.3 | Model of translational suppression via FMRP. A) Process of active translation in which mRNAs 
are translated into protein. The small ribosomal subunit (40S) binds to an AUG codon on the mRNA and 
recruits the large ribosomal subunit (60S). Translation is complete when ribosomes dissociate at the stop 
codon (UAG). B) Translation is repressed by FMRP, on specific mRNAs, in a complex that includes target 
mRNA and a few condensed ribosomes (adopted and modified from [46]) . 
 
A recent study, using HITS-CLIP (high-throughput sequencing of RNA isolated by 
crosslinking and immunoprecipitation) method based on ultraviolet (UV) covalent cross-
linking of mRNA and mRNA binding protein, followed by immunopercipitation and 
sequencing technologies [47], identified more than 800 mRNA targets of FMRP  and 
interestingly, these targets seem to be equally represented in the pre- and postsynapse 
[44]. Another study used PAR-CLIP (photoactivatable ribonucleoside-enhanced 
crosslinking and immunoprecipitation) method based on incorporation of photoreactive 
ribonucleoside analog – 4-thiuridine into RNA transcripts which after UV irradiation 
crosslink with RNA – binding proteins and therefore can be immunoprecipitated. In this 
study more of 8,000 mRNA targets for FMRP was identified [48]. Reported numbers of 
mRNA targets of FMRP seem to be quite high, implicating that FMRP could bind more 
than one third of total mRNA, questioning the specificity of the detected interaction. 
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Moreover, recently published work showed that reported targets disproportionally 
represent the most abundant mRNAs and mRNAs with the longest coding sequence [49].  
 
I.1.2. Translational regulation of FMRP 
In the absence of FMRP, translation is dysregulated and protein synthesis is elevated. It 
is believed that this dysregulation is the main cause of the symptoms in fragile X patients. 
Several studies of the fragile X mouse model have shown that global cerebral protein 
synthesis is elevated in vitro and in vivo [10, 50, 51]. Thus far, it is unclear whether this 
elevated protein synthesis is arising from dysregulation of the primary mRNA targets of 
FMRP, or from a downstream secondary effect mediated by its targets. In addition, the 
prediction that some protein levels are high because of the loss of translational 
repression can be misleading because degradation mechanisms could restore protein 
levels to normal. Therefore, this data should be confirmed on the protein level. Modern 
proteomic workflows allow quantification of changes on the protein levels in a global 
and high throughput fashion. So far, several proteomic studies of FXS were performed. 
Quantitative proteomic analysis of synaptosomes from Fmr1-KO and WT cortical 
neurons revealed more than 100 proteins with altered expression in the absence of 
FMRP, including proteins related to autism and epilepsy [52]. Another study revealed 23 
proteins with differential expression involved in cell differentiation, neurite outgrowth, 
and synaptic vesicle release in the mice hippocampi [53], while heterozygous dfmr1 
Drosophila allowed profiling of 1,617 proteins [54]. 
 
I.1.3. FXS models 
During the past 20 years of FXS research, the research community has created more than 
20 distinct animal models and cell lines in order to study different aspects of this 
disorder. Diversity of these models is ranging from the Aplasyia model which was used 
to gain a better understanding of the associated memory and learning deficits, Gryllus 
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[55] and zebra finch [56] for speech related deficits, to Drosophila [57-59] and mouse 
models [60]. Of course, some of the models are controversial, but models such as 
Drosophila and especially mice are very well established and often used within the fragile 
X research community.  
Generation of the Fmr1-KO mouse in 1994 [60] created a reliable FXS model that 
recapitulates several cellular and behavioral phenotypes that are normally found in 
fragile patients, such as abnormalities in dendritic spine [61], hyperactivity, impairments 
in spatial learning and social behavior [62], audiogenic seizures [63, 64], and 
macroorchidism [60].  
Another important model used to answer fundamental molecular aspects are cell lines. 
For example, primary neurons were used to achieve a clearer  understanding of synaptic 
dysfunction in FXS [52]. Immortalized Fmr1-KO cell line, called STEK was established in 
2002. It was derived from Fmr1-KO mouse embryos and SV40-immortalized. This cell line 
was used to examine the role of FMRP as a transporter associated with mRNPs, 
translational repressor in stress granules and to investigate FMRP domains involved in 
polyribosomal association [65, 66]. Next generation of the STEK cell line was obtained in 
naturally immortalized Fmr1-KO mouse embryonic fibroblasts (MEFs) [67]. This cell line 
was used to identify novel FMRP mRNA targets [67, 68] and to identify dysregulated 
proteins and phosphorylation events (discussed later) in the absence of FMRP [69]. 
 
I.1.4. mGluR5 theory of FXS 
The concept that synapses are able to strengthen or weaken over time was first 
suggested by Santiago Ramón y Cajal in the end of 19th century [70]. Since then, the 
knowledge about synapses and their function have dramatically grown. Modification of 
the synapse in response to an increase or decrease in its activity is called synaptic 
plasticity [71]. Two mechanisms are underlying this process – long term potentiation 
(LTP) and long-term depression (LTD). Long lasting neuronal changes caused by LTP or 
LTD are dependent on two synaptic activity processes: local protein synthesis driven by 
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translation of existing mRNAs and new protein synthesis through transcription and 
translation [72].  All changes are mainly caused by the release of the neurotransmitter 
glutamate and response of the ionotropic glutamate receptors, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA) and 
metabotropic glutamate receptors (mGluRs). 
Today, two forms of LTD are known: LTD activated by postsynaptic NMDA receptors and 
LTD dependent on the group1 mGluR activation [73]. While both LTDs require long term 
protein synthesis, LTD dependent on the mGluR activation requires local protein 
synthesis as well [74, 75]. In 1997 it was shown that FMRP is synthesized in response to 
mGluR5 activation [76], while later it was suggested that FMRP binds mRNA of mGluRs 
and inhibits their translation [50, 77]. The study of the Fmr1 knockout mouse suggests a 
connection between the exaggerated mGluR5 signaling and FXS [78]. This was confirmed 
by two approaches – pharmacological and genetic. Upon treatment of Fmr1-KO mice 
with mGluR5 antagonists such as MPEP and Fenobam [78-80], reversal of many FXS 
abnormalities was achieved. In genetic approach, Fmr1 mutant mice with reduced 
mGluR5 expression (Fmr1-KO/mGluR5 het KO cross – genetic rescue model) showed 
correction of most of the symptoms like seizures, hippocampal synaptic plasticity, ocular 
dominance plasticity, protein synthesis, and dendritic spine density [78]. The fact that 
most of the FXS symptoms can be explained by increased LTD and a consequent increase 
in protein synthesis was coined as the mGluR5 theory of FXS (Figure I.4) [81, 82]. This 
theory led to an intriguing concept that FXS and related genetic disorders (including to a 
certain extent autism), could be treatable by mGluR5 antagonists. 
 
I.1.5. Role of Glycogen synthase kinase in FXS 
Glycogen synthase kinase 3 (GSK-3) is a serine/threonine kinase, encoded by two genes, 
GSK-3α and GSK-3β [83]. Both genes are  ubiquitously  expressed, but GSK-3β is 
prevalently expressed in the brain [84].   
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Figure I.4 | mGluR theory. A) In a normal translational process, mGluR5 has an increasing translation rate, 
while FMRP is repressing it; B) In FXS, the lack of FMRP causes an increase in the translation rate; C) When 
mGluR5 expression is reduced upon lack of FMRP, the translational rate reverts back to the normal rate. 
  
While kinase activation can be enhanced by phosphorylation on tyrosine 279 in GSK-3α 
and tyrosine 216 in GSK-3β [85], main regulation is driven by inhibitory phosphorylation 
on serine 21 in GSK-3α   and serine 9 in GSK-3β [86].  
GSK-3 plays an important role in various neurophysiological processes, such as 
neurogenesis, gliogenesis, cell migration, cell morphology, and axonogenesis [87], as a 
part of Wnt signaling pathway, sonic hedgehog (SHH), Notch pathway [87] and different 
apoptotic pathways [88]. Therefore, it is not surprising that GSK-3 has an impact in the 
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pathophysiology of multiple disorders, such as mood disorders, Alzheimer’s disease, 
diabetes and cancer, and was recently implicated to be involved in general inflammation  
[85]. Increased activation of GSK-3β has been found in the FXS mouse model and this 
activity is associated with excessive mGluR5 signaling [89]. Using lithium (unspecific GSK-
3β inhibitor), significant improvement was accomplished in Drosophila and mouse FXS 
models [90]. Therefore, more effort has been directed towards the inhibition of GSK-3β 
as a potential avenue for FXS treatment. Today, there are lot of potential inhibitors of 
GSK-3β [86].  However, lithium is a preferred choice since it has been used as a mood 
stabilizer to treat bipolar disorders for over 50 years. Although the therapeutic 
mechanisms are not completely understood, it was shown that lithium can reverse 
mGluR-dependent LTD [91], hyperactivity [92], learning deficits, dendritic spine shape, 
anxiety [93] and macroorchidism [94]. Unfortunately, unspecific binding of lithium can 
also cause a variety of side effects. In order to reduce side effects, more specific 
inhibitors were developed, such as thiadiazolidinone (TDZD) derivates. TDZD families are 
non-adenosine triphosphate (ATP) competitive GSK-3 inhibitors that bind to unique 
regions within the kinase. One of them, TDZD-8, has been shown to increase the 
inhibitory serine 9 phosphorylation on GSK-3β and specifically inactive the kinase [95]. 
 
I.2. Biological function of proteins 
I.2.1. Proteome 
Genome sequencing opened a new window within biology. While it is essential to 
understand the genome architecture, it is also important to keep in mind that during 
development the genome is static, but its expression, as measured by the levels of its 
products (RNA and proteins), is dynamic [96]. Transcription and degradation of mRNA as 
well as protein synthesis and degradation play an essential role towards the 
understanding of biological processes. It is clear that studying these molecules one at a 
time is not satisfactory, especially when considering that the number of proteins and 
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their variants is much larger than the number of genes. Therefore, the concept of the 
proteome, all proteins that are expressed by the genome in a cell, tissue or an organism 
at a certain time point or under certain conditions, was proposed in 1995 [97]. The 
research field that studies the proteome is called proteomics and  is used to investigate 
protein function, protein-protein interactions and post-translational modifications 
(PTMs) [98].  
 
I.2.2. Protein modifications 
One primary factor contributing to protein diversity is the result of covalent post-
translational amino acid modifications [99]. The possibility to add modifications opens 
the space for various protein functions such as change in protein activity, cellular 
localization and protein-protein interaction [100]. Since the proteome is dynamic, 
different stimuli can change cellular activity which is often driven by protein 
modifications. The knowledge about the spectrum of different modifications is growing 
rapidly. For example, it is estimated that around 5% of the human proteome consists of 
enzymes [101] that are able to attach more than 200 known post-translational 
modifications [102]. Until recently, it was considered that protein modifications are 
independent off each other. However, it is becoming increasingly evident that crosstalk 
between different modifications can be responsible for the overall cellular activity within 
a certain state [103].  
Protein modifications can be both reversible and irreversible. A classic example of a 
reversible modification is the activation or deactivation of kinases in cellular pathways 
that leads to the addition or removal of phosphate groups. Irreversible modifications 
usually involve proteolytic cleavage, for example in the insulin case when proinsulin is 
cleaved to become active insulin [100]. Since PTMs are very important in protein 
function, any misbalance can lead to improper cellular function or disease. Considering 
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that PTMs cannot be studied at the genome or transcriptome level, mass spectrometry 
has become a powerful tool for both the detection and quantification of PTMs. 
 
I.2.2.1. Protein phosphorylation 
Knowledge about protein phosphorylation as a regulatory physiological mechanism 
originates back to 1955 [104].  Today, this is one of the most important and well-studied 
reversible modifications. It occurs in both prokaryotes and eukaryotes. In eukaryotes 
protein phosphorylation typically occurs on serine, threonine, tyrosine and, to a smaller 
extent, on histidine residues. Prokaryotic organisms predominantly employ histidine and 
aspartate phosphorylation which serves as the hallmark of prokaryotic cell signaling, 
known as two component signal transduction. In addition, phosphorylation of cysteine, 
arginine and lysine was reported, but its function remains unclear [105-108]. Regulation 
of phosphorylation is carried out by two enzymes – a kinase that phosphorylates in an 
almost exclusively conserved mechanism with adenosine triphosphate (ATP) as a 
phosphate group donor; and phosphatase that dephosphorylates proteins.  The 
importance of this modification stems from the fact that it plays a role in many different 
processes such as  cell cycle control, receptor-mediated signal transduction, 
differentiation, proliferation, transformation, and metabolism, therefore its ability to 
regulate different enzymes and receptors in a rapid fashion can be crucial in many 
pathological states [109]. It has been estimated that in eukaryotes, more than a third of 
the proteome is phosphorylated and that about 520 protein kinases are responsible for 
more than 700,000 phosphorylation events [110].  
The low abundant nature of protein phosphorylation  adds an extra challenge towards 
its identification due to fact that phosphorylated proteins are mostly present in a small 
fraction of total proteins [111]. Thus, phosphoprotein and phosphopeptide enrichment 
strategies have to be employed in order to study this modification. These include 
antibody-based enrichment [111], immobilized metal affinity chromatography (IMAC) 
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[112], strong cation exchange chromatography (SCX) [113] or titanium dioxide 
chromatography (TiO2) [114].  Depending on the complexity of the sample, peptides can 
be separated and enriched by SCX followed by TiO2 chromatography enrichment. 
Although challenging, phosphopeptide enrichment coupled with advanced MS 
technology is a primary choice for large scale analysis of the phosphoproteome.  
SCX is based on the difference in the solution charge states of phosphorylated and 
nonphosphorylated peptides. Its stationary phase is negatively charged, and it binds 
positively charged peptides. In acidic conditions, tryptic digested peptides carry on 
average a net charge of +2, due to protonation of N-terminal amino groups and the side 
chains of lysine and arginine. On the other hand, singly phosphorylated peptides carry 
net charge on average a net charge of +1 due to presence of negatively charged 
phosphate group. Therefore, singly phosphorylated peptides bound to the stationary 
phase will elute earlier than average unmodified peptides in a shallow salt gradient 
(Figure I.5)[115]. Consequently, phosphopeptides are enriched in the early SCX elution 
fractions. 
 
 
 
Figure I.5 | Cation exchange chromatography. Positively charged proteins/peptides bind negatively 
charged stationary phase, while negatively charged proteins/peptides are not binding. When all positively 
charged proteins/peptides are bound to the column, they can be eluted using the salt gradient. (Source: 
www.wikibooks.org).  
 
Positively charged proteins 
Negatively charged proteins 
Negatively charged beads 
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TiO2 is a type of metal oxide affinity chromatography which relies on high affinity 
absorption of the phosphate groups. In acidic conditions, TiO2 serves as an anion 
exchange column in which phosphopeptides are bound, and can be eluted under alkaline 
conditions. Next to phosphopeptides, acidic peptides are binding TiO2. To overcome this 
issue 2,5-dohydroxy benzoic acid (DHB) can be used due to the fact that it binds to TiO2 
stronger than acidic peptides, but weaker than phosphopetides (Figure I.6) [109].  
However, DHB can interfere with column separation efficiency and contaminate mass 
spectrometer. An alternative is to use high level of triflouroacetic acid (TFA) which can 
protonate acidic residues and overcome nonspecific binding to TiO2 [116]. 
 
 
 
 Figure I.6 | Depiction of TiO2 in complex with 2,5-dihydroxy benzoic acid (DHB). (adopted and modified 
from[109]) . 
 
I.2.3. Protein turnover 
Cells are living in a dynamic state in which proteins are constantly synthesized and 
degraded [117]. Protein synthesis and/or degradation can be changed due to a 
physiological, developmental or pathological state of the cell [118]. Thus, protein 
expression levels are reflecting the balance between these processes and their dynamic 
interplay is called protein turnover [119]. Until recently, gene expression at the mRNA 
level was used as an estimation of protein abundance. However, through the rise of new 
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techniques it became clear that this correlation is very variable and that the change in 
the protein abundance can be only partially explained by mRNA level [120].  
In early studies, detection of radioactive amino acids coupled with inhibition of protein 
synthesis was used to determine protein turnover. However, translational inhibition by 
actinomycin or cyclohexamide may not reflect turnover rate under physiological 
conditions due to their toxicity and possible disruption in normal cellular activity [121]. 
In addition, tagging strategies together with western blotting and fluorescent detection 
techniques can be used. From a biological standpoint, tagging the protein could change 
its stability, but also time and cost investments are not negligible [122]. Recent advances 
in mass spectrometry combined with stable isotope labeling allows for the measurement 
of protein turnover, for example using dynamic stable isotope labeling by amino acids in 
cell culture (SILAC, see I.3.4.2. section for details).  
 
I.3. Mass spectrometry-based proteomics 
Understanding living organisms and their functions is essential in molecular bioscience. 
The central dogma of molecular biology demonstrates that a gene is transcribed into 
mRNA and mRNA is translated into a protein. However, this process is not 
straightforward: one gene can produce more than one protein due to alternative 
splicing, sequence polymorphisms and post-translational modifications [123].  
During the last two decades, the rise of high throughput "-omics" technologies has paved 
the way for major discoveries in systems biology. The first branch, genomics, can 
essentially map the entire genome of an organism. Furthermore, genes can have 
different expression patterns in different cell types and specific conditions. Technology 
that allows the analysis of gene expression (mRNA) is called transcriptomics. 
Complementary to genomics and transcriptomics is proteomics, which has become the 
method of choice to study gene expression at the protein level. Due to the rapid 
development in mass spectrometry (MS), MS-based proteomics has become the 
dominant technology for studying proteins, protein-protein interactions (PPIs) and post 
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translational modifications (PTMs), directly contributing to a better understanding of the 
organisms and their functions[124]. 
  
I.3.1. Shotgun proteomics 
Initial proteomic approaches used protein separation based on the charge and molecular 
weight, known as two-dimensional gel electrophoresis, which generates protein spots 
which can then be analyzed using MS. Due to limitations such as depth of coverage, low 
protein amount in a spot, a low dynamic range of detection and time consumption, 
further approaches were developed: top-down and bottom-up proteomics [125]. Top-
down proteomics typically uses the whole protein in analysis by MS, while in bottom-up 
or “shotgun” proteomics enzymatically digested proteins are measured by MS. The goal 
of the “shotgun” proteomics is to analyze the complex protein mixtures that are 
extracted from the cell or tissue, and digested by specific enzymes such as trypsin or 
LysC, using a combination of liquid chromatography and tandem mass 
spectrometry[126].  
 
I.3.2. Sample preparation and instrumentation 
For a long period of time,  MS was restricted to small and thermostable compounds due 
to lack of proper ionization techniques [127]. A breakthrough came with the 
development of two “soft” ionization techniques - electrospray ionization (ESI) and 
matrix assisted laser desorption/ionization (MALDI). These two ionization techniques 
introduced MS into protein research and were awarded a Nobel Prize in chemistry in 
2002. This advance made mass spectrometry the preferred method to gain key insights 
into the composition, regulation and function of molecular complexes and pathways 
[128]. Modern mass spectrometers are measuring the mass-to-charge ratio (m/z) of the 
compounds in the sample. Measuring the mass of intact proteins is more challenging 
than measuring the mass of peptides. MS is less sensitive for the proteins as they are 
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more difficult to separate, ionize and analyze in a mass spectrometer then peptides. In 
addition, complex mixtures of multiply charged protein molecules can lead to identical 
masses for two or more different proteins [129]. Thus, a “shotgun” proteomic approach 
is the most suitable for robust protein identification. In this approach, proteins are 
extracted from a biological sample (tissue or cell culture) and digested to peptides, which 
are typically 10-20 amino acids long. Complexity of the resulting peptide mixture can be 
reduced by various separation techniques, such as isoelectric focusing of peptides 
according to their isoelectric point (pI) [130]. Alternatively, 1D SDS-PAGE separation can 
be performed before in-gel protein digestion [131], and extraction of peptides for LC-MS 
analysis. Peptides resulting from protein digestion are typically loaded onto a nanoscale 
HPLC column filled with reversed-phase material, and eluted according to their 
hydrophobicity in a gradient of increasing organic solvent. After elution, peptides are 
ionized and measured by MS (Figure I.7).  
 
I.3.3. Mass spectrometry and peptide fragmentation 
 
A mass spectrometer typically consists of three parts: an ion source, a mass analyzer and 
an ion detector. There are several types of ion sources, mass analyzers and ion detectors. 
Further description of a mass spectrometer is focused on the LTQ-Orbitrap system which 
is used to analyze all experiments described in this thesis.  
As previously mentioned, after elution from the HPLC column, peptides are ionized by 
electrospray ionization (ESI). ESI uses electrical potential to transfer ions from solution 
into the gas phase of the mass spectrometer. In ESI, eluting peptides are electrostatically 
dispersed through the application of high voltage. Next, the solvent is evaporated and 
charged peptide ions are produced [132]. Complex peptide mixtures, especially those 
derived by trypsin (that leaves positively charged residues at C termini) are commonly 
analyzed in the positive ion mode. Ions are entering the mass spectrometer through a 
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transfer capillary. In the vacuum system of the mass spectrometer, ions are guided by 
ion optics into the mass analyzer. To determine the m/z ratios of the intact peptide 
(precursor) ions, ions are trapped in an electrostatic field in the Orbitrap cell, and they 
move around central electrode.  
 
 
 
Figure I.7 | Common mass spectrometry- based proteomics workflow.  Proteins are extracted from the 
biological sample and digested by protease. Resulting peptide mixture can further be fractionated, or 
enriched in case of PTMs. Next, peptides are separated using reversed phase high performance liquid 
chromatography (HPLC) and subjected to mass spectrometry analysis. Mass of the peptide is recorded in 
high resolution full scan (MS) and fragmented in tandem mass spectrometry (MS/MS). MS precursor ion 
can be used to obtain quantification data, whereas MS/MS data is used to identify peptides. Further 
analysis is achieved using bioinformatics tools (adopted from [133]). 
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Frequencies of individual axial oscillations of peptide ions with different masses are 
detected by their current image and the produced signal is converted into a mass to 
charge spectrum using the Fourier transform algorithm [134]. Ionized peptides normally 
appear as isotopic clusters due to C12/C13 ratio [129]. These peaks are separated by 1 Da, 
which can be easily detected by the Orbitrap mass analyzer due to its high resolution and 
mass accuracy (Figure I.8).  
 
 
 
Figure I.8 | Schematic for the LTQ Orbitrap Elite hybrid mass spectrometer.  This mass spectrometer 
combines a linear ion trap and an Orbitrap mass analyzer (adopted and modified from [135]). 
 
 
In order to retrieve the information about primary structure (sequence) of the peptide, 
the most abundant ions are isolated, fragmented and recorded as MS/MS (tandem MS) 
spectra in process called dependent data analysis. Fragmentation of the isolated 
peptides is achieved by collision of the peptides with inert gas molecule (e.g. helium) in 
a process called collision induced dissociation (CID). The most common fragment ions 
generated by CID are b and y fragment ions (Figure I.9).  While a precursor ion spectrum 
(MS spectrum) is acquired in the Orbitrap, a MS/MS spectrum is usually acquired in the 
ion trap mass analyzer with high speed and sensitivity, but low resolution. High 
resolution MS and low resolution MS/MS approach is called “high-low” strategy.  
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Figure I.9 | Collision induced dissociation peptide fragmentation. Peptides can be fragmented into a, b-
and C ions on the N-terminal or x, y and z ions on the C terminal, respectively (adopted from [109]).  
 
Another possibility is to acquire MS/MS spectra in the Orbitrap analyzer using high 
energy collision dissociation (HCD) collision cell. In this approach both type of spectra are 
acquired at a high resolution and mass accuracy (“high-high” approach). It is important 
to have high resolution MS spectra in order to apply more stringent mass tolerance 
during database search, and therefore reduce the search space (the number of 
theoretical peptides sequences matched to measured MS spectra) and increase search 
accuracy and specificity. However, acquisition of high resolution MS spectra requires 
additional time, which may compromise sequencing speed. Therefore, acquisition of 
high or low resolution MS/MS spectra is usually a compromise between sequencing 
speed of the instrument and the quality of the acquired spectra.  
Today it would be impossible to manually process MS raw data due to tremendous 
amount of data acquired. Therefore, several computational tools for protein 
identification have been developed. Several different methods were proposed to assign 
an amino sequence to the MS spectrum, such as extracting the amino acid sequence 
from the fragmentation spectrum (de novo sequencing) or correlating to the spectra 
libraries [136]. However, most often acquired spectra are compared to theoretical 
spectra obtained by in silico digestion. Search engines use different algorithms for MS 
spectral matching based on probability scoring like Mascot [137] and Andromeda [138] or 
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cross-correlation (Sequest [139]). The MS spectrum is correlated to a theoretical peptide and 
the best statistical match allows the peptide to be identified [140]. These identifications can 
result in true and false positive matches, therefore they are evaluated with target-decoy-
based based approach [141]. Derived false discovery rate (FDR) helps to determine the 
number of false positive identifications in a dataset.  
 
I.3.4. Quantitative proteomics 
Although identification of proteins is important, it is not sufficient to completely 
understand biological processes. Understanding of protein dynamics in a cell over time 
or changes in functional perturbations is essential. The ability to determine protein 
abundance for thousands of identical proteins in different states, treatments, or 
perturbations can be measured by MS and makes proteomics method of choice for 
quantitative data. Two main approaches can be used in order to gain this information – 
labeling approach and label-free approach, which can result in relative or absolute 
quantitative data.  
 
I.3.4.1. Labeling techniques 
In order to detect the abundance level of a protein from different samples, peptides are 
differentially labelled by stable isotopes which can then be distinguished upon MS 
analysis. The labelled samples are mixed in equaimolar amounts and analyzed by MS. 
When all labeled forms of the peptide are observed, distinct by the mass difference 
introduced by labeling, respective signal intensities are compared and quantification 
(protein abundance levels) is achieved.   
Stable labeling can be introduced by chemical tagging, enzymatic labeling and metabolic 
incorporation [142, 143] (Figure I.10). 
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Figure I.10 | Labeling techniques in quantitative proteomics. Colors represents different experimental 
conditions. Depending on the used approach samples can be combined at different steps during sample 
preparation. Horizontal lines indicate combining the samples, while dashed lines pinpoint when 
experimental variation in sample preparation can occur (adopted from [144]). 
 
 
In chemical labeling approaches, samples can be labeled prior to or after protein 
digestion. For example, in isotope-coded affinity tags (ICAT) , the tag is covalently bound 
to free cysteines [145], while in tandem mass tags (iTRAQ or TMT) it is bound to primary 
amines [146, 147]. Transfer of “heavy” oxygen (18O) by a protease during protein 
digestion is the main enzymatic labeling strategy [148]. Frequently used metabolic 
labeling is based on incorporation of the labels into living cells by growing the cells in 
media supplemented with “heavy” stable isotopes. Additionally, metabolic labeling can 
be achieved through 15N labeling [149]. While 15N labeling is primarily used for microbes 
and plants, stable isotope labeling by amino acids [150] is the method of the choice in 
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mammalian systems [124]. Due to fact that labeling occurs in living cells, the accuracy of 
quantification will not be affected by errors introduced in sample preparation, since 
samples are combined directly after cell harvest.  
 
I.3.4.2. Stable isotope labeling by amino acids in cell culture (SILAC) 
SILAC is a very powerful and widely applicable metabolic labeling method in which two 
cell populations are grown in media containing either a “light” or “heavy” form of an 
amino acid. The “heavy” version of the stable amino acid isotope contains a fixed number 
of 13C, 15N and/or 2H atoms. Arginine and lysine are extensively used amino acids for two 
practical reasons: when performing a classical tryptic digest, we are ensuring that each 
tryptic peptide is going to have at least one isotope label, and it is crucial to use essential 
amino acids to ensure complete labeling of the proteins in the cell population. In classical 
cell culture, complete labeling (>95%) is achieved after 5-6 cells doublings. As mentioned 
before, after complete labeling, cells are harvested and equally mixed. As most physical 
and chemical properties of the labeled peptides are not changed, peptides co-elute at 
the same time. In the mass spectrometer peptides can be distinguished from each other 
due to the mass shift introduced via “heavy” labeled amino acids (Figure I.11). Intensities 
from the SILAC pairs (“heavy” and “light” peptides) are measured by MS to allow a 
relative comparison of the thousands proteins from the experiment [143].  
Since original SILAC was established, additional applications were developed through the 
years. Dynamic SILAC is an approach for measuring protein turnover. Turnover can be 
measured by “heavy” isotope labeling over time from unlabeled cell culture or vice versa. 
Incorporation of the “heavy” isotope over the time can be measured by MS [151] (Figure 
I.12). However, by definition protein turnover is a balance between protein synthesis 
and protein degradation. 
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Figure I.11 | SILAC typical workflow. Control ells are grown in “light” and knockout cells in “heavy” 
medium. After complete labeling of the cells (around 5 cell doubling times), “light” and “heavy” cells 
harvested and mixed in equal amounts. Next, proteins are digested and following peptide mixture is 
measured on the mass spectrometer. 
 
Thus, increased “heavy to “light” ratios of the particular protein can indicate fast protein 
synthesis or low protein synthesis combined with rapid protein degradation [120]. 
Another application is pulsed SILAC (pSILAC) developed for a direct comparison of 
protein translation rates between two samples. Firstly, both cell lines are grown in “light” 
isotope containing medium. After one cell population is perturbed, the medium is 
exchanged to medium containing “medium”-“heavy” isotope amino acids in one cell 
population and “heavy” isotope amino acids in another cell population. After a certain 
amount of time, cells are harvested, equally mixed and measured by MS.  
 
I INTRODUCTION 
 
25 
 
 
Figure I.12 | Dynamic SILAC typical workflow. Cells are grown in “light” and, at the certain point, switched 
to the “heavy” medium. While synthesizing, proteins are incorporating “heavy” amino acids, which can be 
measured by MS, while collecting different time points. (adopted from [152]). 
 
Preexisting proteins remain in the “light” form, while newly synthesized proteins will 
contain “medium”-“heavy” or “heavy” isotope label, therefore the difference in this ratio 
shows the difference in translation of the corresponding proteins [120]. 
Next to the application of relative quantification, protein turnover and translation, SILAC 
can be used to study temporal changes [153] or protein-protein interactions [154]. 
Additionally, SILAC labeling can be applied to neuronal cell culture, although maximum 
label efficiency is lower (~80%) than in the normal cell culture due to the fact that 
neurons are not dividing [155]. Also, SILAC labeling was expanded to in vivo labeling of 
higher organisms like fruit fly [156] or mouse [157].  
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I.3.4.3. Label-free approaches 
As a result of the rapid development of LC-MS instrumentation, quantification by label-
free approaches became more popular and robust. The main assumption of this 
approach is that under controlled conditions, different samples that are measured 
separately by MS can be compared. Label-free quantification (LFQ) can be obtained by 
MS spectral counting (the number of MS/MS spectra acquired for the corresponding 
protein) or by measuring MS ion current level (areas under the curve (AUC) or extracted 
ion current (XIC)) (Figure I.13) [158].  
Advantages of this approach are: lower costs, since it does not involve additional 
chemistry or sample preparation steps;the fact that quantification of the many samples 
can be simultaneously performed; and support of the higher dynamic range (1:60) in the 
comparison with labeling techniques (1:20) [159]. However, some disadvantages include 
differences in sample preparation, ionization efficiency and variation in chromatography 
retention times between LC-MS runs. Label-free approaches are therefore less accurate 
than stable isotope-based quantitative approaches. 
 
I.3.4.4. Absolute quantification 
Absolute quantification is determination of the absolute abundance of the protein, 
defined in moles or copy numbers This information can be extremely useful within the 
medical field, particularly when looking for biomarkers as a diagnostic tool [160] and 
moreover when modeling biological systems [161]. Most of the techniques applied for 
the absolute quantification rely on the internal standards with a known concentration 
(peptide or protein). For example, one of the popular techniques is called AQUA 
(Absolute Quantification). AQUA employs spiking of a known amount of synthetically 
produced stable isotope label peptide into a sample. The absolute amount of the peptide 
of interest is determined by comparing MS signal between the spike-in standard and 
peptide of interest [162]. 
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Figure I.13 | Label-free typical workflow. Different samples (control and sample) are processed and 
measured separately. Label-free quantification is based on comparison of peak intensity (MS ion current), 
or by MS spectral count of the same peptide. (adopted from[163]). 
 
As an alternative to the internal standards, label-free approaches can be used for 
absolute quantification. A recently developed approach known as the  total protein 
approach (TPA) utilizes the LFQ intensity from a particular protein and is divided by the 
total MS signal (sum of all LFQ intensities). Moreover, the resulting ratio can be 
transformed into copy number per cell by dividing the ratio by molecular weight and 
multiplying it by the Avogadro constant and protein content of the cell [164]. 
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II. AIMS AND OBJECTIVES OF THE THESIS 
Although FXS is a monogenic disease, different clinical symptoms indicate that FMRP is 
involved in the regulation of multiple factors that modulate gene translation and major 
signal transduction pathways in neurons. In order to understand molecular mechanisms 
by which FMRP regulates protein synthesis, it is essential to understand its influence on 
the neuronal proteome and phosphoproteome. Motivated by the lack of data on the 
proteome level during absence of FMRP in neurons, my main aim was to use proteomics 
to identify and quantify protein expression and phosphorylation levels in several cellular 
and animal models of FXS. To this end, I defined the following specific objectives: 
1) Analysis of signal transduction pathways involved in the pathogenesis of FXS at 
the phosphoproteome level in SILAC-labeled murine Fmr1- and Fmr1+ fibroblastic 
cell lines 
a. Identification and quantification of proteins and phosphorylation sites 
dysregulated as a consequence of FMRP loss 
b. Bioinformatic analysis of the proteomics results to identify regulatory 
pathways involved in FXS 
2) Identification of potential new GSK-3β substrates in SILAC-labeled murine Fmr1- 
and Fmr1+ fibroblastic cell lines using GSK-3β inhibition by lithium and TDZD-8 
a. Analysis of the significant changes in  phosphoproteome after inhibiting 
the GSK-3β  kinase with lithium (unspecific inhibitor) and TDZD-8 (specific 
inhibitor) 
b. Identification of potential GSK-3β substrates upon treatments 
c. Analysis of differential GSK-3β activity in Fmr1- and Fmr1+ fibroblastic cell 
lines based on detected potential substrates 
3) Measurement of protein turnover based on dynamic-SILAC method in primary 
cortical neuronal culture (Fmr1-KO and WT)  
a. Large-scale analysis of protein turnover in primary neuronal cell culture  
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b. Comparison of the turnover between WT and Fmr1-KO in cortical 
neuronal culture model 
4) Analysis of pathways involved in the pathogenesis and genetic rescue of FXS at 
the proteome level in mouse hippocampus 
a. Proteome-wide quantitative comparison of protein levels in the 
hippocampi of WT, Fmr1-KO and Fmr1-KO/mGluR5-het cross mice 
b. Absolute quantification of protein levels between WT, Fmr1-KO and 
Fmr1-KO/mGluR5-het cross mice 
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III MATERIALS AND METHODS 
III.1. Materials 
III.1.1. List of chemicals and consumables 
 
Name Company 
0.05% Trypsin-EDTA (1X), Phenol Red Gibco/ Invitrogen 
2,5-dihydrobenzoic acid Sigma-Aldrich 
20*LumiGLO and 20*Peroxide Cell Signaling New England Biolabs 
Acetic Acid Sigma-Aldrich 
Acetonitrile Merck KGaA 
Ammonium Bicarbonate Merck KGaA 
Ammonium Sulphate Merck KGaA 
Anti-GAPDH Pierce Antibody 
Anti-rabbit IgG, HRP-linked Antibody Cell Signaling New England Biolabs 
Anti-prion protein PrP antibody AbCam 
Arginine (Arg0) Silantes 
Arginine (Arg6, Arg10) Silantes 
Bensonase Merck KGaA 
Blotting Papier VWR 
Bovine Serum Albumin Sigma-Aldrich 
Bradford Reagent Bio-Rad Laboratories 
C8/C18 Extraction Discs EmporeTM 
Calcium Chloride Merck KGaA 
Cell scraper Greiner 
Chloroform VWR 
Corning® 500mL Vacuum Filter/Bottle System Corning 
Dialyzed FBS Invitrogen 
Dimethylsulfoxid Sigma-Aldrich 
Dithiothreitol Merck KGaA 
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Name Company 
DMEM medium PAA or PAN Biotech 
DPBS PAA Laboratiories 
EDTA Sigma-Aldrich 
Ethanol Merck KGaA 
Fmr1- MEF cell line Kind gift from Dr. Davidovic 
Fmr1+ MEF cell line Kind gift from Dr. Davidovic 
Formic Acid Merck KGaA 
Glycerol Merck KGaA 
Glycerol-2-Phosphate Sigma-Aldrich 
GSK-3beta (D5C5Z) XP® Rabbit mAb Cell Signaling New England Biolabs 
Hippocampal mouse tissue Kind gift from Prof. Bear 
Hygromycin B Sigma-Aldrich 
Immobiline Drystrips GE Healthcare 
InstantBlue Biozol 
Iodoacetamide Sigma-Aldrich 
IPG-buffer pH 3-10 IPG-buffer pH 3-10 
IPTG Euromedex 
Isopropanol Merck KGaA 
L-glutamine Gibco 
Lithium chloride solution Sigma-Aldrich 
LumiGLO® reagent Cell Signaling New England Biolabs 
Lys-C Wako 
Lysine (Lys0) Silantes 
Lysine (Lys4, Lys8) Silantes 
Methanol Merck KGaA 
Mineral Oil Bio-Rad Laboratories 
NeuroPAN Basal-Media PAN Biotech 
n-octylglucoside Roche 
NuPAGE 12% Bis-Tris Gel Life Technologies (Invitogen) 
NuPAGE LDS Sample Buffer Life Technologies (Invitogen) 
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Name Company 
NuPAGE® MOPS SDS Running Buffer Life Technologies 
Penicilin/Streptomycin PAN 
Phospho-GSK-3-beta (Ser9)Rabbit mAb Cell Signaling New England Biolabs 
Potassium Chloride Merck KGaA 
Potassium Hydrogen Phosphate Merck KGaA 
Protease Inhibitor Cocktail (tablets) Roche 
ReproSil-Pur C18-AQ 3 μm resin Dr. Maisch GmbH 
Resource S Column GE Healthcare 
Roti®-Fluoro PVDF membrane Roth 
SeeBlue® Plus2 Prestained Standard Life Technologies 
Sep-Pak C18 Cartridges Waters 
Sodium Orthovanadate Sigma-Aldrich 
Sponge Pad for Blotting (8) Life Technologies (Invitogen) 
TDZD-8 Sigma-Aldrich 
Thiourea Merck KGaA 
Titanium dioxide Beads Sachtopore 
Transfer Buffer Life Technologies (Invitogen) 
Triethylammonium Bicarbonate Sigma-Aldrich 
Trifluoroacetic Acid Merck Millipore 
Tris Base Sigma-Aldrich 
Trypsin Promega 
Tween 20 Merck KGaA 
Urea Merck KGaA 
WhatmanTM GE Healthcare 
β-mercaptoethanol BDH 
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III.1.1. List of instruments 
 
Instrument Company 
3100 Offgel Fractionator Agilent Technologies 
ÄKTA System GE Healthcare 
Borosilicate Emitters Thermo Scientific 
Cell culture incubator Thermo Fisher Scientific 
Centrifuge (table-top) Eppendorf 
Column Oven Sonation 
Easy-LC nano-HPLC Proxeon Biosystems 
Electrospray ionization source Proxeon Biosystems 
Fusion SL Imager Peg Lab 
LTQ-Orbitrap Elite Thermo Fisher Scientific 
LTQ-Orbitrap XL Thermo Fisher Scientific 
Nano ES Ion Source (ES380) Thermo Scientific 
Spectrophotometer (A595) Thermo Electron Corporation 
Stage-tip Centrifuge Sonation 
Vacuum Centrifuge Eppendorf 
XCell II  Blot Module Invitrogen 
XCell SureLock  Mini-Cell Electrophoresis Invitrogen 
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III.2. Methods 
 
III.2.1. Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides new 
insights into FMRP-dependent signal transduction mechanisms 
 
This chapter of the thesis was adopted from Matic et al [69].  
 
III.2.1.1. Cell culture and SILAC labeling 
A spontaneously immortalized fibroblastic murine Fmr1-KO cell line was established 
from mouse embryonic fibroblasts (MEFs) derived from Fmr1-null C57Bl/6J embryos 
(mouse strain gR2700 available from Jackson Laboratory). Fmr1-KO MEFs cells were then 
transfected with a pTL10 vector containing FMR1 isoform 1 human cDNA or with an 
empty pTL10 vector [165]. Simultaneously, cells were cotransfected with a pIREShyg3 
plasmid (Clontech-BD Bioscience) containing Hygromycin B resistance. This procedure 
resulted in two stable cell lines: one stably re-expressing FMRP, termed as STEK-59 
(Fmr1+ MEFs), and one Fmr1-KO cell line further referred to as STEK-87 (Fmr1- MEFs). 
MEF cells were cultured in DMEM medium (Dulbecco’s modified eagle medium, High 
Glucose (4,5 g/L), PAA or PAN Biotech) lacking arginine, lysine and L-glutamine. L-
glutamine (2 mM, Gibco), penicillin/streptomycin (100 U/ml, PAN), Hygromycin B (from 
Streptomyces hygroscopicus, 150 μg/mL, Sigma-Aldrich) and dialyzed FBS (10 %, 
Invitrogen) were added to the medium. The “light” SILAC media was further 
supplemented with 73 mg/L L-lysine Lys0 and 42 mg/L L-arginine Arg0 (both from 
Silantes), whereas 73 mg/L “heavy” L-lysine Lys8 (13C6,15N2-L-Lysine, Silantes) and 42 
mg/L “heavy” L-arginine Arg10 (13C6,15N4-L-Arginine, Silantes) were added to the 
“heavy” SILAC medium. Both cell lines (Fmr1+ MEFs and Fmr1- MEFs) were grown in an 
incubator (37°C, 5 % CO2) in either “light” or “heavy” SILAC DMEM medium.  
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III.2.1.2. Protein extraction 
To extract SILAC labeled proteins from cell culture, cells were washed twice with 5 mL 
DPBS (PAA Laboratories) and put on ice to prevent protein degradation during the 
following denaturation step with a buffer containing 6 M urea, 2 M thiourea and 10 mM 
Tris-Base. Protease- (complete Mini EDTA-free Proteinase Inhibitor Cocktail) and 
phosphatase inhibitors (glycerol-2-phosphate, sodium fluorite, and sodium 
orthovanadate) were added. DNA and RNA were removed during 10 min incubation with 
benzonase (EMPROVE® bio; Merck) on room temperature (RT) followed by 
centrifugation at 2800 x g (4000 rpm, 10°C, 25 min). The DNA- and RNA- containing 
precipitate was removed afterwards. 
 
III.2.1.3. In-solution protein digestion and isoelectric focusing 
Extracted proteins from each cell line were mixed 1:1 (“light” to “heavy” according to 
Bradford assay, Bio-Rad Laboratories). Protein mixtures were digested according to the 
protocol published by Macek et al. [166]. Portions of the tryptic peptides, 100µg per 
sample, were further fractionated according to their isoelectric point on 3100 OffGel 
fractionators (Agilent) by Off-Gel separation using manufacturer’s instructions. Focusing 
was done with 13cm Immobiline DryStrips pH 3-10 (GE Healthcare), resulting in 12 
fractions per sample. Current was limited to 50 µA and fractionation completed as soon 
as 20 kVh were reached. Fractions were acidified using acidic acid (30 %  ACN, 10 % TFA 
and 5 % acetic acid in water) before desalting on StageTips, described by Ishihama [167]. 
 
III.2.1.4. Phosphopeptide enrichment 
Phosphopeptide enrichment was done as described previously [168] with following 
modifications: 5 mg of digested peptides per sample (a portion of tryptic digestion 
described in previous section)  were separated using strong cation exchange (SCX) 
chromatography with a linear gradient of 0-35 % of SCX solvent B over 32 min which 
resulted in 16 fractions. The resulting 16 fractions were pooled to eleven fractions 
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according to the SCX chromatogram. The flow-through, containing unbound peptides 
was collected separately. Eleven fractions per replicate plus flow-through were further 
processed via TiO2 chromatography. Hereafter phosphopeptides were eluted in three 
steps with elution buffer (40 % ammonium hydroxide solution in 60 % acetonitrile, 
pH 10.5). The TiO2 chromatography was done once or twice per fraction depending on 
phosphopeptide quantities expected from SCX chromatogram. Enrichment of the flow-
through was done five times. 
 
III.2.1.5. Nano-LC-MS/MS analysis 
All peptides were measured on Easy-LC nano-HPLC (Proxeon Biosystems) coupled to an 
LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) for the proteome or an 
LTQ Orbitrap XL (Thermo Fisher Scientific) for the phosphoproteome measurements. 
Liquid chromatography was done on a 15 cm fused silica emitter with an inner diameter 
of 75 μm and a tip diameter of 8 μm in-house made nano-HPLC column, packed with 
reversed-phase ReproSil-Pur C18-AQ 3 μm resin (Dr. Maisch GmbH). Peptides were 
flushed with HPLC solvent A (0.5 % acetic acid) at a flow rate of 500 nL/min with the 
maximum pressure of 280 Bar. Elution was done using segmented 90 min gradient (LTQ 
Orbitrap Elite) or 130 min (LTQ Orbitrap XL) of 5 - 90 % HPLC solvent B (80 % ACN, 0.5 % 
acetic acid) at a flow rate of 200 nL/min. The eluted peptides were ionized in an 
electrospray ionization (ESI) source (Proxeon Biosystems) set to positive ion mode. Full 
scan MS spectra were acquired in the Orbitrap analyzer in a mass range from m/z 300 - 
2000 at a resolution of 120,000 (LTQ Orbitrap Elite) or 60,000 (LTQ Orbitrap XL), followed 
by fragmentation in LTQ mass analyzer of the top-20 (LTQ Orbitrap Elite) or top-5 (LTQ 
Orbitrap XL) most intense precursor ions with collision induced dissociation (CID) at a 
target value of 5000 charges. Dynamic exclusion was used to exclude fragmented masses 
for 90 sec. In addition, for phosphoproteome measurement (LTQ Orbitrap XL), ions were 
fragmented by multi stage activation (MSA) on the neutral loss ions at -98, -49 and -32.6.  
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III.2.1.6. Data processing and analysis 
The mass spectrometry data were processed using MaxQuant suite V 1.3.0.5 [169, 170]. 
Spectra were searched using andromeda search engine [138] against the proteome 
database of Mus musculus (UniProt complete proteome database, downloaded on 25. 
December 2012), consisting of 50,697 protein entries and 247 commonly observed lab 
contaminants. Mass tolerance for the first search was set to 20 ppm, and for the main 
search to 6 ppm. SILAC multiplicity was set to two. Lys0, Arg0 and Lys8, Arg10 were 
defined as “light” and “heavy” samples, respectively. Full tryptic specificity was required 
and a maximum of two missed cleavages were allowed. Carbamidomethylation of 
cysteine was set as fixed modification while oxidation, acetylation (on N-term) and 
phosphorylation on Ser/Thr/Tyr were chosen as variable modifications. Initial mass 
tolerance for the precursor ion was set to 6 parts per million (ppm) and for the fragment 
ions 0.5 Da. For quantification of proteins, minimum two peptides with at least seven 
amino acids had to be detected. The maximum allowed posterior error probability (PEP) 
was set to 1 and the false discovery rate (FDR) to max 1 % for peptides and proteins. Re-
quantification was enabled while “second peptide search” option was disabled. 
The localization probabilities of potential phosphorylation events on Ser/Thr/Tyr were 
calculated based on the posttranslational modification (PTM) score. Quantification of 
phosphorylation sites was normalized with the respective protein abundance, provided 
the protein was quantified in unmodified form. 
 
III.2.1.7. Bioinformatic analysis 
Perseus V 1.3.0.4, a module from the MaxQuant suite [169], was used for comparison of 
SILAC ratio distributions and calculation of the Pearson correlation coefficient in both, 
proteome and phosphoproteome measurements. This was done by extraction of the H/L 
ratios from ProteinGroups.txt file, generated in MaxQuant. Contaminants, reverse hits 
or proteins identified only by modification site were removed, values were Log2 
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transformed and the Pearson correlation coefficient calculated for the H/L ratios of both 
replicates. 
Calculation of significantly changing proteins and phosphorylation sites was also done in 
Perseus V 1.3.0.4 using two-tailed “Significance B” test; p ≤ 0.05. “Significance B” test is 
based on the assumption that the most of the data is following normal distribution. For 
calculation of significantly changing proteins, data must be log transformed to ensure 
equal treatment for up- and down-regulation. Test is using 15.87 and 84.13 percentile as 
an asymmetric estimate for a standard deviation. This deviation is applied on the protein 
subsets which are binned based on their intensity. Therefore this test is considering shift 
of the ratio from the normal distribution and intensity level [169]. H/L ratios were 
transformed to Log2, whereas intensities of peptides or phosphorylation sites were 
Log10 transformed. For significance of phosphorylation sites, H/L ratios were normalized 
by corresponding protein H/L ratios. 
In the same module we performed functional enrichment analysis of Gene Ontology, 
Pfam and KEGG terms for increased and decreased classified proteins and 
phosphorylation sites. We applied truncation based on Benjamini-Hochberg [171] 
corrected p-values with threshold value of 0.05 to test whether specific annotation terms 
are significantly enriched or depleted among the chosen set of proteins of interest. The 
adjusted p-values were +/-log10 transformed and visualized in Excel. List of proteins and 
phosphorylation sites from class 1-3 were divided based on their increasing or decreasing 
level separately uploaded to STRING (The Search Tool for the Retrieval of Interacting 
Genes) database [172, 173]  to look for known and predicted protein interactions. We 
requested the highest confidence score of 0.9 for the predicted protein interaction and 
discarded disconnected nodes. 
The available list of FMRP protein-RNA interaction (pri) or protein-protein interactions 
(ppi) manually curated from the literature [174] was updated with recent references 
(notably ref 9) and used to appreciate the overlap between dysregulated proteins in the 
present datasets of protein levels and phosphorylation events. 
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III.2.1.8. Western-blotting 
 
Work in this chapter was done by Laetitia Davidovic, Physiopathology of Mental 
Retardation, Valbonne, France. 
 
Cell extracts were analysed by western blotting as described previously [174, 175].The 
following primary antibodies were used: 1C3 against FMRP (1:500, [38]); 3Fx against 
FXR1P and cross-reacting with FXR2P (1:500, [176]), anti-β-actin monoclonal antibody 
(1:20,000; Sigma), anti-β-tubulin monoclonal antibody (1:500, clone E7, Iowa 
Developmental Hybridoma Bank, USA), anti-cPLA2 (1:1,000, Santa Cruz) and anti-Prp 
(1:500, clone SAF70, [177]). Digital acquisition of chemiluminescent signal was 
performed using the Las-3000 Imager system (Fujifilm). Quantitation of western-blot was 
performed using the ImageJ software and normalized to the β-actin or β-tubulin signal. 
GraphPad 4 software was used for statistical analysis. 
 
III.2.2. Inhibition of GSK-3β kinase in murine Fmr1-KO cell lines 
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
III.2.2.1. Inhibition of GSK-3β 
Two stable cell lines, STEK-59 (Fmr1+ MEFs) and STEK-87 (Fmr1- MEFs) were established 
as described the in previous section (III.2.1.1.) [165]. In order to inhibit GSK-3β, both cell 
lines were treated with 20 mM lithium (unspecific inhibitor) or 5 µM TDZD-8 (specific 
inhibitor) at different time points (0, 0.5, 1, 3, 6, and 12hours). Inhibition of the kinase 
was determined through the increase of the phosphorylation event at the Ser-9 site of 
the kinase by western blot. We used Anti-Phospho-GSK-3-beta (Ser9) antibody (1:1000, 
Cell Signaling) to detect Ser-9 phosphorylation and GSK-3-beta (1:1000, Cell Signaling) to 
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detect kinase as a loading control. In both cell lines, inhibition was achieved at 3 hours 
when treated with lithium, and 1 hour when treated with TDZD-8 (see Results). 
 
III.2.2.2. Cell culture and SILAC labeling 
Cell lines were cultured in DMEM medium (PAA or PAN Biotech) in deficiency of arginine, 
lysine and L-glutamine. Medium was supplied with L-glutamine (2 mM, Gibco), 
penicillin/streptomycin (100 U/ml, PAN), Hygromycin B (from Streptomyces 
hygroscopicus, 150 μg/mL, Sigma-Aldrich) and dialyzed FBS (10 %, Invitrogen). Two triple 
SILAC experiments were constructed.  Fmr1+ MEFs and Fmr1- MEFs treated with lithium 
were grown in the “light” SILAC medium. Both cell lines without the treatment were 
grown in “medium” SILAC medium, and Fmr1+ MEFs and Fmr1- MEFs treated with TDZD-
8 were grown in “heavy” SILAC medium. Cell lines, with or without corresponding 
treatment, were grown in an incubator at 37°C, with 5 % CO2. In addition, 12 hours prior 
to treatment cells were put in the starvation medium (medium without FBS).  
 
III.2.2.3. Sample preparation  
Sample preparation was done as described previously (III.2.1.2., III.2.1.3.). Each approach 
was performed in biological replicates. Briefly, after cell treatments, proteins were 
extracted. Extracted proteins were mixed in equal amounts, “light” to “medium” to 
“heavy”, resulting in two samples per biological replicate. Mixed proteins were digested. 
For the proteome part, portion of digested proteins (60 µg) was used for Offgel 
separation. The remaining sample (3.5 mg) was acidified with TFA to 0.1% concentration 
(v/v) and used for phosphopeptide enrichment. Afterwards, solid phase extraction was 
performed. Shortly, samples were loaded on to Sep-Pak Vac 1cc C18 Cartridges. Prior to 
loading, columns were activated with Methanol and equilibrated with Solvent A* (2% 
acetonitrile / 1% TFA). After loading the sample, column was washed with Solvent A 
(0.5% acetic acid) and peptides were eluted with 80% ACN / 6% TFA. Next, peptides were 
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incubated with TiO2 beads (1:2, bead to protein ratio) for 10 min. Beads were washed 
with Solvent B and peptides were eluted with 5% NH3.H2O, pH 11.0 in to 20% FA. 
Samples were evaporated in the SpeedVac (Eppendorf) until 50 µl and purified on 
StageTips [167]. 
 
III.2.2.4. LC - MS analysis 
All samples were measured on Easy-LC nano-HPLC (Proxeon Biosystems) coupled to an 
LTQ Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) as described previously 
(II.1.5.). Elution was performed using segmented 90 min gradient (proteome 
measurement) or 130 min (phosphoproteome measurement). Full scan MS spectra were 
acquired in the Orbitrap analyzer in a mass range from m/z 300 - 2000 at a resolution of 
120,000, followed by fragmentation of 15 most intense ions in HCD collision cell with 
normalized collision energy of 35%. The resulting fragments were detected at a resolving 
power of 15,000 in the Orbitrap analyzer. 
 
III.2.2.5. Data processing and analysis 
Data was processed in the same manner as described in III.2.1.6. section with following 
exception. MaxQuant suite 1.5.1.0. was used for processing with multiplicity three, Lys0, 
Arg0 for “light”, Lys4, Arg6 for “medium” and Lys8, Arg10 for “heavy” samples. 
Requantify option was disabled and phosphorylation events ratios were not normalized 
by their respected protein ratios. 
Perseus V 1.5.0.15 [169], was used for calculation of the Pearson correlation and two-
tailed “Significance B” test as described before. 
Functional enrichment analysis of Gene Ontology and KEGG terms was done using DAVID 
online tool [178, 179]. We applied truncation based on Benjamini-Hochberg [171] 
corrected p-values with threshold value of 0.05. List of decreasing phosphorylation sites 
from class 1-3 were uploaded to STRING (The Search Tool for the Retrieval of Interacting 
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Genes) database [172, 173]  to look for known and predicted protein interactions with 
the highest confidence score of 0.9 for the predicted protein interaction and discarded 
disconnected nodes. 
 
III.2.3. Dynamic SILAC of WT and Fmr1-KO primary cortical neurons 
III.2.3.1.SILAC labeling of primary cortical neurons 
 
Work in this chapter was done by Laetitia Davidovic, Physiopathology of Mental 
Retardation, Valbonne, France. 
 
Primary cortical neurons were obtained from C57BL/6J mouse embryos as previously 
described [68]. Neurons were seeded in NeuroPAN-Basal-Media (PAN Biotech) lacking 
arginine and lysine. Medium was supplemented 73 mg/L “heavy” L-lysine Lys8 (13C6, 
15N2-L-Lysine, Silantes) and 42 mg/L “heavy” L-arginine Arg10 (13C6, 15N4-L-Arginine, 
Silantes). Neurons were collected at the following time points: 2, 3, 4, 5, 6 and 10 DIV. 
 
III.2.3.2. Sample preparation 
Samples were prepared as described previously (III.2.1.2., III.2.1.3.). Shortly, at the 
corresponding time points, proteins were extracted. Protein concentration was 
determined using Bradford assay (Bio-Rad Laboratories). 10 µg of each sample was 
digested. After digestion was done, samples were acidify to pH 2 and loaded on the 
StageTips [180]. 
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III.2.3.3. LC-MS analysis 
All samples were subjected to nano-LC-MS/MS measurements on the LTQ-Orbitrap Elite 
(Thermo Fisher Scientific) as described previously (III.2.1.5.). Separation was performed 
using a linear 90 min gradient as described in III.2.2.4. section. 
 
III.2.3.4. Data processing and analysis 
Data was processed as described in III.1.6. section with the exception of multiplicity two, 
Lys0, Arg0 for “light” and Lys4, Arg6 for “heavy” samples. 
Perseus V 1.5.0.15 [169], was used for calculation of the Pearson correlation and box 
plots were created using online tool (http://boxplot.tyerslab.com). 
Protein half-lives were calculated using approach adopted from Schwanhausser et al 
[152]. In this approach, it is assumed that “light” labeled proteins are exponentially 
decaying with the degradation rate constant (kdp). This rate can be calculated using the 
formula 
 
𝑘𝑑𝑝 =
∑ 𝑙𝑜𝑔𝑒(𝑟𝑡𝑖 + 1)𝑡𝑖
𝑚
𝑖=1
∑ 𝑡𝑖
2𝑚
𝑖=1
 
 
 
where m represents the number of time points (𝑡𝑖), and 𝑟𝑡𝑖  the “heavy” to “light” ratio 
of the specific protein at each time point. When we have calculated 𝑘𝑑𝑝, half-life of the 
protein (𝑇1/2) can be extracted from the formula 
 
 
𝑇1/2 =
𝑙𝑜𝑔𝑒2
𝑘𝑑𝑝
 . 
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Functional enrichment analysis of Gene Ontology, Pfam and KEGG terms was performed 
for all quartiles in WT and Fmr1-KO, separately, as described in III.2.1.7. section with 
exception of threshold value of 0.01 (Benjamini-Hochberg corrected p-values). 
 
 
III.2.4. Global identification of differentially regulated proteins in mouse models of 
Fragile X Syndrome  
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
III.2.4.1. Mouse model, preparation of the tissue  
 
Work in this chapter was done by Emily Osterweil, Department of Brain and Cognitive 
Sciences, Massachusetts Institute of Technology, USA. 
Fmr1-KO mutant mice (Jackson Labs) were crossed with Grm5 mutants (Jackson Labs) to 
produce Fmr1-KO/mGluR5-het mice. Fmr1-KO/mGluR5-het, Fmr1-KO and wild type 
littermates were kept on the C57BL/6J background. All mice were treated according to 
the NIH and MIT guidelines, and maintained in 12 : 12 hours light : dark cycle [81].  
Experiments were performed blind to genotype.   
At the P25-32 male littermates were killed by rapid decapitation and hippocampi were 
rapidly dissected [181].  
 
III.2.4.2. Protein extraction and digestion 
Hippocampal tissues were homogenized in denaturation buffer (6 M urea/2 M thiourea 
in 10 mM Tris buffer) with 1% of N-Octyl-β-d-glucopyranoside. Homogenized tissues 
were centrifuged 5 min at 13000 rpm to remove the foam, precisely balanced, then 
centrifuged at 20 000 rpm in the prior cooled ultra-centrifuge at 4°C for 1 hour. Next, the 
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protein extracts were collected and methanol/chloroform precipitation was performed. 
Protein concentration was determined by Bradford assay (Bio-Rad). Extracted proteins, 
10 µg per a sample, were digested as described in III.2.1.3. section. 
 
III.2.4.3. Nano-LC-MS/MS analysis 
The peptides were measured on an EASY-nLC II nano-LC (Proxeon Biosystems) coupled 
to either LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) or LTQ 
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific). The peptides were 
separated by liquid chromatography using 15 cm PicoTip fused silica emitter of 75 µm 
inner diameter (ID) and an 8 µm Tip ID (New Objective) packed in-house with reversed-
phase ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). Sample was loaded onto the 
column using Solvent A (0.5% acetic acid) at 700 nL/min with maximum back pressure of 
280 Bar and subsequently eluted using a segmented gradient of 5-90% solvent B (80% 
ACN in 0.5% acetic acid) at the constant flow rate of 200 nL/min over 230 min. Full scans 
for the MS spectra were acquired between 300 – 2000 Thompson at the resolution of 
60,000 (LTQ Orbitrap Velos) and 120,000 (LTQ Orbitrap Elite). In the linear ion trap the 
15 (LTQ Orbitrap Velos) or 20 (LTQ Orbitrap Elite) most intense ions were selected for 
the further fragmentation with collision induced dissociation (CID) at a target value of 
5000 charges. 
 
III.2.4.4. MS data processing 
Acquired raw data were processed with MaxQuant software (v.1.3.0.5) [169] as 
described before (III.2.1.6.). To perform label-free quantification we enabled the label-
free algorithm and used the “match between runs” option. Raw files were matched 
within time window of 2 minutes as follows. Due to robust recalibration of peptide 
retention times performed by MaxQuant software all LC-MS/MS runs were matched 
between each other. 
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III.2.4.5. Bioinformatic analysis  
III.2.4.5.1. Data preparation and imputation of missing values 
After removal of decoy proteins, commonly observed lab contaminants, and proteins 
only identified by a modification site (“Only identified by Site”) we extracted the label-
free (LFQ) intensities of the remaining protein groups. The resulting data matrix 
consisted of 5,238 rows (protein groups) and 27 columns (nine replicates for each 
genotype) containing label-free intensities. For further analysis we required a minimum 
of nine valid columns for each protein group to retain cases in which a protein is 
completely missing in two out of three genotypes. Label-free intensities were log10-
transformed and missing values were imputed to simulate protein abundances near the 
detection limit as described in Deeb at al [182] using values 1.4 for ‘downshift’ and 0.3 
for width, respectively (Supplementary Figure III.1).  
 
III.2.4.5.2. Normalization and filtering 
LFQ intensities across the different measurements were normalized according to the 
Quantile method [183] using function ‘normalize.quantiles’ form the ‘preprocessCore’ R-
package (Supplementary Figure III.2). To increase statistical power in finding differential 
proteins, we removed proteins with no or only negligible variation of expression across 
the genotypes prior to hypothesis testing. To that end we calculated pairwise ratios of 
averaged LFQ intensities between different genotypes and determined outliers of the 
resulting distribution.  We calculated the significance of each protein ratio with respect 
to the distance of the median of the distribution of all protein ratios as well as its signal 
intensity. This approach was introduced in [169] to determine the significance of proteins 
ratios in a typical quantitative MS-based proteomics experiment and referred to as 
“Significance B” (psigB).  All proteins with psigB > 0.1 in a pairwise comparison were not 
considered in hypothesis testing for differential expression. 
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III.2.4.5.3. Linear mixed effect model analysis of variance 
Based on the imputed, normalized, and log-transformed LFQ intensities we applied 
analysis of variance (ANOVA) to test for differential expression between pairs of 
genotypes. We modeled the expression values as response of a linear mixed effects 
model (LMEM) consisting of one fixed effect (genotype), and two random effects (the 
different batches of experiments and the general error term). The modeling and ANOVA 
was performed in R using functions ‘lmer’ and ‘anova’, respectively, which are part of 
the R-package ‘lmerTest’.  
Proteins having a p-value below 0.015 were considered as potential candidates for 
differential expression between the phenotypes. We chose this threshold based on 
empirically observed p-values of positive controls in our dataset, e.g. the expression 
mGluR5 is known to be reduced by a factor of two in the mGluR5-het model compared 
to Fmr1-KO and WT, respectively. 
For false discovery estimation among all tested hypotheses we adjusted the p-values for 
multiple hypothesis testing by the method of Benjamini & Hochberg [184]. For the list of 
potential differential proteins we report the false discovery rate as the maximal adjusted 
p-value in the corresponding list. Principle component analysis was performed in R using 
the function ‘prcomp’. 
 
III.2.4.6. Calculation of absolute protein abundances 
We calculated absolute amounts for each protein using the total protein approach (TPA) 
described in [164]. Briefly, individual LFQ intensities were divided by the sum of all LFQ 
intensities of every protein of a sample which corresponds to the total MS signal of the 
proteome in that sample. 
 
III.2.4.7. String analysis 
List of significantly changing proteins from ANOVA analysis was separately uploaded to 
STRING database [172, 173] for each pairwise comparison to look for known and 
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predicted protein interactions. We use 0.4 confidence score for the predicted protein 
interaction and discarded disconnected nodes. 
 
III.2.4.8. Western blot validation 
Equal amounts of the protein extract, 20µg, were loaded on the SDS-PAGE gel, followed 
by separation at 200V for 1 hour. Proteins were transferred to a PVDF membranes using 
XCell II™ Blot Module (Invitrogen) and membranes were blocked overnight with PBS and 
1% Tween20. Membranes were washed in PBST and incubated for 1 hour using the 
following antibodies: Anti-prion protein PrP antibody (1:5000, AbCam), Anti-Fragile X 
Mental Retardation Protein Antibody (1:500, Millipore) and Anti-GAPDH (1:2000, Pierce 
Antibody). 
After washing, incubations with HRP linked secondary antibody against mouse or rabitt 
were done for 1 hour (1:4000, Cell Signaling Technology). LumiGLO® reagent (Cell 
Signaling Technology) and Fusion SL Imager (PegLab) were used to visualize the proteins. 
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IV RESULTS 
 
IV.1. Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides 
new insights into FMRP-dependent signal transduction mechanisms 
 
This chapter of the thesis was adopted from Matic et al [69].  
 
To compare the proteome and the phosphoproteome of the Fmr1- and the control Fmr1+ 
MEF cell lines, two SILAC experiments in a reverse labeling manner were performed. 
SILAC-labeled cells were lysed, their proteins extracted and digested with trypsin. 
Smaller portions of the digests were separated by isoelectric focusing (for proteome 
measurement), whereas the larger portion was subjected to two stages of 
phosphopeptide enrichment, using SCX and TiO2 chromatographies (for 
phosphoproteome measurement). All LC-MS/MS measurements were performed on the 
LTQ-Orbitrap mass spectrometers and MS data were processed by MaxQuant software 
package (Figure IV.1). 
As a quality control step, we checked incorporation of SILAC labels. Incorporation was 
verified in dedicated mass spectrometry runs and calculated using the formula 
 
(
𝐻
𝐿 )
1 + (
𝐻
𝐿 )
∗ 100 
 
 
in which, (H/L) refers to the unnormalized ratio of the quantified peptide with the 
“heavy” label to the corresponding “light” peptide. Mass spectrometry runs confirmed 
full labeling of the MEF proteome (Table IV.1).  
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Figure IV.1 | Proteomic and phosphoproteomic workflow for two replicates of SILAC labeled cells. Fmr1- 
MEFs and Fmr1+ MEFs cells were grown in SILAC labeled medium for 14 days. In biological replicate 1 Fmr1- 
MEFs were “heavy” and Fmr1+ MEFs  “light” labeled, while in biological replicate 2 labeling was inversed. 
After labeling, cells were harvested, followed by cell lysis and protein extraction. Full incorporation of SILAC 
amino acids was confirmed. After 1:1 mixing of “heavy” and “light” cell lysates and subsequent in-solution 
digestion, one part was used for the proteomic workflow, which includes separation by OffGel and 
measurement by nano-HPLC MS/MS on a LTQ-Orbitrap Elite and further processing by MaxQuant software. 
The larger part of digested proteins was fractionated by SCX and phosphopeptides were enriched by TiO2 
chromatography before subsequent measurements by nano-HPLC MS/MS on a LTQ-Orbitrap XL. 
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Table IV.1 | Incorporation rates of “heavy” isotopes of arginine and lysine in cells after 9 days of growth 
in SILAC media. “Heavy” isotopes were incorporated during cell growth. The rate describes the percentage 
of “heavy” amino acid isotopes in the cells proteins. Cells were considered fully labeled since the 
incorporation rate was high (above 95 %).  
 
 
 Fmr1+ MEF Fmr1- MEF 
Arginine 0.968 0.966 
Lysine 0.966 0.965 
Combined 0.967 0.965 
 
 
 “Heavy” (Arg10, Lys8) and “light” (Arg0, Lys0) labeled cell lysates were mixed in equal 
amounts based on Bradford measurements. Digested peptides were measured by MS in 
order to verify mixing using the formula 
 
Measured Protein Concentration *  (H/L) = True Protein Concentration 
 
in which mixing error is calculated based on the median of unnormalized evidences 
(Table IV.2).  
 
 
Table IV.2 | SILAC heavy/light mixing error. Summary of unnormalized proportions of “heavy” labeled 
evidences compared to “light” labeled evidences. The numbers of detected and quantified evidences are 
listed additionally.  
 
 Median (H/L) 
Detected 
evidences 
Quantified 
evidences 
Proteome biological replicate 1 0.87 65,857 63,461 
Proteome biological replicate 2 0.77 65,169 62,686 
Phosphoproteome biological replicate 1 0.88 24,406 23,683 
Phosphoproteome biological replicate 2 0.67 18,785 18,262 
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Both of these quality steps, incorporation and mixing check, were done as a standard 
quality control for following SILAC experiments. 
Pearson correlation coefficients between SILAC ratios measured in two biological 
replicates were r = -0.932 for the proteome and r = -0.708 for the phosphoproteome 
data, indicating high reproducibility at both levels (Figure IV.2 A, B). Inverse correlation 
is a consequence of inverse SILAC labeling. 
 
IV.1.1. Overview of proteome and phosphoproteome results 
Combined analysis of 24 MS runs from isoelectric focusing (proteome analysis) and 44 
MS runs from phosphopeptide enrichment resulted in 56,352 identified peptide 
sequences from 6,703 protein groups. Identified protein groups were filtered for 
contaminants, reverse (decoy) hits and proteins identified by modification site. The 
estimated false discovery rate (FDR) was 0.36 % at the peptide level and 2.09 % at the 
protein group level. From 6,235 detected endogenous MEF proteins, 4,195 were 
quantified in both replicates, of which 266 were changing significantly in both biological 
replicates (134 were increasing and 132 decreasing). Scatter plots of measured protein 
ratios are shown separately for both replicates in Figure IV.2 C, D. 
The phosphoproteome analysis revealed 9,181 phosphorylation events on 2,494 
proteins. Since we expected expression differences at both proteome and 
phosphoproteome levels, we normalized phosphopeptide ratios with protein ratios. The 
total number of quantified phosphorylation events that could be normalized by the 
respective protein ratio was 6,040, of which 142 showed significant changes in both 
replicates (86 phosphorylation sites were increasing and 56 phosphorylation sites were 
decreasing in Fmr1- cells compared to the Fmr1+ cells). Distributions of phosphorylation 
events measured in both replicates are shown in Figure IV.2 E, F. 
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Figure IV.2 | Correlations of proteome and phosphoproteome 
Correlation between biological replicates at the A) proteome; and B) phosphoproteome level. Each dot 
represent a SILAC protein or phosphorylation site ratio measured in both biological replicates. Negative 
correlation is a consequence of inversed SILAC labeling.  
Distributions of quantified proteins from C) biological replicate 1; D) biological replicate 2; E) 
phosphorylation sites replicate 1 and F) biological replicate 2. Intensity is log10, H/L ratios log2 
transformed. Red dots represent significant (p < 0.05) outliers, which are reported separately for increased 
and decreased in Fmr1- MEF. 
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We next compared our quantified proteome dataset with reported mRNA targets or 
protein interactors of FMRP [44, 185-196] (see Material and Methods section). This 
comparison revealed 383 proteins, of which 23 were significantly changing in at least one 
biological replicate in our dataset. Surprisingly, the levels of only eight proteins were 
significantly increasing in Fmr1- MEFs, as should be expected for mRNA targets for which 
FMRP would repress translation [197], while 15 were significantly decreasing. This 
limited overlap can have several reasons, starting from the proteome coverage obtained 
in our study (we estimate that we quantified about one third of all expressed proteins in 
the cell), studied system (original mRNA data are derived from the mouse brain), and 
additional regulatory mechanisms that likely influence the final level of an FMRP target 
protein in the cell, such as protein degradation. All detected proteins and 
phosphorylation events of proteins that are known mRNA targets or protein interactors 
of FMRP are listed in Supplementary Table IV.1. 
 
IV.1.2. Validation by western blotting 
 
Work in this chapter was done by Laetitia Davidovic, Physiopathology of Mental 
Retardation, Valbonne, France. 
 
The mass spectrometry-based quantification was further validated by western blot 
(Figure IV.3). Analysis using the anti-FMRP mAb1C3 confirmed the expression of FMRP 
in Fmr1+ MEFs and its absence in Fmr1- MEFs (Figure IV.3A). Western-blot analysis with 
the 3Fx antibody recognizing the homologues of FMRP, all isoforms of Fxr1p and Fxr2p, 
showed that the lack of FMRP did not affect their levels of expression (Figure IV.3B). This 
confirms the mass spectrometry measurements and previous observations that the 
absence of FMRP is not compensated by upregulation of its homologues [198].  
Two candidate proteins which were significantly dysregulated in the MS experiments 
were validated. First, semi-quantitative western-blotting analysis confirmed that Fmr1- 
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MEFs express lower levels of the major prion protein (Prp) than Fmr1+ MEFs (Figure IV.3C 
left panel), exhibiting a significant decrease of 62 % (p=0.0361; Figure IV.3C right panel). 
Since PrP has a role in the formation of synapses [199] and in memory processing in the 
rat hippocampus [200], we hypothesize that reduced levels of Prp could contribute to 
the cognitive deficits observed in the Fmr1-KO mouse. Second, a significant increase in 
cytosolic calcium-dependent phospholipase A2 (Pla2g4a known as cPLA2, Figure IV.3D 
left panel) levels which is increased by 82 % in Fmr1- MEFs as compared to Fmr1+ MEFs 
(p=0.0079 was observed; Figure IV.3D right panel). cPLA2 releases arachidonic acid from 
membrane phospholipids. Importantly, cPLA2 participates in cerebellar long-term 
depression and motor learning [201]. It is tempting to speculate that abnormal 
overexpression of cPLA2 in the brain could participate in the cerebellar dysfunctions 
observed in Fmr1-KO mice [202]. Significantly higher concentrations of cPLA2 have been 
reported in red blood cells of patients with autism[203], linking cPLA2 to another form 
of cognitive disorder. 
 
IV.1.3. Regulatory pathway analysis 
For downstream bioinformatic analysis and pathway mapping, detected proteins and 
phosphorylation events were clustered into three classes based on quantification 
confidence as described in Table IV.3. Proteins and phosphorylation events that were 
not significantly changing in any of the replicates were not further considered. To 
investigate general processes and pathways that differ between the Fmr1+ and Fmr1- 
MEFs, classified proteins and phosphorylation sites were used to perform functional 
enrichment analysis of Gene Ontology (GO), Pfam and KEGG terms. 
The set of proteins and phosphorylation events with increased levels revealed significant 
overrepresentation of terms related to cell cycle, nucleotide metabolism and p53 
pathway (proteome level), as well as vasopressin-regulated water reabsorption and 
ribosome (phosphoproteome level) (Supplementary Table IV.2). 
IV Results: Quantitative phosphoproteomics of murine Fmr1-KO cell lines 
 
56 
 
 
Figure IV.3 | Western-blot analysis of Fmr1-KO MEFS reexpressing (Fmr1+) or not (Fmr1-) FMRP. A) 
Western-blot analysis of with anti-FMRP 1C3 antibody. β -tubulin (β-tub) signal is used to verify equal 
loading of lanes; B) Western-blot analysis of Fmr1+ or Fmr1- MEFs with anti-Fxr1P/Fxr2p antibody #3FX 
recognizing the homologues of Fmrp, Fxr1p (short and medium isoforms) and Fxr2p. β -tubulin (β -tub) 
signal is used to verify equal loading of lanes; C) Representative western-blot of Prp protein levels in Fmr1+ 
or Fmr1- MEFs. Densitometric quantification of western-blots reveal that depletion of Fmr1 leads to a 
significant decrease of Prp protein levels relative to Fmr1+ cells; C) Representative western-blot of cPLA2 
protein levels in Fmr1+ or Fmr1- MEFs. Densitometric quantification of western-blots show that depletion 
of Fmr1 leads to a significant increase in cPLA2 protein levels. Data are presented as means  SEM of n=5 
experiments. The asterisks * and ** indicate respectively p<0.05 and p<0.01 of the Mann & Whitney test. 
 
 
Proteins and phosphorylation events with decreased levels pointed to significant 
overrepresentation of functions related to peroxisome proliferator-activated receptor 
(PPAR) pathway, lysosome and extracellular matrix interaction (proteome level), as well 
as gap junction, Alzheimer’ s disease, long-term potentiation, long-term depression, 
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axon guidance, Wnt and MAP kinase pathways (phosphoproteome level) 
(Supplementary Table IV.3).  
 
Table IV.3 | Classification of quantified proteins and phosphorylation sites. Class 1 includes proteins or 
phosphorylation sites which were significantly changing in both replicates. Class 2 consists of proteins 
phosphorylation sites which were significantly changing in at least one replicate, and have the same trend 
in both replicates. Class 3 was significant in at least one replicate and had a missing value in the other 
replicate. 
 
 
 Proteins Phosphorylation sites 
 Increased in 
Fmr1- KO 
Decreased in 
Fmr1- KO 
Increased in 
Fmr1- KO 
Decreased in 
Fmr1- KO 
Class 1 134 132 86 56 
Class 2 77 75 131 129 
Class 3 34 59 124 157 
Classes 1+2+3 245 266 341 342 
 
 
Next, the STRING [172, 173] database was searched for known and predicted protein-
protein interactions among classified proteins and phosphorylation events detected in 
the dataset. The STRING analysis revealed strong clusters of cell cycle-related and 
ribosomal proteins among proteins with increased levels in Fmr1- cells (Supplementary 
Figure IV.1A). Interestingly, a cluster of proteins of the ubiquitin/proteasome system was 
also present in that part of the dataset, pointing to a possible increase of protein 
degradation as a consequence of FMRP loss. Among proteins with decreased levels in 
Fmr1- cells, the STRING analysis detected several members of the gluthatione-S-
transferase (GST) protein family, as well as PTEN/ phospholipase pathway and Notch 
signaling (Supplementary Figure IV.1B). The decrease in GST members can be linked to 
the increase in oxidative stress markers observed in the brain of Fmr1-KO mice [174, 
204]. In phosphoproteome dataset, increased phosphorylation was observed on clusters 
of proteins related to pre-mRNA processing, DNA replication, ribosomal proteins and 
several proteins involved in nuclear transport, such as nucleoporins (Figure IV.4A), 
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revealing that FMRP influence on these processes is largely mediated at protein 
phosphorylation level. Among proteins with decreased phosphorylation levels in Fmr1- 
cells several proteins from the MAPK pathway were detected (Figure IV.4B). To gain a 
more detailed insight into differences in specific signal transduction networks, classified 
proteins and phosphorylation events onto highly conserved pathways from Kyoto 
Encyclopedia of Genes and Genomes (KEGG)[205] were mapped, focusing on the mTOR, 
p53, Wnt and MAPK pathways.  
 
 
 
 
 
 
Figure IV.4 | Known and predicted protein interactions of detected phosphoproteins in Fmr1- STEK cells. 
A) proteins with increased phosphorylation; B) proteins with decreased phosphorylation. Interactions were 
retrieved from the STRING database using all phosphorylation sites from classes 1-3. 
 
 
IV.1.3.1. mTOR signaling Pathway 
In Fmr1- cells, the levels of mTOR and the main proteins of the Akt-mTOR pathway were 
not significantly changing in steady states were not significantly changing 
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(Supplementary Figure IV.2). However, the data showed a significant decrease in the 
phosphorylation level on ERK (see below), as well as decreased phosphorylation levels 
of IRS1 and Rictor. Interestingly, a significant decrease in levels of PTEN was detected. 
PTEN is an inhibitor of the PI3K-AKT cascade pathway which is associated with memory 
and learning process [206] and whose downregulation is connected to autism[207] and 
FXS [208]. Also, significant increase of phosphorylation on the S6 protein was observed. 
Likely, this is consequence of activated p70 S6 kinase [209] and points to increase of 
mTOR activity and protein synthesis in Fmr1- MEFs.  
The mammalian target of rapamycin (mTOR), a serine/threonine kinase is a signaling 
node that plays an important role in cellular processes such as protein synthesis and 
proliferation [210]. Notably, the mTOR/Akt pathway controls mGluR5-mediated activity-
dependent protein synthesis involved in synaptic plasticity. There are contradictory 
statements on the contribution of the Akt-mTOR pathway on the exaggerated global 
protein synthesis in FXS. While Sharma et al. suppose a possible role for mTOR signaling 
in increased mGluR-LTD and assume a causal relationship between elevated mTOR 
signaling and over-activation of group 1 mGluRs [211], Osterweil et al. showed that 
mTOR does not contribute to the increased protein synthesis [212]. These authors also 
showed that ERK1/2 pathway is responsible for elevated protein synthesis, still the 
pathway by itself is not overactive, but rather hypersensitive to stimulation [211, 212].  
 
IV.1.3.2. p53 Signaling Pathway 
Dataset revealed significant increase of the p53 protein in Fmr1- cells as well as 
significant changes in eight other proteins linked to p53 signaling. Chk1, Cdk4/6, Cyclin 
B, Cdc2 and p53R2 were increased, whereas KAI, PTEN and TSAP6 were decreased 
(Supplementary Figure IV.3).  
Using adult neuronal progenitor/stem cells (aNPCs) as a model, Luo et al. showed that 
FMRP regulates Cyclin D and Cdk4 mRNAs involved in cell cycle progression [213]. In 
addition, Liu et al showed that Cyclin B is upregulated in Drosophila FXS model [214], 
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which supports proposed involvement of FMRP in cell cycle control. Although there is to 
date very little evidence linking p53 signaling to FXS, recent reports show the 
involvement of FMRP in the DNA damage response [215, 216], a cellular response which 
triggers activation of the p53 pathway. Also, p53 mRNA is a putative target of FMRP since 
its 3’UTR harbors a G-quadruplex RNA structure [217] that is an RNA motif bound with 
high affinity by FMRP [189, 218]. Furthermore, there are several reports on the role of 
p53 in autism. Sheikh et al. examined a possible apoptosis signaling deregulation in the 
brain of autistic subjects and found increased levels of p53 [219]. Taken together, these 
results point to involvement of p53 and its downstream targets in dysregulated cell cycle 
control in FXS. 
 
IV.1.3.3. WNT Signaling Pathway 
The canonical Wnt pathway is crucial for activation of neuronal differentiation during 
neurogenesis and its inhibition induces hippocampus-dependent learning deficits [220, 
221]. For this reason it was hypothesized that defective Wnt signaling might be linked to 
human mental disorders like FXS. Indeed, reduced Wnt signaling in aNPCs was found by 
Luo et al. in the hippocampus of Fmr1-KO mice [222]. Data revealed decrease of FRP 
level, which normally blocks Wnt canonical pathway (Supplementary Figure IV.4). Since 
it is reported that Wnt signaling is reduced in FXS, it is possible that this is one of the 
compensatory mechanisms. In addition, decreased levels of Knypek was detected. It was 
shown previously that Knypek influences synaptic formation and that is involved in 
AMPAR mobility[223]. In Wnt/calcium pathway significant decrease both in PLC levels 
and its phosphorylated forms, significant dephosphorylation of PKC, as well as significant 
dephosphorylation of the transcription factor NFAT was detected. Therefore, it can be 
hypothesized that calcium homeostasis and Wnt/calcium dependent gene expression 
may be affected in molecular pathogenesis of FXS. 
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IV.1.3.4. MAPK Signaling Pathway 
The generated data points to a general downregulation of the canonical MAPK pathway, 
including related receptors and signaling nodes such as EGF-receptor, Ras and ERK1/2 
(Supplementary Figure IV.5). It showed a decrease in ERK2 levels and a significant 
decrease in the phosphorylation status of ERK2 Thr183 and Tyr185, based on statistical 
significance mentioned in the methods section. Decreased levels of ERK1/2 and its 
phosphorylation are associated with cell proliferation, migration and differentiation, also 
in the central nervous system, and these processes are therefore expected to be affected 
in FXS [224]. Deficits in proper neurogenesis and neuronal differentiation in the absence 
of FMRP were previously described [225]. Importantly, a significant reduction in basal 
phosphorylation of ERK1/2 was also observed previously in the CA1 region of the Fmr1-
KO hippocampus [212]. In addition, a significant increase of Filamin A (FLNA) levels with 
concomitant significant decrease in its phosphorylation levels was observed.  
Interestingly, it was previously reported that Filamin A phosphorylation modulates actin 
neuronal remodeling [214] and that its downregulation in dfmr1-null Drosophila 
participates in abnormal neuronal branching [226]. Importantly, in Fmr1- cells, significant 
increase in level of the cytoskeleton regulator PAK kinase was observed. This kinase was 
previously reported to be a drug target for FXS and autism therapy [227, 228]. 
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IV.2. Inhibition of GSK-3β kinase in murine Fmr1-KO cell lines 
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
GSK-3 plays important role in various processes through different pathways [87]. Its 
abnormal activity has been implicated in different diseases such as Alzheimer’s disease, 
mood disorders, diabetes and cancer. Evidence that inhibition of GSK-3β can restore a 
number of abnormalities in FXS is an important indication of overlap between FXS and 
other diseases [86]. Therefore, GSK-3 is considered to be an important drug target, 
among other diseases, for the FXS. Based on the present literature, knowledge about 
GSK-3 implication in signaling pathways is not quite clear. In addition, from proposed 
GSK-3 substrates only a small portion is confirmed, leaving open space to investigate how 
many of these substrates are indeed regulated by GSK-3. Pharmacological blocking of 
the kinase can help to identify new substrates and provide better knowledge of its role 
in the signaling network.  Here, we use triple SILAC based approach in order to compare 
changes on phosphoproteome level after applying two different GSK-3 inhibitors on the 
MEF cell lines. Both, Fmr1+ MEF and Fmr1- MEF “light” cells were treated with unspecific 
GSK-3 inhibitor lithium for 3 hours, “medium” labeled cells were untreated, while 
“heavy” cells were treated with specific GSK-3β TDZD-8 inhibitor for 1 hour, respectively.  
IV.2.1. Inhibitor treatment 
An essential element towards finding new kinase substrates is the identification of 
downregulated phosphorylation events upon blocking the kinase. To this end, Fmr1+ 
MEF and Fmr1- MEF cell lines were treated with 2 different inhibitors – 20mM unspecific 
GSK-3 inhibitor and 5µM specific GSK-3β TDZD-8 inhibitor at different time points (0, 0.5, 
1, 3, 6, 12 hours). To test when the kinase is blocked, we performed Western blot analysis 
of different time points of MEFs cell lysates using antibody specific for phosphorylation 
of serine 9 in GSK-3β. Increased phosphorylation level demonstrates inhibition of the 
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GSK-3β kinase upon treatment [86]. The analysis showed an increased phosphorylation 
level of serine 9 after 1 hour in lithium, and 3 hours in TDZD-8 treatment (Figure IV.5). 
These time points were chosen for subsequent SILAC experiments. 
IV.2.2. Proteome and phosphoproteome analysis 
As a part of standard quality check, incorporation of the SILAC labels and mixing check 
were verified by MS (Supplementary Table IV.4 and Supplementary Table IV.5). 
Extracted proteins from SILAC-labeled cells were equally mixed, for each cell line 
separately, and digested with trypsin. A small portion of the digested proteins were 
further fractionated according to their isoelectric point for proteome measurement and 
the remaining portion was subsequently enriched for phosphopetides using TiO2 
enrichment. 
 
Figure IV.5 | Western blot analysis of GSK-3β inhibition. A) Western blot analysis of lithium treatment in 
Fmr1+ MEFs; B) Western blot analysis of lithium treatment in Fmr1- MEFs; C) Western blot analysis of TDZD-
8 treatment in Fmr1+ MEFs; D) Western blot analysis of TDZD-8 treatment in Fmr1- MEFs.  
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Peptides were analyzed on the LTQ Orbitrap Elite coupled to the EASY-nLC. Experiments 
were performed in biological replicates and the resulting data was processed by 
MaxQuant software package [169] (Figure IV.6).  
Combined analysis of 68 proteome and phosphoproteome MS runs resulted in 
identification of 51,048 peptide sequences (FDR 0.24%), 6,016 protein groups (FDR 
1.41%) and 7,285 unique phosphorylation events (FDR 0.30%), of which 5,168 
phosphorylation events were localized to a specific Ser/Thr/Tyr residue (Supplementary 
Table IV.6). 
Correlation between biological replicates was similar for proteome and 
phosphoproteome level. Changes on both levels were not high which led to a generally 
low correlation and low reproducibility between biological replicates with exception of 
Fmr1+ MEF cell line treated with TDZD-8 (Supplementary Figure IV.6, Supplementary 
Figure IV.7). This indicated that TDZD-8 is a more specific inhibitor of GSK-3β and 
therefore more suitable for analysis of its potential substrates.  
In order to find phosphorylation events that are changing, we applied Significance B 
calculation (see Methods). In general, Fmr1+ MEF cells were less affected by treatment 
than Fmr1- MEF cells implicating that Fmr1- cells are more sensitive to lithium and TDZD-
8 treatments. Distributions for both cell lines are shown in Supplementary Figure IV.8 
and Supplementary Figure IV.9.  
For further bioinformatic analysis, phosphorylation events were clustered into three 
classes based on quantification confidence. A total of 180 phosphorylation sites in Fmr1+ 
MEF cells and 276 sites in Fmr1- MEF cells were significantly changing in at least one 
biological replicate upon lithium treatment; in case of TDZD-8 treatment, 215 sites were 
significantly changing in Fmr1+ MEF cells and 265 sites in Fmr1- MEF (Figure IV.7). 
Detailed classification is presented in Table IV.4. 
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Figure IV.6 | Proteomic and phosphoproteomic workflow of MEF cells inhibitory treatment. Fmr1- MEFs 
and Fmr1+ MEFs cells were grown in SILAC labeled medium. In experiment 1, Fmr1+ MEFs treated with 
lithium were “light” and MEFs treated with TDZD-8 were “heavy” labeled, whereas untreated MEFs were 
labeled “medium”. In the second experiment, the same labeling and treatment were applied on the Fmr1- 
MEFs. After applied treatment, cells were harvested, lysed and proteins were extracted. Next, equally 
mixed proteins, for each experiment separately, were digested. Small part of peptides was used for offgel 
separation (proteome analysis), while another part was purified via solid phase extraction and sequentially 
incubated with TiO2 beads (phosphoproteome analysis). Samples were measures by nano-HPLC MS/MS on 
a LTQ-Orbitrap Elite and further processed using the MaxQuant software.  
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Figure IV.7. Distribution of significantly changing phosphorylation sites. A) Significantly changing 
phosphorylation sites in lithium treatment in Fmr1+ MEFs; B) Significantly changing phosphorylation sites 
in TDZD-8 treatment in Fmr1+ MEFs; C) Significantly changing phosphorylation sites in lithium treatment in 
Fmr1- MEFs; D) Significantly changing phosphorylation sites in TDZD-8 treatment in Fmr1+ MEFs. Red dots 
are representing phosphorylation sites that are significantly changing in both biological replicates (Group 
1), blue dots are phosphorylation sites that are significantly changing in one biological replicate and have 
the same direction in another biological replicate (Group 2), and black dots are phosphorylation sites that 
are not significantly changing.  
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A 
B 
Table IV.4 | Classification of quantified phosphorylation sites. A) Significantly changing phosphorylation 
sites in lithium treatment; B) Significantly changing phosphorylation sites in TDZD-8 treatment. Class 1 
includes phosphorylation sites which were significantly changing in both replicates. Class 2 consists of 
phosphorylation sites which were significantly changing in one replicate, and have the same trend in 
another replicate (with a cutoff of 0.7 and 1.41, which is around 1 SD). Class 3 was significant in one 
replicate and had a missing value in the second replicate.  
 
 
 
Lithium treatment 
Fmr1+ MEFs Fmr1- MEFs 
Class 1 Class 2 Class 3 Class 1 Class 2 Class 3 
Downregulated 3 9 69 18 14 105 
Upregulated 6 10 83 18 9 112 
Total 9 19 152 36 23 217 
 
 
 
TDZD-8 treatment 
Fmr1+ MEFs Fmr1- MEFs 
Class 1 Class 2 Class 3 Class 1 Class 2 Class 3 
Downregulated 18 20 53 8 16 122 
Upregulated 17 25 82 13 16 92 
Total 35 45 135 21 30 214 
 
 
IV.2.3. Identification of GSK-3β substrates  
Due to low correlation and lack of reproducibility between biological replicates during 
lithium treatment, we decided to focus on TDZD-8 treatment. TDZD-8 is proven to 
specifically bind GSK-3β, therefore treatment with such inhibitor should cause less side 
effects. In order to identify GSK-3β kinase substrates in MEF cells we looked for 
decreased phosphorylation upon TDZD-8 treatment. In Fmr1+ MEF cells a total of 91 
phosphorylation sites showed decreased phosphorylation levels, whereas in Fmr1- MEF 
cells 146 phosphorylation sites showed decreased phosphorylation levels upon TDZD-8 
treatment. These phosphorylation events were potential substrates of the GSK-3β 
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kinase. Next, we compared our list with a list of known and proposed substrates from 
the literature [229]. 
In Fmr1+ MEF cells, inhibition by TDZD-8 confirmed one reported substrate (MAP1B), 
whereas in Fmr1- MEF cells it confirmed four reported substrates (CTNND1, DPYSL2, 
DPYSL3 and NDRG1); all of them were significantly downregulated in at least one 
biological replicate (Figure IV.8 A-D). Interestingly, all six downregulated 
phosphorylation events from MAP1B, with GSK-3 motif, had a decreased 
phosphorylation level only in the Fmr1+ MEF cell line, while in Fmr1- MEF was not 
regulated. MAP1B is known as a major substrate of GSK-3β and is involved in axonal 
growth regulation by binding microtubules in its phosphorylated state [230].  
 
Figure IV.8 | Overview of overlap with known substrates and GSK motif in our phosphoproteome data 
upon TDZD-8 treatment. A) Overlap with reported (known and proposed) substrates in Fmr1+ MEFs; B) 
Overlap with reported (known and proposed) substrates in Fmr1- MEFs; C) Number of phosphorylation 
proteins with GSK motif in Fmr1+ MEFs; D) Number of phosphorylation proteins with GSK motif in Fmr1+ 
MEFs. 
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The best known GSK-3β function is its involvement in the canonical WNT signaling 
pathway, where it is creating the “C” destruction complex via association with 
adenomatous polyposis coli (APC), axin and β-catenin. Once phosphorylated, β-catenin 
is degraded via ubiquitination/proteosome-dependent proteolysis. Dephosphorylation 
of β-catenin is important for its translocation to the nucleus and induction of 
transcription [231]. In our data, we confirmed the downregulation of β-catenin only upon 
lithium treatment in Fmr1- MEF (Supplementary Figure IV.10), while in other treatments 
(Fmr1+, lithium and TDZD-8) we were not able to quantify it. However, we quantified 
another member of the catenin family, δ-catenin, where we measured a significant 
decrease in the phosphorylation level in Fmr1- MEF cells in both treatments, and in Fmr1+ 
MEF is not significantly changing. δ-catenin is connected to mental retardation, learning 
deficits, synaptic plasticity, reduced LTP, spine and synapse morphogenesis and signaling 
of group I mGluR receptors [232-234]. Although a known GSK-3β target, δ-catenin was 
so far not connected with FXS and we propose that it could play an important role in 
molecular pathogenesis of the disorder. 
We next compared potential substrates detected in Fmr1+ MEFs and Fmr1- MEF cell lines 
(Figure IV.9) upon TDZD-8 treatment. Somewhat surprisingly, we found a poor overlap, 
pointing to the fact that different cell lines have distinct responses to GSK-3β inhibition. 
Although in Fmr1- cells we detected a seemingly higher number of potential substrates, 
overall they were regulated to a much lower extent and most of them were quantified 
only in one replicate (class 3). This can be due to decreased specificity of the TDZD-8 in 
Fmr1- MEFs, or decreased specificity of the kinase (or both). Two common 
phosphorylation events belong to the same tumor protein D54, protein which have not 
been connected to the GSK-3β. This protein is known to play a role in cell growth, 
apoptosis and vesicle trafficking [235], which is in agreement with known GSK-3β 
functions. 
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Figure IV.9 | Overlap of downregulated phosphorylation events upon TDZD-8 treatment in Fmr1+ and 
Fmr1- MEFs.  
 
List of the potential substrates, from class 1 and class 2, detected in this study in Fmr1+ 
MEFs and Fmr1+ MEFs is shown is Table IV.5 and Table IV.6, respectively, while class 3 is 
shown in Supplementary Table IV.7 and Supplementary Table IV.8. 
 
IV.2.4. Functional enrichment analysis of potential GSK-3β substrates 
In order to gain insights into the GSK-3β-mediated signaling, we performed functional 
enrichment analysis of Gene Ontology (GO) and KEGG terms of phosphoproteins that 
were significantly downregulated upon TDZD-8 treatment in Fmr1+ and Fmr1- MEF cells. 
Processes related to focal adhesion, adherents junction and regulation of actin 
cytoskeleton were significantly overexpressed among potential GSK-3β substrates in 
Fmr1+ MEF cells. Moreover, enrichment revealed overexpression of cytoskeletal protein 
binding, cytoskeleton organization and actin binding in Fmr1+ MEFs, and cell cycle, 
division processes, ribonucleotide binding and GTPase and ATP binding in Fmr1- MEFs 
(Supplementary Table IV.9). 
 
Table IV.5 | Potential substrates of GSK-3β in Fmr1+ MEFs (class 1 and class 2). Table contains protein 
name of the potential substrate, presence of GSK-3 motif, overlap with known substrate [229], position of 
phosphorylated amino acid and phosphorylated residue. 
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Protein.names 
GSK-3 
motif 
Reported 
substrates 
Position Amino.acid 
Acetyl-CoA carboxylase 1   79 S 
Actin, cytoplasmic 1   239 S 
Alpha-actinin-3   160 S 
Cyclin-dependent kinase 17   146 S 
Cofilin-2   3 S 
Drebrin +  142 S 
E3 ubiquitin-protein ligase DTX3L +  9 S 
Filamin A-interacting protein 1-like +  842 S 
Filamin A-interacting protein 1-like   551 S 
Golgi membrane protein 1   213 S 
Heat shock protein beta-1   74 S 
Heat shock protein beta-1   15 S 
Interferon-activable protein 204 +  190 S 
Interferon-activable protein 204 +  106 T 
Microtubule-associated protein 1B  + 992 S 
Microtubule-associated protein 1B + + 1497 S 
Microtubule-associated protein 1B + + 1438 S 
Microtubule-associated protein 1B + + 1422 S 
Microtubule-associated protein 1B + + 1293 S 
Microtubule-associated protein 1B + + 1775 S 
Nestin +  1837 S 
Nestin +  1565 S 
Nexilin   296 S 
PDZ and LIM domain protein 5 +  359 S 
Phosphatase and actin regulator 4   593 S 
Protein PML +  17 S 
Protein phosphatase 1 regulatory subunit 12A +  299 S 
Protein prune homolog 2 +  2638 S 
Protein prune homolog 2   1682 S 
Tyrosine-protein phosphatase non-receptor type 12   434 S 
TBC1 domain family member 15   32 S 
Tns1 protein +  836 S 
Tumor protein D54   166 S 
tRNA methyltransferase 10 homolog A   21 T 
Vinculin +  346 S 
Vinculin +  290 S 
Vinculin   721 S 
14-3-3 protein zeta/delta   207 S 
Table IV.6 | Potential substrates of GSK-3β in Fmr1- MEFs (class 1 and class 2). Table contains protein 
name of the potential substrate, presence of GSK-3 motif, overlap with known substrate [229], position of 
phosphorylated amino acid and phosphorylated residue. 
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Protein.names 
GSK-3 
motif 
Reported 
substrates 
Position Amino.acid 
Sperm-specific antigen 2 homolog   90 S 
Tumor protein D54   166 S 
Transmembrane protein 106B   34 S 
Mitogen-activated protein kinase kinase kinase kinase 5   433 S 
Supervillin   294 S 
Arfip1 protein   132 S 
Centrosomal protein of 170 kDa   443 S 
GTP-binding protein RAD   25 S 
cAMP-dependent protein kinase type II-beta regulatory subunit   112 S 
Tyrosine-protein phosphatase non-receptor type 12   448 S 
High mobility group protein HMGI-C +  44 S 
Cadherin-11   714 S 
NAD kinase   48 S 
Receptor-interacting serine/threonine-protein kinase 2   411 S 
Epidermal growth factor receptor kinase substrate 8   684 S 
Protein NDRG1  + 2 S 
Septin-10   424 S 
SH3 domain-containing kinase-binding protein 1   193 S 
Echinoderm microtubule-associated protein-like 3   177 S 
Ppp2r5d protein   565 S 
Ribonuclease inhibitor   2 S 
Suppression of tumorigenicity 5 protein   512 S 
Ppfia1 protein   571 T 
Plectin   4032 T 
 
These differences could represent a consequence of a different activity of GSK-3β in 
Fmr1+ and Fmr1- MEF cells. 
To gain a better insight into predicted protein-protein interactions we searched proteins 
with significantly dowregulated phosphorylation events in the STRING database [172, 
173]. The STRING analysis confirmed clusters from functional enrichment analysis. 
Proteins involved in adherent junction are clustering together in Fmr1+ cells, and DNA 
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replication, RNA processing and cytoskeleton organization in Fmr1- cells (Figure IV.10). 
Results of functional enrichment and STRING analysis upon lithium treatment are shown 
in Supplementary Figure IV.11 and Supplementary Table IV.10. 
 
 
 
 
 
 
Figure IV.10 | Known and predicted protein interactions of detected phosphoproteins upon TDZD-8 
treatment. A) proteins with decreased phosphorylation in Fmr1+ cell line; B) proteins with decreased 
phosphorylation in Fmr1- cell line.  
 
 
 
 
 
 
IV.3. Dynamic SILAC of WT and Fmr1-KO primary cortical neurons 
Physiological, developmental or pathological state of the cell can change protein level 
through protein synthesis and/or protein degradation [118]. In this dynamic state, 
abundance of proteins is a consequence of protein turnover - balance between these 
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processes. Advances in proteomics have allowed large scale determination of the protein 
turnover and protein half-lives using SILAC metabolic labeling. In order to measure 
FMRP-dependent protein turnover, we performed dynamic SILAC labeling of WT and 
Fmr1-KO primary cortical neurons. Neurons were grown in “heavy” SILAC medium and 
collected at different time points (2, 3, 4, 5, 6 and 10 DIV). After cell lysis, proteins were 
extracted, digested with trypsin and resulting peptides were measured on LTQ-Orbitrap 
Elite. Acquired MS data were processed and incorporation of heavy SILAC label was 
quantified by MaxQuant [169] software package (Figure IV.11). Experiment was done in 
biological replicate. 
Six time points from WT and Fmr1-KO neurons, in biological replicate, resulted in 24 runs. 
We identified 19,421 non-redundant peptides (FDR 0.25%) and 2,557 proteins (FDR 
1.63%).  
 
IV.3.1. Turnover rates in WT and Fmr1-KO cortical neurons 
As a prerequisite to the turnover calculation, we checked for overall incorporation rates 
of the SILAC label in the analyzed neurons. Considering that proteins are constantly 
synthesizing and degrading, incorporation of “heavy” labeled proteins should increase 
with time and higher turnover proteins should incorporate the label faster. In our 
incorporation curves, we observed an almost identical increasing trend of incorporation 
in WT and Fmr1-KO neurons, respectively (Figure IV.12). However, Fmr1-KO neurons had 
slightly higher incorporation rate than WT neurons. In addition, our first time point (2 
DIV) had an incorporation level around 50% and at the last time point (10 DIV) 
incorporation  
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Figure IV.11 | Proteomic workflow for dynamic SILAC. WT and Fmr1-KO cortical neurons were grown in 
SILAC labeled medium. Neurons were collected at different time points. After collection of the neurons, 
proteins were extracted and digested. Samples were measured by nano-HPLC MS/MS on a LTQ-Orbitrap 
Elite and incorporation of heavy SILAC label was quantified by MaxQuant software. 
 
 
 
Figure IV.12 | Incorporation rate in WT and Fmr1-KO cortical neurons. WT is shown in blue, and Fmr1-KO 
in red color. Solid lines present the first, and dashed lines the second biological replicate. 
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was around 80% which is considered as maximal achievable labeling of neurons due to 
the fact that they are not dividing. 
For calculation of protein turnover rates and half-lives we adopted approach from 
Schwanhausser et al [152]; see Methods. In order to obtain more reliable results, for the 
turnover rate calculation we considered proteins with at least 3 SILAC ratios in all time 
points and with coefficient of determination (R2, correlation coefficient between 
measured and estimated ratios) higher than 0.7  in all biological replicates of WT and 
Fmr1-KO. After we applied this filter, we were left with 622 proteins with a SILAC ratio in 
all samples (Supplementary Table IV.11). Pearson correlation coefficients of protein 
half-lives between biological replicates were ≥ 0.99, indicating high reproducibility 
(Figure IV.13 A and Figure IV.13 B), and pearson correlation between mean of WT and 
Fmr1-KO was ≥ 0.99, indicating high similarity between different genotypes (Figure IV.13 
C). Interestingly, however the measured protein half-lives were shorter in the WT than 
in KO cells. This was reflected in the median of half- lives: in Fmr1-KO neurons median 
was 102 hours, while in WT was 88 hours, indicating faster turnover in WT neurons.  
 
IV.3.2. Proteins with high and low turnover 
In order to determine which proteins have high or low turnover, we binned distributions 
of the protein half-lives into four quartiles (Figure IV.14). Proteins with half-lives in 
quartile 1 are defined as proteins with high turnover, in quartile 2 as moderately high 
turnover, quartile 3 as moderately low turnover, and quartile 4 as ones with low protein 
turnover.  
Although proteins in Fmr1-KO have somewhat lower turnover rate, statistically, our data 
confirms that most of the proteins have similar half-life in WT and Fmr1-KO neurons. 
Functional enrichment analysis of Gene Ontology (GO), Pfam and KEGG terms was 
performed in order to see which processes and pathways differ in each quartile for WT 
and Fmr1-KO neurons, separately. 
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Figure IV.13 | Correlation of half-lives. A) Between biological replicates in WT cortical neurons; B) Between 
biological replicates in Fmr1-KO cortical neurons; C) Between mean of biological replicates - WT and KO. 
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Figure IV.14 | Box plots of protein half-lives. Green box plots represent WT and blue one Fmr1-KO. 
 
In WT and Fmr1-KO neurons proteins with the lowest turnover rate are proteins involved 
in oxidative phosphorylation, Alzheimer’s, Parkinson’s and Huntington’s disease (Figure 
IV.15 A), whereas proteins with the highest turnover rate are involved in phagosome, 
Wnt signaling pathway and gap junction (Figure IV.15 B). Results of functional 
enrichment analysis for other processes are shown in Supplementary Tables 12-15. This 
analysis confirmed that the pool of proteins with high or low protein turnover does not 
differ between WT and Fmr1-KO neurons. However, it is evidently possible to distinguish 
proteins from different quartiles based on their involvement in different pathways and 
processes. 
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Figure IV.15 | Functional enrichment analysis in WT and Fmr1-KO neurons. A) Enrichment of KEGG terms 
in quartile 4; B) Enrichment of KEGG terms in quartile 1 in first top 15 KEGG terms based on corrected p-
values. 
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IV.4. Global identification of differentially regulated proteins in mouse models 
of Fragile X Syndrome 
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
It is believed that dysregulated translation and elevated protein synthesis is the main 
cause of the symptoms in fragile X patients. To this end, it is not clear which proteins are 
affected by this imbalance. Additionally, the connection between  FXS and exaggerated 
mGluR5 signaling [78] was confirmed by pharmacological and genetic approaches 
(development of Fmr1-KO/mGluR5 het KO cross – genetic rescue model of FXS). 
Therefore, in this part of the project we aimed to analyze differences in protein 
expression levels in the WT, the FXS mouse model, and the “FXS rescue” mouse model. 
To that end we measured nine biological replicates of the WT, Fmr1 KO and Fmr1-
KO/mGluR5-het cross mice hippocampi by employing label-free quantification. 
Furthermore, we applied total protein approach (TPA) to determine absolute protein 
levels [164]. 
All samples were measured using high resolution mass spectrometry, resulting in 81 
LC/MS runs during 14 days of measuring time LTQ Orbitrap Velos or LTQ Orbitrap Elite 
(Thermo Fisher Scientific) coupled to the EASY-nLC II liquid chromatographer (Proxeon 
Biosystems). Workflow overview is shown in Supplementary Figure IV.12. 
 
IV.4.1. Reproducibility and data validation 
To test reproducibility we investigated Pearson correlation coefficient between protein 
intensities recorded in biological and technical replicates (Figure IV.16). As expected, 
correlation between measurements of same genotype was high (>0.8), and there was no 
major difference between different experiments and genotypes in comparison with 
biological replicates measured in the same experiment. Similar correlation between 27 
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samples pointed out that measured proteomes of the corresponding mice are very 
similar to each other. 
 
 
Figure IV.16 | Correlation matrix of all WT, Fmr1-KO and Fmr1-KO/mGluR5 het samples. Color and 
thickness of the lines indicate correlation. The thicker the line is, correlation is higher. 
 
In order to validate our data, we looked for the positive controls: FMRP, which should be 
absent in Fmr1-KO mice; and mGluR5, which should be reduced by ca. 50% in Fmr1-
KO/mGluR5-het mice (Figure IV.17 A and Figure IV.17 B). Although a low amount of 
FMRP was observed Fmr1-KO mice, manual inspection of the data revealed that this was 
an artifact of the “match between run (MBR)” option used during data processing 
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(Supplementary Figure IV.13). Additional validation for FMRP protein was done by 
Western blot in which FMRP is detectable in WT, but not in knockout mice (Figure IV.17 
C). Importantly, the levels of mGluR5 were measured to be ca. 50% reduced in the Fmr1-
KO/mGluR5-het mice, validating the ability of the label-free approach to quantify 2-fold 
changes in protein abundance in our dataset. 
The connection between FXS and exaggerated mGluR5 activity was suggested by Bear et 
al. [78]. Still, it was unclear whether increased activity comes from increased expression 
of mGluR5, its increased activity, or both. There are few studies addressing this question 
[236, 237]. In our data, relative protein expression of mGluR5 in Fmr1-KO revealed no 
significant difference in comparison with WT, which is in agreement with results of Dolen 
et al [81]. (Figure IV.17 B). 
 
Figure IV.17 | Positive controls and data validation. A) Relative expression of FMRP in WT, Fmr1-KO and 
Fmr1-KO/mGluR5; B) relative expression of mGluR5 in WT, Fmr1-KO and Fmr1-KO/mGluR5 het; C) Western 
blot analysis of FMRP in WT, Fmr1-KO and Fmr1-KO/mGluR5 het.  
IV Results: Global identification of differentially regulated proteins in mouse models of FXS 
 
83 
 
IV.4.2. Quantitative proteome of FXS mouse models 
Label free quantification analysis of WT, Fmr1-KO and Fmr1-KO/mGluR5-het cross mice 
resulted in 2,627,231 MS/MS spectra that identified 61,479 non-redundant peptides and 
5,238 protein groups (Supplementary table IV.16). Estimation for the false discovery 
rate at the peptide level was 0.39% and at the protein group level 1.76%. After data was 
imputed, normalized, and LFQ intensities were log-transformed as described in the 
Methods, we applied ANOVA to test for differential expression of proteins among 
different genotypes. ANOVA analysis resulted in 68 significantly changing proteins 
between WT and Fmr1-KO, 45 between Fmr1-KO and Fmr1-KO/mGluR5-het cross mice 
and 106 between WT and Fmr1-KO/mGluR5-het cross mice. Summary of significantly 
upregulated and downregulated proteins is showed in Table IV.7.  
 
Table IV.7 | Overview of significantly changing proteins in pairwise comparison. Significantly changing 
proteins Fmr1-KO vs WT, Fmr1-KO vs Fmr1-KO_mGluR5-het and Fmr1-KO_mGluR5-het vs WT. 
 
 Significantly changing proteins 
 Fmr1-KO / WT Fmr1-KO / Fmr1-KO_mGluR5-het Fmr1-KO_mGluR5-het / WT 
Downregulated 19 17 57 
Upregulated 49 28 49 
 
 
 
Principal component analysis (PCA) applied to the whole dataset initially could not show 
any significant difference between different genotypes (Figure IV.18 A); however, it 
could separate genotypes when applied to significantly changing proteins only, 
indicating that these proteins indeed have different expression levels between tested 
mice (Figure IV.18 B). As expected, PCA shows that two most distinct genotypes are WT 
and rescue mouse model. Next, we compared our dataset with known mRNA targets of 
FMRP [44]. Although 582 proteins overlapped with mRNA dataset, only two proteins had 
higher expression, while two had lower expression level in Fmr1-KO in comparison with 
WT. Although it is expected that a higher number of mRNA targets would have a higher 
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expression in Fmr1-KO (considering that FMRP should repress  translation [68]), it seems 
that other controlling mechanisms are influencing protein level in the brain. We also note 
that the HITS-CLIP study that detected FMRP targets (41) was performed in a different 
tissue (whole mouse brain) and that it is lately debated whether it correctly reported 
endogenous FMRP targets [49]. 
 
 
 
Figure IV.18 | Principal component analysis. A) All proteins from corresponding compared pairs; B) 
Significantly changing proteins from corresponding compared pairs. 
 
One of the proteins with significantly different expression between WT and Fmr1-KO 
mice was the Major prion protein (PrP), which was shown to be downregulated in Fmr1-
KO brain (Figure IV.19 A).  Since Prp has a role in short and long memory processing [238, 
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239] and it could potentially be involved in pathogenesis of FXS, we validated the MS 
data by western blotting. Western blot results were in agreement with MS data, 
confirming that Prp has higher expression level in WT in comparison with Fmr1-KO 
(Figure IV.19 B).  
 
 
Figure IV.19 | Data validation. A) Relative expression of PrP in WT, Fmr1-KO and Fmr1-KO/mGluR5 het; B) 
Western blot analysis of Prp in WT, Fmr1-KO and Fmr1-KO/mGluR5 het.  
 
 
IV.4.3. STRING analysis of significantly regulated proteins 
A list of significantly changing proteins between WT and Fmr1-KO, Fmr1-KO and Fmr1-
KO/mGluR5-het cross mice and WT and Fmr1-KO/mGluR5-het cross mice were 
separately uploaded to STRING (The Search Tool for the Retrieval of Interacting Genes) 
database [240, 241] to look for known and predicted protein interactions. Significantly 
changing proteins were uploaded together for every pairwise comparison.  
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STRING analysis of Fmr1-KO and WT revealed a node of ribosomal proteins which have 
higher protein expression in Fmr1-KO (Figure IV.20). It was reported that FMRP is 
associated with ribosomes [42, 242], mostly with the 60s ribosomal subunit, but 
association with the 40s ribosomal subunit was detected as well [243]. We detected 
many ribosomal proteins, but found six from 60s and three from 40s ribosomal subunit 
with higher expression in Fmr1-KO. Additionally, the same trend in terms of direction is 
observed for mitochondrial ribosomal proteins and mitochondrial transcription factors 
Tfam and Gfm1. Mitochondrial dysfunction was previously connected to Fragile X-
associated tremor/ataxia syndrome and autism caused by increased nitrative/oxidative 
stress [244, 245]. Our data suggests that mitochondrial transcription regulation is also 
likely to be disturbed in FXS.  
Moreover, some other proteins like scaffold proteins of the postsynaptic density (PSD) 
Dlgap3, AMPA-type glutamate receptor (AMPAR) subunit Gria4 and dynamin-1 were 
detected as significantly downregulated. Considering their known function, they could 
be involved in FXS pathogenesis (see discussion).   
Network analysis of Fmr1-KO and Fmr1-KO/mGluR5-het cross mice was performed in 
order to see a difference in mechanism between FXS mouse model and its rescue. 
Mostly, predicted interactions are between proteins involved in metabolism 
(Supplementary Figure IV.14). Small node with Citron Rho-interacting kinase (Cit) and 
Rho guanine nucleotide exchange factor 17 (Afhgef17), RNA targets reported by Darnell 
et al. [44], and Cell division control protein 42 homolog are downregulated in Fmr1-KO. 
These proteins are known to be involved in neurogenesis [246, 247]. Moreover, it was 
shown that Cit is functionally linked to Fmr1 gene [248] and that this kinase is interacting 
with mGluR5 receptor[249]. Citron kinase is also known to form a complex with PSD-95 
and it is concentrated at the postsynaptic side of glutaminergic synapses [250], therefore 
it is possible that this kinase plays an important role in the rescue mechanism of FXS. The 
most numerous group of significantly changing proteins resulted from WT and Fmr1-
KO/mGluR5-het cross mice comparison (Supplementary Figure IV.16). 
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Figure IV.20 | STRING analysis. Network of significantly changing proteins from pairwise analysis of Fmr1-
KO and WT genotype. Red color indicates increased protein expression, and green decreased protein 
expression in Fmr1-KO, respectively. Black circles indicate that these proteins are overlapping with proteins 
from Darnell et al. dataset. 
 
This comparison shows that WT and rescue mouse model are the most diverse genotype 
groups, despite the fact that the FXS phenotype of the rescue model is more similar to 
WT than it is to Fmr1 KO. STRING analysis revealed a node of ribosomal proteins that 
have higher expression levels in the rescue model than in the WT. This indicates that the 
higher expression level of ribosomal proteins in FXS mouse model was not reverted by 
the reduction of mGluR5 activity and therefore likely does not play role in the rescue 
mechanism.  
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IV.4.4. Estimation of absolute protein levels  
It was previously reported that protein synthesis is elevated in the hippocampus of 
Fragile X mouse model [51, 81, 181]. We applied the total protein approach (TPA) to 
estimate the absolute level of measured proteins in all three analyzed genotypes. Briefly, 
individual LFQ intensities were divided by the sum of all LFQ intensities of every protein 
of a sample which corresponds to the total MS signal of the proteome in that sample 
[164]. Comparison of absolute protein levels did not show any significant difference in 
absolute level between WT, Fmr1-KO and rescue mouse model. Surprisingly, when TPA 
was applied separately to significantly changing proteins, we observed that proteins with 
higher expression level in Fmr1-KO (in comparison to WT) tend to be more abundant 
than those with lower expression levels (Figure IV.21). We argue that this fact may be 
the reason for seemingly higher overall protein expression levels reported in previous 
studies (see discussion). Conversely, abundance of significantly changing proteins was 
similar in WT and the rescue model. 
 
Figure IV.21 | Comparison of absolute protein abundance between WT, Fmr1-KO and Fmr1-KO/mGluR5 
het. TPA was calculated by dividing individual LFQ intensities by the sum of all LFQ intensities of every 
protein of a sample. Next, TPA values were multiply by 100 in order to get percentage scale (y axis).
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V DISCUSSION 
Fragile X Syndrome (FXS), caused by silencing of the Fmr1 gene and its product FMRP, is 
still a disorder with unclear pathology. Function of FMRP as an RNA binding protein with 
many targets related to protein synthesis and signal transduction pathways makes this 
disorder attractive to study using proteomic tools. Although lot of research was done in 
this field in the last decade, only a few studies applied global proteomic approaches [52, 
53, 251]. Therefore, this thesis presents the first systematic proteomic large-scale 
analysis of different FXS models. 
 
V.1. Quantitative phosphoproteomics of murine Fmr1-KO cell lines provides 
new insights into FMRP-dependent signal transduction mechanisms 
Comparison of the proteome and phosphoproteome of the Fmr1-KO MEF cell lines, 
performed in this thesis, is the first global large-scale study on this cellular model of FXS. 
We detected 266 proteins and 146 phosphorylation events that are significantly 
changing between Fmr1- and Fmr1+ MEF cells in both replicate measurements. By 
mapping proteins and phosphorylation events to the signaling pathways we confirmed 
downregulation of MAPK signaling pathway in Fmr1- cells, which was previously 
associated with FXS [224] and is dysregulated in other neurological disorders related to 
intellectual impairment [252, 253]. Other pathways like mTOR, Wnt, p53 and MAPK 
signaling pathway express several dysregulated proteins that were known to be 
associated with autism, but not with FXS. cPLA is an example which we validated by 
western blot. This enzyme is associated with long term potentiation (LTP), memory 
process, gene transcription and phospholipid turnover. Its increased protein level leads 
to disruption of the membrane structure which leads to cognitive impairment and 
increased oxidative stress [254] which is known to be associated with FXS [255]. In 
general, strong molecular overlap is connecting FXS and autism. Up to 35% individuals 
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with FXS are diagnosed with autism [6], therefore better understanding of molecular 
mechanism in FXS can be beneficial for better understanding of autism as well. 
 
V.2. Inhibition of GSK-3β kinase in murine Fmr1-KO cell lines 
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
When a kinase plays an important role in diverse pathways like GSK-3, it is not surprising 
that its regulation is implicated in different diseases. One of the disorders with disturbed 
GSK-3β activity is FXS. In different FXS models, increased GSK-3β activity has been 
inhibited using lithium (unspecific GSK-3β inhibitor), which showed a reversal of mGluR-
dependent LTD [91], hyperactivity [92], learning deficits, dendritic spine shape, anxiety 
[93] and macroorchidism [94]. Therefore, GSK-3β is a promising target in treatment of 
FXS. 
In order to better understand the function of the kinase, it is crucial to know its 
substrates. So far, around 100 substrates of GSK-3 are known, but it is believed that some 
are still undiscovered [229]. In order to look for new substrates in a large scale 
experiment, proteomics is a great tool of choice, which thus far has not been used in this 
context. Conventional approaches are normally labor- and time-consuming, with an 
outcome of one or few substrates, therefore proteomics screening could indeed result 
in a much higher number of substrates. 
Here we applied a SILAC approach to compare the phosphoproteome of Fmr1+ and Fmr1- 
MEF cells treated with lithium as an unspecific, and TDZD-8 as a specific inhibitor of GSK-
3β kinase. Experiments were performed in biological replicates and showed low 
reproducibility in lithium treatment between replicates on the level of the proteome and 
phosphoproteome. One of the possible reasons for this could be weak and unspecific 
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interaction of lithium with GSK-3β, which would lead to unspecific inhibition of the 
kinase. Indeed, off-target effects of lithium have been previously reported [256]. 
Conversely, treatment with TDZD-8 showed a good correlation between biological 
replicates (r > 0.7) in Fmr1+ MEF cells and a weak correlation in the Fmr1- MEF cells. We 
were interested in proteins with downregulated phosphorylation upon TDZD-8 
treatment, since TDZD-8 is known to specifically inhibit GSK-3β and reduction of kinase 
activity should inevitably lead to a reduction of phosphorylation levels on its direct 
substrates. We focused on a total of 91 significantly decreased phosphorylation events 
in Fmr1+ and 146 decreased phosphorylation events in Fmr1- MEF cells. Although the 
number of downregulated phosphorylation events seems to be higher in Fmr1- cells, it is 
important to note that poor reproducibility between replicates and generally lower 
extent of regulation point to impaired specificity of the kinase (or inhibitor) in Fmr1- cells. 
This result alone may reflect dysregulation of the kinase in FXS. 
By comparing our data with the list of the reported GSK-3β substrates [229], we were 
able to confirm several of them; however most of our significantly decreased 
phosphorylation events present potential new substrates of the kinase. Approximately 
half of the potential substrates contain a GSK-3 motif, which is an additional supporting 
argument for a direct substrate, although it is known that the GSK-3 motif is not very 
specific, as one of the best known targets (β-catenin) does not contain it [231].  
Correlation between TDZD-8 treatment in Fmr1- and Fmr1+ cells showed different 
influence of the inhibitor in these two cell lines. Interestingly, overlap of significantly 
decreased phosphorylation events in Fmr1- and Fmr1+ MEF cell lines revealed only two 
events that are common to both. Both phosphorylation events belong to the same tumor 
protein D54 that was previously not known as a GSK-3β substrate and is involved in cell 
growth and apoptosis.  Moreover, functional enrichment analysis revealed implication 
of the potential substrates in cytoskeleton organization and actin binding in Fmr1+ MEFs, 
while in Fmr1- MEFs potential substrates seem to be more involved in cell cycle, DNA 
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replication and RNA processing. Involvement of GSK-3β in cytoskeletal reorganization is 
well known [257], however the role of the kinase in DNA replication and mismatch repair 
was recently reported [258]. A study showed that inhibition of the kinase protects mouse 
hippocampal neurons from radiation by accelerating double strand–break efficiency 
[258]. Another study showed downregulation of DNA damage/repair pathway in FXS 
patients [259]. Therefore, these results could indeed implicate a different role of GSK-3β 
in MEF cells. Moreover, downregulation of 6 phosphorylation event on MAP1B, a well 
know substrate, was detected only in Fmr1+ MEF cell line. When phosphorylated, MAP1B 
is coordinating microtubule dynamics and inhibition of these dynamics results in 
disturbed axon guidance and branching [260]. Since abnormal axon branching is one of 
the leading symptoms in FXS, we speculate that this could be a direct consequence of a 
dysregulation of the GSK-3β kinase in FXS. This could be due to disturbed priming 
phosphorylation, which is often required for GSK-3β substrate phosphorylation. Another 
reason could be disturbed MAPK pathway in FXS, or more specific ERK 1/2 kinases. It was 
shown that phosphorylation of MAP1B by GSK-3β requires activity of ERK 1/2 [261]. Since 
we showed a downregulation of the MAPK pathway in the FXS model, it is possible that 
the lack of regulation of MAP1B by GSK-3β in Fmr1- MEFs is a consequence of this 
aberrant signaling.  
Fmr1-KO mouse embryonic fibroblasts (MEFs) is well established FXS model [67, 68], 
however, when studying implications of GSK-3β targets in neuronal development, 
another model (as neuronal cell line) with a similar approach should be considered due 
to a lack of expression of certain receptors and proteins that are not present in 
fibroblastic cell line. 
 
V.3. Dynamic SILAC of WT and Fmr1-KO primary cortical neurons 
In the cell, proteins are constantly synthetized and degraded. Therefore, different 
methods were developed in order to measure protein synthesis and turnover [122] , such 
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as different tagging strategies coupled with inhibition of translation [262]. Recent 
advances in proteomics have allowed a large scale determination of the protein turnover 
in cells using SILAC metabolic labeling. By using this approach, determination of protein 
half-lives was possible for hundreds of proteins at the same time [152]. While it is 
possible to completely label “standard” cells, neurons are considered more problematic 
due to the fact that they are not dividing. In 2008, Spellman et al. showed that neurons 
can achieve high level of SILAC incorporation (≥ 80%), and that SILAC can be applied to  
non-dividing cells [155]. We combined this knowledge and applied dynamic SILAC 
labeling of WT and Fmr1-KO primary cortical neurons in order to measure protein 
turnover and retrieve information about protein half-lives. To our knowledge, this is the 
first study of protein turnover in neurons.   
Our first time point (DIV 2) had an incorporation rate of ~ 50%. Unfortunately, in this 
experimental design we were not able to get proteins with lower incorporation rates. 
Specifically, when neurons are seeded in the SILAC media they take 2 days to adhere, 
therefore earlier points would not be biologically appropriate. As a consequence, in this 
data we are missing proteins with fast protein turnover. 
In addition to a global measurement of protein half-lives, we aimed to compare protein 
turnover between neurons derived from WT and Fmr1-KO mice. WT neurons showed 
approximately 5% higher incorporation rate than Fmr1-KO neurons, pointing to the 
higher overall turnover in WT neurons. This was also reflected in the median of the half-
lives in Fmr1-KO neurons median, which was 102 hours compared to only 88 hours in the 
WT, again indicating higher turnover in WT neurons. This was surprising, considering the 
fact that one of the main problems in FXS is elevated protein synthesis, which, if 
compensated by protein degradation, should lead to higher turnover in Fmr1-KO 
neurons. However, as mentioned before, we could not cover earlier time points and it is 
possible that faster protein synthesis, combined with rapid protein degradation, lead to 
turnover times that were below the limit of our detection.  
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In general, when we looked at the individual protein half-live difference between WT 
and Fmr1-KO we were not able to find any statistically significant change. However, we 
could see the difference between the proteins with high and low protein turnover based 
on their involvement in different pathways and processes. In addition, it is possible that 
proteins with fast protein turnover are carrying the difference between WT and Fmr1-
KO, which we are not able to see with our current experimental design. The experimental 
design could be changed in a way that two groups of neurons are grown at the same 
time. The first group of the neurons should be grown in “light” and the second in “heavy” 
medium. After the neurons are attached (around two days), “light” medium can be 
exchanged with “heavy” medium because it should contain all different factors that 
neurons excreted in first two days, and that are needed for neuronal survival. Since 
neurons should be starting to incorporate “heavy” labels after they are attached, early 
points could be collected. This experimental approach currently being implemented.  
Nevertheless, even without early time points, for the first time, we showed that it is 
possible to use the SILAC approach in primary neurons to retrieve information about 
protein half-lives which is useful for the research community. 
 
V.4. Global identification of differentially regulated proteins in mouse models 
of Fragile X Syndrome 
 
This chapter of the thesis is manuscript in preparation from Matic el al.  
 
The main problem in FXS is dysregulated translation and elevated protein synthesis. So 
far, it is not very clear which and how many proteins, and their levels are influenced by 
this dysregulation. In addition, suggested connection of FXS and exaggerated mGluR5 
signaling [78] led to the development of Fmr1-KO/mGluR5 het KO cross – genetic rescue 
model of FXS , which showed correction of most of FXS symptoms [78]. Therefore, we 
V Discussion 
 
95 
 
aimed to analyze differences in protein expression levels in the WT, the FXS mouse 
model, and the “FXS rescue” mouse model. This data represents the biggest proteome-
wide quantitative comparison of protein levels in the hippocampi between WT, Fmr1-KO 
mice and Fmr1-KO/mGluR5-het cross mice. Fmr1-KO mouse model is a reliable FXS 
model that recapitulates several cellular and behavioral phenotypes of FXS, while Fmr1-
KO/mGluR5 het KO cross is a great genetic rescue model whose better understanding 
could help to gain more insights in the FXS pathogenesis.      
Phenotypically these three mice models are easily distinguishable. However, Pearson 
correlation between biological replicates and different genotypes revealed no major 
difference at the proteome level, which means that these mice are, surprisingly, very 
similar to each other. Nevertheless, we aimed to look for proteins that are significantly 
changing between these genotypes by applying pairwise ANOVA analysis and looking for 
known protein interactions among them. In Fmr1-KO and WT comparison we found 
significantly regulated proteins that are known to be involved in involved in memory, 
learning and LTP and moreover, our data suggests that mitochondrial transcription 
regulation is disturbed in FXS model. 
Interestingly, scaffold proteins of the postsynaptic density (PSD) Dlgap3 and AMPA-type 
glutamate receptor (AMPAR) subunit Gria4 were detected as significantly 
downregulated. The mRNA of Dlgap3 is a reported target of FMRP [44, 196, 263]. Schütt 
et al. analyzed protein levels of PSD in 2 weeks and 2 months old mice and observed an 
increase in protein levels of Dlgap3 only in hippocampus of 2-month old mice. Another 
study reported a decreased level of Dlgap3 in prefrontal cortex of 2-4 months old Fmr1-
KO mice [264]. Among other symptoms, FXS mouse model includes compulsive repetitive 
behaviors. It is known that a loss of Dlgap3 leads to the same behaviors which was shown 
in Dlgap3 KO mouse model [265]. Wan et al. studied effects of Dlgap3 deletion on 
AMPAR synaptic transmission [266]. They found that a Dlgap3 deletion is causing a 
reduction in AMPAR-mediated neurotransmission which can be reversed by reducing 
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mGluR5 activity. It is known that regulation of AMPAR trafficking has an important role 
in synaptic plasticity process involved in memory and learning [72, 267]. Nakamoto et al. 
observed that AMPAR internalization, a major mechanism for synaptic depression, is 
increased in FMRP deficient dendrites as a result of exaggerated mGluR5 signaling [80].  
Our data suggests that a decreased protein level of Gria4 can be the consequence of a 
decreased protein level of Dlgap3. In addition, it is possible that the protein level of 
Dlgap3 depends on the age of the mice and that its decreased level plays important role 
during early development that can influence mice behavior later. 
It is known that AMPAR endocytosis which occurs via clathrin-mediated endocytosis 
requires activity of dynamin [268]. Dynamin 1 is the main dynamin isoform in the 
neurons [269]. Recently, it was shown that dynamin-1 is involved in memory formation 
and its inhibition leads to reduced LTP [270]. In our dataset we observed downregulation 
of dynamin-1 in Fmr1-KO mice.  
In the network analysis of FXS and rescue model, we expected to see proteins involved 
in the rescue mechanism. Considering mGluR5 theory, these proteins should be 
upregulated in FXS model in comparison with rescue model. Most of the proteins with 
this trend seem to be involved in metabolism. Unexpectedly, ones that are overlapping 
with known RNA targets from FMRP [44] are showing the opposite effect.   
Overlapping our data with known RNA targets [44] of FMRP serves as an additional 
validation of our data. However, overlap in this project, as well in proteome and the 
phosphoproteome of the Fmr1-KO MEF cell lines project, turns to be quite poor when it 
comes to a significantly changing proteins. Since FMRP is established as an RNA-binding 
protein which inhibits translation [68], it is expected, if certain protein is a FMRP target, 
to have increased protein level in FXS model. However, in our data we have only few 
proteins with increased protein levels, while others are having decreased levels. 
“Proteomic” cause of limited overlap could come from uncompleted proteome coverage 
or additional regulatory mechanisms that could influence the final protein level. Recently 
published work showed that previously reported FMRP targets disproportionally 
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represent the most abundant mRNAs, as well as ones with the longest coding sequence 
[49]. Thus, it seems to be clear that there is a certain bias in the reported list of mRNA 
targets of FMRP. Moreover, we showed that most of the proteins that are significantly 
changing in our data are in the range of lower abundant proteins and therefore more 
prone to quantification error. Therefore, we note that the overlap of proteomic and 
transcriptomic data should not be strictly required to validate direct targets of FMRP. 
Increased protein synthesis is one of the hallmarks of FXS. By using radioactive metabolic 
labeling in mouse hippocampal slices it was shown that total protein content is elevated 
around 10% in the FXS model [81, 181]. Since it is not clear whether this is a consequence 
of increased synthesis of the whole proteome or only of its fraction, we estimated 
absolute protein amount in the measured samples. Our results showed no difference in 
the total proteome of all three genotypes. However, we did observe the change in the 
FXS model when absolute protein amounts were calculated only for significantly 
changing proteins: proteins with higher expression level in Fmr1-KO tend to be more 
abundant that those that have lower expression level, which leads to imbalance that – 
when analyzed by methods that address only complete proteome, such as global 32S 
incorporation – may be reflected as overall increase of protein expression. Therefore, 
our results indicates that the previously reported increased global protein synthesis in 
Fmr1-KO can rather be driven by a relatively small number of upregulated proteins rather 
than the whole proteome. Our additional observation was that regulated proteins in WT 
and rescue model have a similar abundance. This observation is in agreement with the 
study from Dolen et al. [81] which reported a reduction of increased protein synthesis 
level in hippocampal slices by selective reduction in the mGluR5 gene. However, 
considering the fact that the portion of the proteins that are changing is rather small 
(<1%), this hypothesis is not statistically significant. Our results can be explained by the 
fact that we measured only around one quarter of estimated proteome or that we 
cannot detect very small change in the proteome due to technical lack of our method.  
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VI CONCLUSIONS 
In this thesis several different proteomic approaches were applied to different cellular 
and animal models of fragile X syndrome in order to gain better understanding of the 
molecular mechanisms of the disorder. The following conclusions can be drawn from the 
obtained results:    
1) Analysis of signal transduction pathways involved in the pathogenesis of FXS at 
the phosphoproteome level in SILAC-labeled murine Fmr1- and Fmr1+ fibroblastic 
cell lines 
a. Our study represents the first global large-scale analysis of proteome and 
phosphoproteome of the Fmr1-KO MEF cell lines in which we detected 
266 proteins and 142 phosphorylation sites that are significantly changing 
in both biological replicates. 
b. We confirmed a downregulation of the MEK/ERK pathway in absence of 
FMRP, with decreased phosphorylation on ERK1/2. We detected 
differential expression of several proteins involved in mTOR, Wnt, p53 
and MAPK signaling cascades, that were known to be associated with 
autism, but not with FXS. Significant increase of p53 and several related 
proteins revealed for the first time involvement of p53 signaling in 
molecular pathogenesis of FXS, while decrease in Wnt/calcium pathway 
pointed to problems in calcium homeostasis. In addition, we detected a 
significantly reduced level of the major prion protein that could have an 
important role in cognitive deficits in FXS patients.  
2) Identification of potential new GSK-3β substrates in SILAC-labeled murine Fmr1- 
and Fmr1+ fibroblastic cell lines using GSK-3β inhibition by lithium and TDZD-8 
a. Our study revealed a total of 180 phosphorylation sites in Fmr1+ MEF cells 
and 276 phosphorylation sites in Fmr1- MEF cells that were significantly 
changing in at least one biological replicate upon lithium treatment; 215 
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phosphorylation sites were significantly changing in Fmr1+ MEF cells and 
265 phosphorylation sites in Fmr1- MEF cells upon TDZD-8 treatment. 
b. Lithium treatment led to unspecific inhibition of the kinase, as reflected 
in poor reproducibility between biological replicates. Reproducibility was 
much better in TDZD-8 treatment, where we quantified 91 significantly 
downregulated phosphorylation sites in Fmr1+ MEF cells and 146 in Fmr1- 
MEF cells. Most of these events are potential new substrates of GSK-3β. 
c. We postulate that specificity of the GSK-3β kinase is decreased in Fmr1- 
MEF cells but not in Fmr1+ cells. Expected downregulation of multiple 
phosphorylation events on MAP1B, a well characterized GSK-3β 
substrate, was observed only in Fmr1+ MEF cell line treated with TDZD-8. 
Since MAP1B is coordinating microtubule dynamics and abnormal axon 
branching is one of the leading symptoms of FXS, therefore we postulate 
that the lack of regulation of MAP1B by GSK-3β is a likely cause for 
aberrant morphology of neurons in FXS. 
3) Measurement of protein turnover based on dynamic-SILAC method in primary 
cortical neuronal culture (Fmr1-KO and WT)  
a. This data represents the first large scale analysis of protein turnover in 
primary neuronal culture of WT and FXS model. We identified 2,557 
proteins, and calculated half-lifes for 622 proteins. 
b. WT neurons showed slightly higher incorporation rate than Fmr1-KO 
neurons. However, there was no significant change in individual protein 
half-live between WT and Fmr1-KO. 
4) Analysis of pathways involved in the pathogenesis and genetic rescue of FXS at 
the proteome level in mouse hippocampus 
a. This data represents the largest proteome-wide quantitative comparison 
of protein levels in the hippocampi between WT, Fmr1 KO mice and Fmr1 
KO/mGluR5-het cross mice. Pairwise comparison of the genotypes 
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confirmed known data, but also revealed dysregulation of additional 
proteins known to be involved in involved in memory, learning and LTP. 
Moreover, we also detected potential disruption of mitochondrial 
transcription regulation in FXS model. We confirmed a reduced level of 
the major prion protein in the FXS mouse model, observed in the first part 
of the thesis, which additionally pointed to its involvement in 
pathogenesis of FXS. 
b. We did not observe a significant difference in the total proteome 
expression levels between the three analyzed genotypes. Data showed a 
modest change in FXS model when absolute protein amounts were 
observed separately for significantly changing proteins. This points to the 
fact that previously observed global increase of protein synthesis in the 
neurons of FXS mice may in fact be carried by relatively few abundant 
proteins that are increasingly synthesized in FXS.  
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ABSTRACT: Fragile X mental retardation protein (FMRP) is
an RNA-binding protein that has a major eﬀect on neuronal
protein synthesis. Transcriptional silencing of the FMR1 gene
leads to loss of FMRP and development of Fragile X syndrome
(FXS), the most common known hereditary cause of
intellectual impairment and autism. Here we utilize SILAC-
based quantitative phosphoproteomics to analyze murine
FMR1− and FMR1+ ﬁbroblastic cell lines derived from
FMR1-KO embryos to identify proteins and phosphorylation
sites dysregulated as a consequence of FMRP loss. We quantify
FMRP-related changes in the levels of 5,023 proteins and
6,133 phosphorylation events and map them onto major signal transduction pathways. Our study conﬁrms global
downregulation of the MAPK/ERK pathway and decrease in phosphorylation level of ERK1/2 in the absence of FMRP,
which is connected to attenuation of long-term potentiation. We detect diﬀerential expression of several key proteins from the
p53 pathway, pointing to the involvement of p53 signaling in dysregulated cell cycle control in FXS. Finally, we detect diﬀerential
expression and phosphorylation of proteins involved in pre-mRNA processing and nuclear transport, as well as Wnt and calcium
signaling, such as PLC, PKC, NFAT, and cPLA2. We postulate that calcium homeostasis is likely aﬀected in molecular
pathogenesis of FXS.
KEYWORDS: fragile X syndrome, autism, phosphoproteomics, FMRP, FMR1, MEF
■ INTRODUCTION
Fragile X syndrome (FXS) is the leading known cause of
inherited intellectual disability1 and autism spectrum disorders
(ASD).2,3 FXS is generally caused by an abnormal CGG
trinucleotide repeat expansion and hypermethylation in the 5′
untranslated region of the fragile X mental retardation 1 gene
(FMR1), resulting in FMR1 silencing and absence of fragile X
mental retardation protein (FMRP).4,5 FMRP is an RNA-
binding protein,6 which is mainly expressed in neurons and
testes.7 It contains two (central) RNA-binding KH domains
and one (C-terminal) RGG box8 through which it can bind
hundreds of mRNA molecules in brain,9 many of which are
encoded by genes related to autism. FMRP associates with
polyribosomes10−12 and inﬂuences protein synthesis via
translational regulation.13,14 Overall, the FMRP/RNA inter-
action is a complex process involving diﬀerent RNA-binding
domains and several RNA motifs. In addition, it can be
inﬂuenced by other RNA-binding proteins interacting with
FMRP.15−17 It seems clear that FMRP binds to mRNA targets
that encode both pre- and postsynaptic proteins and
participates in the control of activity-dependent synaptic
translation. Some of the target mRNAs encode important
signaling proteins such as the metabotropic (mGluR5)9,18 or
ionotropic (NMDA receptor subunits)9,19 glutamate receptors,
members of the mTOR9 signaling pathways, and other proteins
that are involved in regulation of translation, which makes it
likely that FMRP inﬂuences major signaling pathways in the
cell. Furthermore, FMRP was described as a key player in the
transport and localization of target mRNA molecules in the
neuronal dendritic arborization toward the synapse where they
undergo localized translation.20 A loss of FMRP causes altered
synaptic development and function21 as well as disruptions in
synaptic plasticity.22 These abnormalities are the molecular
bases of intellectual disability but also of other neurological/
psychiatric pathologies associated with the FXS phenotype,
such as autism, epilepsy, hyperactivity, and attention deﬁcit
disorder. It is therefore necessary to identify proteins and
phosphorylation events dysregulated in FXS, as they may
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contribute to our understanding of the molecular pathogenesis
and present drug targets for treatment of the disorder.
FMRP is highly conserved across species, and several Fmr1-
knockout (KO) cell lines and animals have been established as
FXS models.23−25 One of them is an Fmr1-KO mouse SV40-
immortalized ﬁbroblast cell line model, termed the STEK cell
line, that is derived from Fmr1-KO embryos and has previously
been used to examine the role of FMRP as a translational
repressor in stress granules.24 Another generation of STEK cells
was obtained by stable transfection of the longest isoform of
FMRP (human ISO1) in naturally immortalized Fmr1-KO
mouse embryonic ﬁbroblasts (MEFs).26 This cellular model,
used in this study, has also been used to identify several novel
RNA targets of FMRP16,26,27 and to study the role of FMRP in
the dynamics of P bodies.28
Modern proteomic workﬂows allow quantiﬁcation of changes
on the protein and phosphorylation site levels in a global and
high throughput fashion. Stable isotope labeling by amino acid
in cell culture (SILAC) or isobaric tags for relative and absolute
quantitation (iTRAQ) strategies have been previously applied
to the study of Drosophila and mouse models of FXS.29−31 In
the SILAC-based quantitative proteomic analysis of synaptoso-
mal preparations from Fmr1-KO and WT cortical neurons, Liao
et al. detected 132 proteins with altered expression in the
absence of FMRP, including proteins related to autism and
epilepsy.29 In another study, iTRAQ was used to quantify
proteomes of FMR1-KO vs WT mice hippocampi; this study
resulted in quantiﬁcation of 23 proteins with diﬀerential
expression involved in cell diﬀerentiation, neurite outgrowth,
and synaptic vesicle release.30 Finally, heterozygous dfmr1∓
Drosophila labeled in vivo with SILAC allowed proﬁling of 1,617
proteins and identiﬁcation of some proteins known to be
diﬀerentially regulated in FXS, such as actin-binding protein
proﬁlin and microtubulin-associated protein futsch.31
Phosphorylation can alter protein function and activity and
plays a signiﬁcant regulatory role in a wide range of biochemical
and cellular processes,32 including signaling pathways and
transduction cascades. Despite the fact that several signaling
pathways are known to be aﬀected in FXS,33,34 global protein
phosphorylation dynamics in FXS-related model systems was
so far not investigated. Here we perform a quantitative analysis
on the proteome and phosphoproteome of murine FMR1− and
FMR1+ MEF cells by using high resolution mass spectrometry
in combination with SILAC.35 Metabolic SILAC-labeling
enabled us to identify and quantify thousands of proteins and
phosphorylation events and map them to major regulatory
pathways, giving unprecedented insights in the pathophysiology
of FXS.
■ MATERIALS AND METHODS
Cell Culture and SILAC Labeling
A spontaneously immortalized ﬁbroblastic murine Fmr1-KO
cell line was established from mouse embryonic ﬁbroblasts
(MEFs) derived from FMR1-null C57Bl/6J embryos (mouse
strain gR2700 available from Jackson Laboratory). FMR1-KO
MEFs cells were then transfected with a pTL10 vector
containing FMR1 isoform 1 human cDNA or with an empty
pTL10 vector.36 Simultaneously, cells were cotransfected with a
pIREShyg3 plasmid (Clontech-BD Bioscience) containing
Hygromycin B resistance. This procedure resulted in two
stable cell lines: one stably re-expressing FMRP, termed as
STEK-59 (FMR1+ MEFs), and one Fmr1-KO cell line further
referred to as STEK-87 (FMR1− MEFs). MEF cells were
cultured in DMEM medium (Dulbecco’s modiﬁed eagle
medium, High Glucose (4.5 g/L), PAA, or PAN Biotech)
lacking arginine, lysine, and L-glutamine. L-Glutamine (2 mM,
Gibco), penicillin/streptomycin (100 U/mL, PAN), Hygrom-
ycin B (from Streptomyces hygroscopicus, 150 μg/mL, Sigma-
Aldrich), and dialyzed FBS (10%, Invitrogen) were added to
the medium. The “light” SILAC media was further
supplemented with 73 mg/L L-lysine Lys0 and 42 mg/L L-
arginine Arg0 (both from Silantes), whereas 73 mg/L “heavy”
L-lysine Lys8 (13C6,15N2-L-lysine, Silantes) and 42 mg/L
“heavy” L-arginine Arg10 (13C6,15N4-L-Arginine, Silantes)
were added to the “heavy” SILAC medium. Both cell lines
(FMR1+ MEFs and FMR1− MEFs) were grown in an incubator
(37 °C, 5% CO2) in either “light” or “heavy” SILAC DMEM
medium. A complete overview of applied methods is shown in
Figure 1.
Protein Extraction
To extract SILAC-labeled proteins from cell culture, cells were
washed twice with 5 mL of DPBS (PAA Laboratories) and put
on ice to prevent protein degradation during the following
denaturation step with a buﬀer containing 6 M urea, 2 M
thiourea, and 10 mM Tris-Base. Protease (complete Mini
EDTA-free Proteinase Inhibitor Cocktail) and phosphatase
inhibitors (glycerol-2-phosphate, sodium ﬂuorite, and sodium
orthovanadate) were added. DNA and RNA were removed
during 10 min incubation with benzonase (EMPROVE bio;
Merck) at room temperature (RT) followed by centrifugation
at 2800g (4000 rpm, 10 °C, 25 min). The DNA- and RNA-
containing precipitate was removed afterward.
In-Solution Protein Digestion and Isoelectric Focusing
Extracted proteins from each cell line were mixed 1:1 (“light” to
“heavy” and vice versa; according to Bradford assay, Bio-Rad
Laboratories). Protein mixtures were digested according to the
protocol published by Macek et al.37 Portions of the tryptic
peptides, 100 μg per sample, were further fractionated
according to their isoelectric point on 3100 OﬀGel fractionators
(Agilent) by Oﬀ-Gel separation using manufacturer’s instruc-
tions. Focusing was done with 13 cm Immobiline DryStrips pH
3−10 (GE Healthcare), resulting in 12 fractions per sample.
Current was limited to 50 μA and fractionation completed as
soon as 20 kVh were reached. Fractions were acidiﬁed using
acidic acid (30% ACN, 10% TFA, and 5% acetic acid in water)
before desalting on StageTips, described by Ishihama.38
Phosphopeptide Enrichment
Phosphopeptide enrichment was done as described previ-
ously39 with the following modiﬁcations: 5 mg of digested
peptides per sample (a portion of tryptic digestion described in
previous section) were separated using strong cation exchange
(SCX) chromatography with a linear gradient of 0−35% of
SCX solvent B over 32 min, which resulted in 16 fractions. The
resulting 16 fractions were pooled to 11 fractions according to
the SCX chromatogram. The ﬂow-through, containing un-
bound peptides, was collected separately. Eleven fractions per
replicate plus ﬂow-through were further processed via TiO2
chromatography. Hereafter, phosphopeptides were eluted in
three steps with elution buﬀer (40% ammonium hydroxide
solution in 60% acetonitrile, pH 10.5). The TiO2 chromatog-
raphy was done once or twice per fraction depending on the
phosphopeptide quantities expected from the SCX chromato-
gram. Enrichment of the ﬂow-through was done ﬁve times.
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Nano-LC-MS/MS Analysis
All peptides were measured on Easy-LC nano-HPLC (Proxeon
Biosystems) coupled to an LTQ Orbitrap Elite mass
spectrometer (Thermo Fisher Scientiﬁc) for the proteome or
an LTQ Orbitrap XL (Thermo Fisher Scientiﬁc) for the
phosphoproteome. Liquid chromatography was done with a 15
cm fused silica emitter with an inner diameter of 75 μm and a
tip diameter of 8 μm, in-house made nano-HPLC column,
packed with reversed-phase ReproSil-Pur C18-AQ 3 μm resin
(Dr. Maisch GmbH). Peptides were ﬂushed with HPLC solvent
A (0.5% acetic acid) at a ﬂow rate of 500 nL/min with the
maximum pressure of 280 bar. Elution was done using
segmented 90 min gradient (LTQ Orbitrap Elite) or 130 min
(LTQ Orbitrap XL) of 5−90% HPLC solvent B (80% ACN,
0.5% acetic acid) at a ﬂow rate of 200 nL/min. The eluted
peptides were ionized in an electrospray ionization (ESI)
source (Proxeon Biosystems) set to positive ion mode. Full
scan MS spectra were acquired in the orbitrap analyzer in a
mass range from m/z 300−2000 at a resolution of 120,000
(LTQ Orbitrap Elite) or 60,000 (LTQ Orbitrap XL), followed
by fragmentation in an LTQ mass analyzer of the top 20 (LTQ
Orbitrap Elite) or top 5 (LTQ Orbitrap XL) most intense
precursor ions with collision induced dissociation (CID) at a
target value of 5000 charges. Dynamic exclusion was used to
exclude fragmented masses for 90 s. In addition, for
phosphoproteome measurement (LTQ Orbitrap XL), ions
were fragmented by multistage activation (MSA) on the neutral
loss ions at −98, −49, and −32.6.
Data Processing and Analysis
The mass spectrometer data were processed using MaxQuant
suite V 1.3.0.5.40,41 Spectra were searched using andromeda
search engine42 against the proteome database of Mus musculus
(UniProt complete proteome database, downloaded on 25
December 2012), consisting of 50,697 protein entries and 247
commonly observed lab contaminants. The mass tolerance for
the ﬁrst search was set to 20 ppm, and to 6 ppm for the main
search. The multiplicity was set to two. Lys0, Arg0 and Lys8,
Arg10 for “light” and “heavy” samples, respectively. Full tryptic
speciﬁcity was required, and a maximum of two missed
cleavages were allowed. Carbamidomethylation of cysteine was
set as ﬁxed modiﬁcation, while oxidation, acetylation (on N-
term), and phosphorylation on Ser/Thr/Tyr were chosen as
variable modiﬁcations. The initial mass tolerance for the
precursor ion was set to 6 ppm and 0.5 Da at the fragment ion
level. For quantiﬁcation of proteins, a minimum of two peptides
with at least seven amino acids had to be detected. The
maximum allowed posterior error probability (PEP) was set to
1, and the false discovery rate (FDR) to max 1% for peptides
and proteins. Requantiﬁcation was enabled while the second
peptides were disabled.
The localization probabilities of potential phosphorylation
events on Ser/Thr/Tyr were calculated based on the post-
translational modiﬁcation (PTM). Quantiﬁcation of phosphor-
ylation sites was normalized with the respective protein
abundance, provided the protein was quantiﬁed.
Bioinformatic Analysis
Perseus V 1.3.0.4, a module from the MaxQuant suite,40 was
used for calculation of the Pearson correlation for both
proteome and phosphoproteome. This was done by extraction
of the H/L ratios from the ProteinGroups.txt ﬁle, generated in
MaxQuant. Contaminants, reverse hits or identiﬁed by site,
were removed, values Log2 transformed, and the Pearson
correlation calculated for the H/L ratios of both replicates.
The calculation of signiﬁcantly changing proteins and
phosphorylation sites was also done in Perseus V 1.3.0.4
(two-tailed “Signiﬁcance B” test; p ≤ 0.05). H/L ratios were
transformed to Log2, whereas intensities of peptides or
phosphorylation sites were Log10 transformed. For signiﬁcance
of phosphorylation sites, H/L ratios were normalized by
corresponding protein H/L ratios.
In the same module we performed functional enrichment
analysis of Gene Ontology, Pfam, and KEGG terms for
increased and decreased classiﬁed proteins and phosphorylation
sites. We applied truncation based on Benjamini−Hochberg43
corrected p-values with a threshold value of 0.05 to test whether
speciﬁc annotation terms are signiﬁcantly enriched or depleted
among the chosen set of proteins of interest. The adjusted p-
values were ±log10 transformed and visualized in Excel. The
Figure 1. Proteomic and phosphoproteomic workﬂow for two
replicates of SILAC-labeled cells. FMR1− MEFs and FMR1+ MEFs
cells were grown in SILAC-labeled medium for 14 days. In biological
replicate 1, FMR1− MEFs were “heavy” and FMR1+ MEFs “light”
labeled, while, in biological replicate 2, labeling was inversed. After
labeling, cells were harvested, followed by cell lysis and protein
extraction. Full incorporation of SILAC amino acids was conﬁrmed.
After 1:1 mixing of “heavy” and “light” cell lysates and subsequent in-
solution digestion, one part was used for the proteomic workﬂow,
which includes separation by OﬀGel and measurement by nano-HPLC
MS/MS on a LTQ-Orbitrap Elite and further processing by MaxQuant
software. The greater part of digested proteins was fractionated by
SCX, and phosphopeptides were enriched by TiO2 chromatography
before subsequent measurements by nano-HPLC MS/MS on a LTQ-
Orbitrap XL.
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list of proteins and phosphorylation sites from classes 1−3 was
divided based on their increasing or decreasing levels separately
uploaded to the STRING (The Search Tool for the Retrieval of
Interacting Genes) database44,45 to look for known and
predicted protein interactions. We requested the highest
conﬁdence score of 0.9 for the predicted protein interaction
and discarded disconnected nodes.
The available list of FMRP protein−RNA interactions (pri)
or protein−protein interactions (ppi) manually curated from
the literature46 was updated with recent references (notably ref
9) and used to appreciate the overlap between dysregulated
proteins in the present data sets of protein levels and
phosphorylation events.
Western Blotting
Cell extracts were analyzed by Western blotting as described
previously.46,47 The following primary antibodies were used:
1C3 against FMRP (1:50048); 3Fx against FXR1P and cross-
reacting with FXR2P (1:50049), anti-β-actin monoclonal
antibody (1:20,000; Sigma), anti-β-tubulin monoclonal anti-
body (1:500, clone E7, Iowa Developmental Hybridoma Bank,
USA), anti-cPLA2 (1:1,000, Santa Cruz), and anti-Prp (1:500,
clone SAF7050). Digital acquisition of the chemiluminescent
signal was performed using the Las-3000 Imager system
(Fujiﬁlm). Quantitation of Western blot was performed using
the ImageJ software and normalized to the β-actin or β-tubulin
signal. GraphPad 4 software was used for statistical analysis.
■ RESULTS AND DISCUSSION
To compare the proteome and the phosphoproteome of the
FMR1− and the control FMR1+ MEF cell lines, we performed
two SILAC experiments in reverse labeling manner. Brieﬂy,
SILAC-labeled cells were lysed, and their proteins were
extracted and digested with trypsin. A smaller portion of the
digests was separated by isoelectric focusing (for proteome
measurement), whereas the larger portion was subjected to two
stages of phosphopeptide enrichment, using SCX and TiO2
chromatographies (for phosphoproteome measurement). All
LC-MS/MS measurements were performed on the LTQ-
Orbitrap mass spectrometers and MS data were processed by
MaxQuant software package (Figure 1). Incorporation of
SILAC labels was veriﬁed in dedicated mass spectrometry runs,
which conﬁrmed full labeling of the MEF proteome
(Supporting Information Table 1). “Heavy” (Arg10, Lys8)
and “light” (Arg0, Lys0) labeled cell lysates were mixed in equal
amounts as veriﬁed by MS measurements (Supporting
Information Table 2). Pearson correlation coeﬃcients between
SILAC ratios measured in two biological replicates were r =
−0.932 for the proteome and r = −0.708 for the
phosphoproteome data, indicating high reproducibility at
both levels (Figure 2A, B). Inverse correlation is a consequence
of inverse SILAC labeling.
Overview of Proteome and Phosphoproteome Results
Combined analysis of 24 MS runs from isoelectric focusing
(proteome analysis) and 44 MS runs from phosphopeptide
enrichment resulted in 56,352 identiﬁed peptide sequences
from 6,703 protein groups. Identiﬁed protein groups were
ﬁltered for contaminants, reverse (decoy) hits, and proteins
identiﬁed by modiﬁcation site. The estimated false discovery
rate (FDR) was 0.36% at the peptide level and 2.09% at the
protein group level. From 6,235 detected endogenous MEF
proteins, 4,195 were quantiﬁed in both replicates, of which 266
were changing signiﬁcantly in both biological replicates (134
were increasing and 132 decreasing). Scatter plots of measured
protein ratios are shown separately for both replicates in Figure
2C, D.
The phosphoproteome analysis revealed 9,181 phosphor-
ylation events on 2,494 proteins. Since we expected expression
diﬀerences at both proteome and phosphoproteome levels, we
normalized phosphopeptide ratios with protein ratios. The total
number of quantiﬁed phosphorylation events that could be
normalized by the respective protein ratio was 6,040, of which
142 showed signiﬁcant changes in both replicates (86
phosphorylation sites were increasing, and 56 phosphorylation
sites were decreasing in FMR1− cells compared to the FMR1+
cells). Distributions of phosphorylation events measured in
both replicates are shown in Figure 2E, F.
We next compared our quantiﬁed proteome data set with
reported mRNA targets or protein interactors of FMRP9,51−62
(see Materials and Methods section). This comparison revealed
383 proteins, of which 23 were signiﬁcantly changing in at least
one biological replicate in our data set. Surprisingly, the levels
Figure 2. Correlations of proteome and phosphoproteome.
Correlation between biological replicates at the (A) proteome and
(B) phosphoproteome levels. Each dot represents a SILAC protein or
phosphorylation site ratio measured in both biological replicates.
Negative correlation is a consequence of inversed SILAC labeling.
Distributions of quantiﬁed proteins from (C) biological replicate 1;
(D) biological replicate 2; (E) phosphorylation sites replicate 1; and
(F) biological replicate 2. Intensity is log10, H/L ratios log2
transformed. Red dots represent signiﬁcant (p < 0.05) outliers,
which are reported separately for increased and decreased in FMR1−
MEF.
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of only eight proteins were signiﬁcantly increasing in FMR1−
MEFs, as should be expected for mRNA targets for which
FMRP would repress translation,16 while 15 were signiﬁcantly
decreasing. This limited overlap can have several reasons,
starting from the proteome coverage obtained in our study (we
estimate that we quantiﬁed about one-third of all expressed
proteins in the cell), studied system (original mRNA data are
derived from the mouse brain), and additional regulatory
mechanisms that likely inﬂuence the ﬁnal level of an FMRP
target protein in the cell, such as protein degradation. All
detected proteins and phosphorylation events of proteins that
are known mRNA targets or protein interactors of FMRP are
listed in Supporting Information Table 3.
Validation by Western Blotting
The mass spectrometry-based quantiﬁcation was further
validated by Western blot (Figure 3). Analysis using the anti-
FMRP mAb1C3 conﬁrmed the expression of FMRP in FMR1+
MEFs and its absence in FMR1− MEFs (Figure 3A). Western
blot analysis with the 3Fx antibody recognizing the homologues
of FMRP, all isoforms of Fxr1p and Fxr2p, showed that the lack
of FMRP did not aﬀect their levels of expression (Figure 3B).
This conﬁrms the mass spectrometry measurements and
previous observations that the absence of FMRP is not
compensated by upregulation of its homologues.63
We also validated two candidate proteins signiﬁcantly
dysregulated in the MS experiments. First, semiquantitative
Western blotting analysis conﬁrmed that FMR1− MEFs express
lower levels of the major prion protein (Prp) than FMR1+
MEFs (Figure 3C left panel), exhibiting a signiﬁcant decrease of
62% (p = 0.0361; Figure 3C right panel). Since PrP has a role
in the formation of synapses64 and in memory processing in the
rat hippocampus,65 we hypothesize that reduced levels of Prp
could contribute to the cognitive deﬁcits observed in the
FMR1-KO mouse. Second, we observed a signiﬁcant increase in
cytosolic calcium-dependent phospholipase A2 (Pla2g4a known
as cPLA2, Figure 3D left panel) levels which is increased by
82% in FMR1− MEFs as compared to FMR1+ MEFs (p =
0.0079; Figure 3D right panel). cPLA2 releases arachidonic acid
from membrane phospholipids. Importantly, cPLA2 partic-
ipates in cerebellar long-term depression and motor learning.66
It is tempting to speculate that abnormal overexpression of
cPLA2 in the brain could participate in the cerebellar
dysfunctions observed in Fmr1-KO mice.67 Signiﬁcantly higher
concentrations of cPLA2 have been reported in red blood cells
of patients with autism,68 further linking systemic dysregula-
tions of cPLA2 to autism.
Regulatory Pathway Analysis
For downstream bioinformatic analysis and pathway mapping,
detected proteins and phosphorylation events were clustered
into three classes based on quantiﬁcation conﬁdence as
described in Table 1. Proteins and phosphorylation events
that were not signiﬁcantly changing in any of the replicates
were not further considered.
To investigate general processes and pathways that diﬀer
between the FMR1+ and FMR1− MEFs, we ﬁrst used classiﬁed
proteins and phosphorylation sites to perform functional
enrichment analysis of Gene Ontology (GO), Pfam, and
KEGG terms. The set of proteins and phosphorylation events
with increased levels revealed signiﬁcant overrepresentation of
terms related to cell cycle, nucleotide metabolism, and p53
pathway (proteome level), as well as vasopressin-regulated
water reabsorption and ribosome (phosphoproteome level)
(Supporting Information Table 4). Proteins and phosphor-
ylation events with decreased levels pointed to signiﬁcant
overrepresentation of functions related to peroxisome pro-
liferator-activated receptor (PPAR) pathway, lysosome and
extracellular matrix interaction (proteome level), as well as gap
junction, Alzheimer’ s disease, long-term potentiation, long-
term depression, axon guidance, and Wnt and MAP kinase
pathways (phosphoproteome level) (Supporting Information
Table 5).
We next searched the STRING44,45 database for known and
predicted protein−protein interactions among classiﬁed
proteins and phosphorylation events detected in our data set.
Figure 3. Western blot analysis of FMR1-KO MEFs reexpressing
(FMR1+) or not (FMR1−) FMRP. (A) Western blot analysis with anti-
FMRP 1C3 antibody. β-tubulin (β-tub) signal is used to verify equal
loading of lanes. (B) Western blot analysis of FMR1+ or FMR1‑ MEFs
with anti-Fxr1P/Fxr2p antibody #3FX recognizing the homologues of
Fmrp, Fxr1p (short and medium isoforms), and Fxr2p. β-tubulin (β-
tub) signal is used to verify equal loading of lanes. (C) Representative
Western blot of Prp protein levels in FMR1+ or FMR1‑ MEFs.
Densitometric quantiﬁcation of Western blots reveals that depletion of
Fmr1 leads to a signiﬁcant decrease of Prp protein levels relative to
FMR1+ cells. (D) Representative Western blot of cPLA2 protein levels
in FMR1+ or FMR1− MEFs. Densitometric quantiﬁcation of Western
blots shows that depletion of Fmr1 leads to a signiﬁcant increase in
cPLA2 protein levels. Data are presented as means ± SEM of n = 5
experiments. The asterisks * and ** indicate respectively p < 0.05 and
p < 0.01 of the Mann and Whitney test.
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The STRING analysis revealed strong clusters of cell cycle-
related and ribosomal proteins among proteins with increased
levels in FMR1− cells (Supporting Information Figure 1A).
Interestingly, a cluster of proteins of the ubiquitin/proteasome
system was also present in that part of the data set, pointing to
a possible increase of protein degradation as a consequence of
FMRP loss. Among proteins with decreased levels in FMR1−
cells, the STRING analysis detected several members of the
gluthatione-S-transferase (GST) protein family, as well as
PTEN/phospholipase pathway and Notch signaling (Support-
ing Information Figure 1B). The decrease in GST members can
be linked to the increase in oxidative stress markers observed in
the brain of Fmr1-KO mice.46,69 In the phosphoproteome data
set, we observed increased phosphorylation on clusters of
proteins related to pre-mRNA processing, DNA replication,
ribosomal proteins, and several proteins involved in nuclear
transport, such as nucleoporins (Figure 4A), revealing that the
FMRP inﬂuence on these processes is largely mediated at the
protein phosphorylation level. Among proteins with decreased
phosphorylation levels in FMR1− cells, we detected several
proteins from the MAPK pathway (Figure 4B).
To gain a more detailed insight into diﬀerences in speciﬁc
signal transduction networks, we mapped classiﬁed proteins
and phosphorylation events onto highly conserved pathways
from Kyoto Encyclopedia of Genes and Genomes (KEGG),70
focusing on the mTOR, p53, Wnt, and MAPK pathways.
mTOR Signaling Pathway
In FMR1− cells, we observed that the levels of mTOR and the
main proteins of the Akt-mTOR pathway were not signiﬁcantly
changing in steady states (Supporting Information Figure 2).
However, our data showed a signiﬁcant decrease in the
phosphorylation level on ERK (see below) and we also
observed decreased phosphorylation levels of IRS1 and Rictor.
Interestingly, we detected a signiﬁcant decrease in levels of
PTEN, an inhibitor of the PI3K-AKT cascade pathway which is
associated with memory and learning process71 and whose
downregulation is connected to autism72 and FXS.73 We also
observed a signiﬁcant increase of phosphorylation on the S6
protein, which is a likely consequence of activated p70 S6
kinase74 and points to an increase of mTOR activity and
protein synthesis in FMR1− MEFs.
The mammalian target of rapamycin (mTOR), a serine/
threonine kinase, is a signaling node that plays an important
role in cellular processes such as protein synthesis and
proliferation.75 Notably, the mTOR/Akt pathway controls
mGluR5-mediated activity-dependent protein synthesis in-
volved in synaptic plasticity. There are contradictory statements
on the contribution of the Akt-mTOR pathway on the
exaggerated global protein synthesis in FXS. While Sharma et
al. suppose a possible role for mTOR signaling in increased
mGluR-LTD and assume a causal relationship between elevated
Table 1. Classiﬁcation of Quantiﬁed Proteins and
Phosphorylation Sitesa
Proteins Phosphorylation sites
Increased in
FMR1-KO
Decreased in
FMR1-KO
Increased in
FMR1-KO
Decreased in
FMR1-KO
Class 1 134 132 86 56
Class 2 77 75 131 129
Class 3 34 59 124 157
Classes
1 + 2 + 3
245 266 341 342
aClass 1 includes proteins or phosphorylation sites which were
signiﬁcantly changing in both replicates. Class 2 consists of protein
phosphorylation sites which were signiﬁcantly changing in at least one
replicate and have the same trend in both replicates. Class 3 was
signiﬁcant in at least one replicate and had a missing value in the other
replicate.
Figure 4. Known and predicted protein interactions of detected phosphoproteins in Fmr1− STEK cells: (A) proteins with increased
phosphorylation; (B) proteins with decreased phosphorylation. Interactions were retrieved from the STRING database using all phosphorylation
sites from classes 1−3.
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mTOR signaling and overactivation of group 1 mGluRs,76
Osterweil et al. showed that mTOR does not contribute to the
increased protein synthesis.77 These authors also showed that
the ERK1/2 pathway is responsible for elevated protein
synthesis; still, the pathway by itself is not overactive but
rather hypersensitive to stimulation.76,77
p53 Signaling Pathway
Our data set revealed a signiﬁcant increase of the p53 protein in
FMR1− cells as well as signiﬁcant changes in eight other
proteins linked to p53 signaling. Chk1, Cdk4/6, Cyclin B,
Cdc2, and p53R2 were increased, whereas KAI, PTEN, and
TSAP6 were decreased (Supporting Information Figure 3).
Using adult neuronal progenitor/stem cells (aNPCs) as a
model, Luo et al. showed that FMRP regulates Cyclin D and
Cdk4 mRNAs involved in cell cycle progression.78 In addition,
Liu et al. showed that Cyclin B is upregulated in the Drosophila
FXS model,79 which supports proposed involvement of FMRP
in cell cycle control. Although there is to date very little
evidence linking p53 signaling to FXS, recent reports show the
involvement of FMRP in the DNA damage response,80,81 a
cellular response which triggers activation of the p53 pathway.
Also, p53 mRNA is a putative target of FMRP, since its 3′UTR
harbors a G-quadruplex RNA structure82 that is an RNA motif
bound with high aﬃnity by FMRP.55,83 Furthermore, there are
several reports on the role of p53 in autism. Sheikh et al.
examined a possible apoptosis signaling deregulation in the
brain of autistic subjects and found increased levels of p53.84
Taken together, our results point to involvement of p53 and its
downstream targets in dysregulated cell cycle control in FXS.
WNT Signaling Pathway
The canonical Wnt pathway is crucial for activation of neuronal
diﬀerentiation during neurogenesis, and its inhibition induces
hippocampus-dependent learning deﬁcits.85,86 For this reason it
was hypothesized that defective Wnt signaling might be linked
to human mental disorders such as FXS. Indeed, reduced Wnt
signaling in aNPCs was found by Luo et al. in the hippocampus
of FMR1-KO mice.87 Our data revealed a decrease of FRP level,
which normally blocks the Wnt canonical pathway (Supporting
Information Figure 4). Since it is reported that Wnt signaling is
reduced in FXS, it is possible that this is one of the
compensatory mechanisms. In addition, we detected decreased
levels of Knypek, which was shown previously to inﬂuence
synaptic formation and is involved in AMPAR mobility.88 In
the Wnt/calcium pathway we detected a signiﬁcant decrease
both in the PLC levels and those of its phosphorylated forms,
signiﬁcant dephosphorylation of PKC, as well as signiﬁcant
dephosphorylation of the transcription factor NFAT. We
therefore postulate that calcium homeostasis and Wnt/
calcium-dependent gene expression may be aﬀected in
molecular pathogenesis of FXS.
MAPK Signaling Pathway
Our data point to a general downregulation of the canonical
MAPK pathway, including related receptors and signaling
nodes such as EGF-receptor, Ras, and ERK1/2 (Supporting
Information Figure 5). We observed a decrease in ERK2 levels
and a signiﬁcant decrease in the phosphorylation status of
ERK2 Thr183 and Tyr185, based on statistical signiﬁcance
mentioned in the Materials and Methods section. Decreased
levels of ERK1/2 and its phosphorylation are associated with
cell proliferation, migration, and diﬀerentiation, also in the
central nervous system, and these processes are therefore
expected to be aﬀected in FXS.89 Deﬁcits in proper
neurogenesis and neuronal diﬀerentiation in the absence of
FMRP were previously described.90 Importantly, a signiﬁcant
reduction in basal phosphorylation of ERK1/2 was also
observed previously in the CA1 region of the FMR1-KO
hippocampus.77 We also observed a signiﬁcant increase of
Filamin A (FLNA) levels with a concomitant signiﬁcant
decrease in its phosphorylation levels. Interestingly, it was
previously reported that Filamin A phosphorylation modulates
actin neuronal remodelling79 and that its downregulation in
dfmr1-null Drosophila participates in abnormal neuronal
branching.91 Importantly, in Fmr1− cells we also detected a
signiﬁcant increase in the level of the cytoskeleton regulator
PAK kinase, which was previously reported to be a drug target
for FXS and autism therapy.92,93
■ CONCLUSIONS
Our data represent the ﬁrst global large-scale analysis of the
proteome and phosphoproteome of the Fmr1-KO MEF cell
lines, a commonly used Fmr1-KO model. Since the control
Fmr1-KO MEF cells were re-expressing human FMRP ISO1,
we expect that the presented data reﬂect mostly the function of
this particular FMRP isoform; however, overlaps with other
FMRP isoforms as well with FMRP paralogs (FXR1P or
FXR2P) are possible. We detected 266 proteins and 142
phosphorylation sites that are signiﬁcantly changing in both
biological replicates and analyzed them in the context of the
major signal transduction implicated in FXS. We conﬁrm
downregulation of the MEK/ERK pathway in the absence of
FMRP, with decreased phosphorylation on ERK1/2. We report
diﬀerential expression of several proteins involved in mTOR,
Wnt, p53, and MAPK signaling cascades, that were known to
be associated with autism, but not with FXS. We detect
signiﬁcant increase of p53 and proteins linked to the p53
signaling. This study opens new avenues and motivates further
investigation in neuronal cultures and in vivo FXS models to
connect current insights to early signaling events from
receptors that are not expressed or functional in MEF cells.
This will ultimately lead to a better understanding of the
molecular mechanisms dysregulated in FXS.
■ ASSOCIATED CONTENT
*S Supporting Information
Incorporation rates of “heavy” isotopes of arginine and lysine in
cells after 9 days of growth in SILAC media; SILAC heavy/light
mixing error; detected proteins and phosphorylation sites;
functional enrichment analysis of Gene Ontology, Pfam, and
KEGG terms in increased proteins and phosphorylation sites
from classes 1−3; functional enrichment analysis of Gene
Ontology, Pfam, and KEGG terms in decreased proteins and
phosphorylation sites from classes 1−3; STRING analysis;
classiﬁed proteins and phosphorylation events mapped onto the
mTOR signaling pathway; classiﬁed proteins and phosphor-
ylation events mapped onto the p53 signaling pathway;
classiﬁed proteins and phosphorylation events mapped onto
the Wnt signaling pathway; classiﬁed proteins and phosphor-
ylation events mapped onto the MAPK signaling pathway. This
material is available free of charge via the Internet at http://
pubs.acs.org.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr5006372 | J. Proteome Res. 2014, 13, 4388−43974394
■ AUTHOR INFORMATION
Corresponding Authors
*Phone: +33/(0)493/95 77 62. Fax: + 33/(0)493/95 77 08. E-
mail: davidovic@ipmc.cnrs.fr.
*Phone: +49/(0)7071/29-70556. Fax: +49/(0)7071/29-5779.
E-mail: boris.macek@uni-tuebingen.de.
Author Contributions
⊥K.M. and T.E. contributed equally to this work.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
The authors gratefully thank Prof. E.W. Khandjian (Centre de
Recherche Universite ́ Laval-Robert Giﬀard, Queb́ec, Canada)
for kindly providing the SV40-transformed STEK cell line in
which were performed experiments preliminary to this study.
L.D. thanks Joel̈le Chabry and Geŕard Lambeau (IPMC,
Valbonne, France) for providing antibodies and advice for their
use. Our work was supported by CNRS, FRAXA Foundation,
Universite ́ de Nice, and ANR JCJC MetaboXFra (to L.D.),
INSERM, Agence Nationale de la Recherche: ANR-11-LABX-
0028-01, Blanc SVSE4-2012, and Blanc SVSE8-2012 (to B.B.),
and FP7 PRIME-XS Consortium (to B.M.).
■ REFERENCES
(1) Coffee, B.; Keith, K.; Albizua, I.; Malone, T.; Mowrey, J.;
Sherman, S. L.; Warren, S. T. Incidence of Fragile X Syndrome by
Newborn Screening for Methylated FMR1 DNA. Am. J. Human Genet.
2009, 85 (4), 503−514.
(2) Wang, L. W.; Berry-Kravis, E.; Hagerman, R. J. Fragile X: leading
the way for targeted treatments in autism. Neurotherapeutics 2010, 7
(3), 264−274.
(3) Reddy, K. S. Cytogenetic abnormalities and fragile-X syndrome in
Autism Spectrum Disorder. BMC Med. Genet. 2005, 6, 3.
(4) Pieretti, M.; Zhang, F. P.; Fu, Y. H.; Warren, S. T.; Oostra, B. A.;
Caskey, C. T.; Nelson, D. L. Absence of expression of the FMR-1 gene
in fragile X syndrome. Cell 1991, 66 (4), 817−822.
(5) Verkerk, A. J.; Pieretti, M.; Sutcliffe, J. S.; Fu, Y. H.; Kuhl, D. P.;
Pizzuti, A.; Reiner, O.; Richards, S.; Victoria, M. F.; Zhang, F. P.; et al.
Identification of a gene (FMR-1) containing a CGG repeat coincident
with a breakpoint cluster region exhibiting length variation in fragile X
syndrome. Cell 1991, 65 (5), 905−14.
(6) Ashley, J. C. T.; Wilkinson, K. D.; Reines, D.; Warren, S. T.
FMR1 protein: conserved RNP family domains and selective RNA
binding. Science 1993, 262 (5133), 563−566.
(7) Hinds, H. L.; Ashley, C. T.; Sutcliffe, J. S.; Nelson, D. L.; Warren,
S. T.; Housman, D. E.; Schalling, M. Tissue specific expression of
FMR-1 provides evidence for a functional role in fragile X syndrome.
Nat. Genet. 1993, 3 (1), 36−43.
(8) Siomi, H.; Siomi, M. C.; Nussbaum, R. L.; Dreyfuss, G. The
protein product of the fragile X gene, FMR1, has characteristics of an
RNA-binding protein. Cell 1993, 74 (2), 291−298.
(9) Darnell, J. C.; Van Driesche, S. J.; Zhang, C.; Hung, K. Y.; Mele,
A.; Fraser, C. E.; Stone, E. F.; Chen, C.; Fak, J. J.; Chi, S. W.; Licatalosi,
D. D.; Richter, J. D.; Darnell, R. B. FMRP stalls ribosomal
translocation on mRNAs linked to synaptic function and autism.
Cell 2011, 146 (2), 247−61.
(10) Khandjian, E. W.; Corbin, F.; Woerly, S.; Rousseau, F. The
fragile X mental retardation protein is associated with ribosomes. Nat.
Genet. 1996, 12 (1), 91−3.
(11) Siomi, M. C.; Zhang, Y.; Siomi, H.; Dreyfuss, G. Specific
sequences in the fragile X syndrome protein FMR1 and the FXR
proteins mediate their binding to 60S ribosomal subunits and the
interactions among them. Mol. Cell. Biol. 1996, 16 (7), 3825−32.
(12) Feng, Y.; Absher, D.; Eberhart, D. E.; Brown, V.; Malter, H. E.;
Warren, S. T. FMRP associates with polyribosomes as an mRNP, and
the I304N mutation of severe fragile X syndrome abolishes this
association. Mol. Cell 1997, 1 (1), 109−18.
(13) Laggerbauer, B.; Ostareck, D.; Keidel, E. M.; Ostareck-Lederer,
A.; Fischer, U. Evidence that fragile X mental retardation protein is a
negative regulator of translation. Hum. Mol. Genet. 2001, 10 (4), 329−
38.
(14) Li, Z.; Zhang, Y.; Ku, L.; Wilkinson, K. D.; Warren, S. T.; Feng,
Y. The fragile X mental retardation protein inhibits translation via
interacting with mRNA. Nucleic Acids Res. 2001, 29 (11), 2276−2283.
(15) Davidovic, L.; Huot, M. E.; Khandjian, E. W. Lost once, the
Fragile X Mental Retardation protein is now back onto brain
polyribosomes. RNA Biol. 2005, 2 (1), 1−3.
(16) Bechara, E. G.; Didiot, M. C.; Melko, M.; Davidovic, L.;
Bensaid, M.; Martin, P.; Castets, M.; Pognonec, P.; Khandjian, E. W.;
Moine, H.; Bardoni, B. A novel function for fragile X mental
retardation protein in translational activation. PLoS Biol. 2009, 7 (1),
e16−e16.
(17) Maurin, T.; Zongaro, S.; Bardoni, B. Fragile X Syndrome: From
molecular pathology to therapy. Neurosci. Biobehav. Rev. 2014,
DOI: 10.1016/j.neubiorev.2014.01.006.
(18) Higashimori, H.; Morel, L.; Huth, J.; Lindemann, L.; Dulla, C.;
Taylor, A.; Freeman, M.; Yang, Y. Astroglial FMRP-dependent
translational down-regulation of mGluR5 underlies glutamate trans-
porter GLT1 dysregulation in the fragile X mouse. Hum. Mol. Genet.
2013, 22 (10), 2041−54.
(19) Schutt, J.; Falley, K.; Richter, D.; Kreienkamp, H. J.; Kindler, S.
Fragile X mental retardation protein regulates the levels of scaffold
proteins and glutamate receptors in postsynaptic densities. J. Biol.
Chem. 2009, 284 (38), 25479−87.
(20) Dictenberg, J. B.; Swanger, S. A.; Antar, L. N.; Singer, R. H.;
Bassell, G. J. A direct role for FMRP in activity-dependent dendritic
mRNA transport links filopodial-spine morphogenesis to fragile X
syndrome. Dev. Cell 2008, 14 (6), 926−39.
(21) Bassell, G. J.; Warren, S. T. Fragile X syndrome: loss of local
mRNA regulation alters synaptic development and function. Neuron
2008, 60 (2), 201−214.
(22) Pfeiffer, B. E.; Huber, K. M. The state of synapses in fragile X
syndrome. Neuroscientist 2009, 15 (5), 549−567.
(23) Fmr1 knockout mice: a model to study fragile X mental
retardation. The Dutch-Belgian Fragile X Consortium. Cell 1994, 78,
(1), 23−33.
(24) Mazroui, R.; Huot, M. E.; Tremblay, S.; Filion, C.; Labelle, Y.;
Khandjian, E. W. Trapping of messenger RNA by Fragile X Mental
Retardation protein into cytoplasmic granules induces translation
repression. Hum. Mol. Genet. 2002, 11 (24), 3007−17.
(25) Mientjes, E. J.; Nieuwenhuizen, I.; Kirkpatrick, L.; Zu, T.;
Hoogeveen-Westerveld, M.; Severijnen, L.; Rife, M.; Willemsen, R.;
Nelson, D. L.; Oostra, B. A. The generation of a conditional Fmr1
knock out mouse model to study Fmrp function in vivo. Neurobiol. Dis.
2006, 21 (3), 549−55.
(26) Castets, M.; Schaeffer, C.; Bechara, E.; Schenck, A.; Khandjian,
E. W.; Luche, S.; Moine, H.; Rabilloud, T.; Mandel, J.-L.; Bardoni, B.
FMRP interferes with the Rac1 pathway and controls actin
cytoskeleton dynamics in murine fibroblasts. Hum. Mol. Genet. 2005,
14 (6), 835−844.
(27) Nolze, A.; Schneider, J.; Keil, R.; Lederer, M.; Hüttelmaier, S.;
Kessels, M. M.; Qualmann, B.; Hatzfeld, M. FMRP regulates actin
filament organization via the armadillo protein p0071. RNA 2013, 19
(11), 1483−1496.
(28) Didiot, M. C.; Subramanian, M.; Flatter, E.; Mandel, J. L.;
Moine, H. Cells lacking the fragile X mental retardation protein
(FMRP) have normal RISC activity but exhibit altered stress granule
assembly. Mol. Biol. Cell 2009, 20 (1), 428−37.
(29) Liao, L.; Park, S. K.; Xu, T.; Vanderklish, P.; Yates, r. J. R.
Quantitative proteomic analysis of primary neurons reveals diverse
changes in synaptic protein content in fmr1 knockout mice. Proc. Natl.
Acad. Sci. U. S. A. 2008, 105 (40), 15281−15286.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr5006372 | J. Proteome Res. 2014, 13, 4388−43974395
(30) Klemmer, P.; Meredith, R. M.; Holmgren, C. D.; Klychnikov, O.
I.; Stahl-Zeng, J.; Loos, M.; van der Schors, R. C.; Wortel, J.; de Wit,
H.; Spijker, S.; Rotaru, D. C.; Mansvelder, H. D.; Smit, A. B.; Li, K. W.
Proteomics, ultrastructure, and physiology of hippocampal synapses in
a fragile X syndrome mouse model reveal presynaptic phenotype. J.
Biol. Chem. 2011, 286 (29), 25495−25504.
(31) Xu, P.; Tan, H.; Duong, D. M.; Yang, Y.; Kupsco, J.; Moberg, K.
H.; Li, H.; Jin, P.; Peng, J. Stable isotope labeling with amino acids in
Drosophila for quantifying proteins and modifications. J. Proteome Res.
2012, 11 (9), 4403−4412.
(32) Olsen, J. V.; Blagoev, B.; Gnad, F.; Macek, B.; Kumar, C.;
Mortensen, P.; Mann, M. Global, in vivo, and site-specific
phosphorylation dynamics in signaling networks. Cell 2006, 127 (3),
635−648.
(33) Bhakar, A. L.; Dolen, G.; Bear, M. F. The pathophysiology of
fragile X (and what it teaches us about synapses). Annu. Rev. Neurosci.
2012, 35, 417−43.
(34) De Rubeis, S.; Bagni, C. Regulation of molecular pathways in
the Fragile X Syndrome: insights into Autism Spectrum Disorders. J.
Neurodev. Disord. 2011, 3 (3), 257−69.
(35) Ong, S.-E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.;
Steen, H.; Pandey, A.; Mann, M. Stable isotope labeling by amino acids
in cell culture, SILAC, as a simple and accurate approach to expression
proteomics. Mol. Cell Proteomics 2002, 1 (5), 376−386.
(36) Castets, M.; Schaeffer, C.; Bechara, E.; Schenck, A.; Khandjian,
E. W.; Luche, S.; Moine, H.; Rabilloud, T.; Mandel, J. L.; Bardoni, B.
FMRP interferes with the Rac1 pathway and controls actin
cytoskeleton dynamics in murine fibroblasts. Hum. Mol. Genet. 2005,
14 (6), 835−44.
(37) Macek, B.; Mijakovic, I.; Olsen, J. V.; Gnad, F.; Kumar, C.;
Jensen, P. R.; Mann, M. The serine/threonine/tyrosine phosphopro-
teome of the model bacterium Bacillus subtilis. Mol. Cell. Proteomics
2007, 6 (4), 697−707.
(38) Ishihama, Y.; Rappsilber, J.; Mann, M. Modular stop and go
extraction tips with stacked disks for parallel and multidimensional
peptide fractionation in proteomics. J. Proteome Res. 2006, 5 (4), 988−
994.
(39) Olsen, J. V.; Macek, B. High accuracy mass spectrometry in
large-scale analysis of protein phosphorylation. Methods Mol. Biol.
2009, 492, 131−42.
(40) Cox, J.; Mann, M. MaxQuant enables high peptide identification
rates, individualized p.p.b.-range mass accuracies and proteome-wide
protein quantification. Nat. Biotechnol. 2008, 26 (12), 1367−72.
(41) Cox, J.; Matic, I.; Hilger, M.; Nagaraj, N.; Selbach, M.; Olsen, J.
V.; Mann, M. A practical guide to the MaxQuant computational
platform for SILAC-based quantitative proteomics. Nat. Protoc. 2009,
4 (5), 698−705.
(42) Cox, J.; Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J.
V.; Mann, M. Andromeda: a peptide search engine integrated into the
MaxQuant environment. J. Proteome Res. 2011, 10 (4), 1794−805.
(43) Benjamini, Y.; Hochberg, Y. Controlling the False Discovery
RateA Practical and Powerful Approach to Multiple Testing. J. R.
Stat. Soc., Ser. B: Methodological 1995, 57 (1), 289−300.
(44) Jensen, L. J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevey, C.;
Muller, J.; Doerks, T.; Julien, P.; Roth, A.; Simonovic, M.; Bork, P.;
von Mering, C. STRING 8a global view on proteins and their
functional interactions in 630 organisms. Nucleic Acids Res. 2009, 37
(Database issue), D412−6.
(45) Franceschini, A.; Szklarczyk, D.; Frankild, S.; Kuhn, M.;
Simonovic, M.; Roth, A.; Lin, J.; Minguez, P.; Bork, P.; von Mering, C.;
Jensen, L. J. STRING v9.1: protein-protein interaction networks, with
increased coverage and integration. Nucleic Acids Res. 2013, 41
(Database issue), D808−15.
(46) Davidovic, L.; Navratil, V.; Bonaccorso, C. M.; Catania, M. V.;
Bardoni, B.; Dumas, M. E. A metabolomic and systems biology
perspective on the brain of the fragile X syndrome mouse model.
Genome Res. 2011, 21 (12), 2190−202.
(47) Davidovic, L.; Bechara, E.; Gravel, M.; Jaglin, X. H.; Tremblay,
S.; Sik, A.; Bardoni, B.; Khandjian, E. W. The nuclear MicroSpherule
protein 58 is a novel RNA-binding protein that interacts with fragile X
mental retardation protein in polyribosomal mRNPs from neurons.
Hum. Mol. Genet. 2006, 15 (9), 1525−1538.
(48) Devys, D.; Lutz, Y.; Rouyer, N.; Bellocq, J. P.; Mandel, J. L. The
FMR-1 protein is cytoplasmic, most abundant in neurons and appears
normal in carriers of a fragile X premutation. Nat. Genet. 1993, 4 (4),
335−40.
(49) Khandjian, E. W.; Bardoni, B.; Corbin, F.; Sittler, A.; Giroux, S.;
Heitz, D.; Tremblay, S.; Pinset, C.; Montarras, D.; Rousseau, F.;
Mandel, J.-L. Novel Isoforms of the Fragile X Related Protein FXR1P
are Expressed During Myogenesis. Hum. Mol. Genet. 1998, 7 (13),
2121−2128.
(50) Demart, S.; Fournier, J. G.; Creminon, C.; Frobert, Y.; Lamoury,
F.; Marce, D.; Lasmezas, C.; Dormont, D.; Grassi, J.; Deslys, J. P. New
insight into abnormal prion protein using monoclonal antibodies.
Biochem. Biophys. Res. Commun. 1999, 265 (3), 652−7.
(51) Siomi, M. C.; Siomi, H.; Sauer, W. H.; Srinivasan, S.; Nussbaum,
R. L.; Dreyfuss, G. FXR1, an autosomal homolog of the fragile X
mental retardation gene. EMBO J. 1995, 14 (11), 2401−8.
(52) Zhang, Y.; O’Connor, J. P.; Siomi, M. C.; Srinivasan, S.; Dutra,
A.; Nussbaum, R. L.; Dreyfuss, G. The fragile X mental retardation
syndrome protein interacts with novel homologs FXR1 and FXR2.
EMBO J. 1995, 14 (21), 5358−66.
(53) Sung, Y. J.; Conti, J.; Currie, J. R.; Brown, W. T.; Denman, R. B.
RNAs That Interact with the Fragile X Syndrome RNA Binding
Protein FMRP. Biochem. Biophys. Res. Commun. 2000, 275 (3), 973−
980.
(54) Brown, V.; Jin, P.; Ceman, S.; Darnell, J. C.; O’Donnell, W. T.;
Tenenbaum, S. A.; Jin, X.; Feng, Y.; Wilkinson, K. D.; Keene, J. D.;
Darnell, R. B.; Warren, S. T. Microarray Identification of FMRP-
Associated Brain mRNAs and Altered mRNA Translational Profiles in
Fragile X Syndrome. Cell 2001, 107 (4), 477−487.
(55) Schaeffer, C.; Bardoni, B.; Mandel, J. L.; Ehresmann, B.;
Ehresmann, C.; Moine, H. The fragile X mental retardation protein
binds specifically to its mRNA via a purine quartet motif. EMBO J.
2001, 20 (17), 4803−13.
(56) Schenck, A.; Bardoni, B.; Moro, A.; Bagni, C.; Mandel, J. L. A
highly conserved protein family interacting with the fragile X mental
retardation protein (FMRP) and displaying selective interactions with
FMRP-related proteins FXR1P and FXR2P. Proc. Natl. Acad. Sci. U. S.
A. 2001, 98 (15), 8844−9.
(57) Chen, L.; Yun, S. W.; Seto, J.; Liu, W.; Toth, M. The fragile x
mental retardation protein binds and regulates a novel class of mRNAs
containing u rich target sequences. Neuroscience 2003, 120 (4), 1005−
1017.
(58) Dolzhanskaya, N.; Sung, Y. J.; Conti, J.; Currie, J. R.; Denman,
R. B. The fragile X mental retardation protein interacts with U-rich
RNAs in a yeast three-hybrid system. Biochem. Biophys. Res. Commun.
2003, 305 (2), 434−441.
(59) Miyashiro, K. Y.; Beckel-Mitchener, A.; Purk, T. P.; Becker, K.
G.; Barret, T.; Liu, L.; Carbonetto, S.; Weiler, I. J.; Greenough, W. T.;
Eberwine, J. RNA Cargoes Associating with FMRP Reveal Deficits in
Cellular Functioning in Fmr1 Null Mice. Neuron 2003, 37 (3), 417−
431.
(60) Westmark, C. J.; Malter, J. S. FMRP mediates mGluR5-
dependent translation of amyloid precursor protein. PLoS Biol. 2007, 5
(3), e52.
(61) Zhang, M.; Wang, Q.; Huang, Y. Fragile X mental retardation
protein FMRP and the RNA export factor NXF2 associate with and
destabilize Nxf1 mRNA in neuronal cells. Proc. Natl. Acad. Sci. U. S. A.
2007, 104 (24), 10057−10062.
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